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Part A: Introduction 
The introduction consists of 11 content areas: 
1. Background 
2. Epidemiology 
3. Barriers to Treatment 
4. Effective Interventions and Guidelines 
5. Definition of Terms 
6. Creation of the Guide 
7. RAM Methodology 
8. Limitations to the RAM Process and Gaps Identified in the Research 
9. How To Use the Clinical Guide 
10. Introduction Web Resources 
11. References 
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Background 
The nation’s opioid epidemic continues to compromise the health and well-being of individuals, families, 
and communities. Federal policymakers and agencies are developing, implementing, and funding strategies 
focused on turning the tide (U.S. Department of Health and Human Services [HHS], 2016]) to address 
opioid misuse, opioid use disorder (OUD), fatal and non-fatal drug overdoses, prenatal substance exposure, 
dissolution or breakup of families, and financial ruin experienced in communities nationwide. 
Epidemiology 
In 2015, more than 27 million people in the United States reported current use of an illicit drug or misuse of 
prescription drugs in the past 30 days (Center for Behavioral Health Statistics and Quality [CBHSQ], 2016). The 
number of women of childbearing age, defined as ages 15–44, who reported past-month heroin use increased 
to 109,000 in 2013–2014, an increase of 31 percent from 2011–2012 (CBHSQ, 2015, Table 6.71A). The number 
of women ages 15–44 who reported past-month misuse of prescription pain relievers such as OxyContin© 
increased to 98,000 in the same period, an increase of 5.3 percent (CBHSQ, 2015, Table 6.71A). The Centers for 
Disease Control and Prevention (CDC) estimates that one-third of reproductive-age women enrolled in Medicaid 
and more than one-quarter of those with private insurance filled a prescription for an opioid pain medication 
each year between 2008 and 2012 (Ailes et al., 2015). The prevalence of OUD during pregnancy more than 
doubled between 1998 and 2011 to 4 per 1,000 deliveries (Maeda, Bateman, Clancy, Creanga, & Leffert, 2014). 
Neonatal abstinence syndrome (NAS) is a group of physiologic and neurobehavioral signs of withdrawal that 
may occur in a newborn who was exposed to psychotropic substances (e.g., opioids) in utero. Opioid use, 
whether resulting from prescription misuse or from illicit use, has consequences for the mother–infant dyad, with 
anywhere from 50 to 80 percent of opioid-exposed infants developing NAS (Jones, Chisolm, Jansson, & Terplan, 
2012; Patrick, Dudley, et al., 2015). 
From 2009 to 2012, the number of infants diagnosed with NAS increased from 3.4 to 5.8 per 1,000 hospital births, 
with more than 20,000 infants diagnosed with NAS in 2012 (Patrick, Davis, Lehmann, & Cooper, 2015). The rate of 
NAS per 1,000 hospital births is not uniform across the nation; rates in rural regions are generally higher than those 
in urban regions (Villapiano, Winkelman, Kozhimannil, Davis, & Patrick, 2017). The increase in numbers of infants with 
NAS, along with other complications, and approach the hospital takes to treating NAS contributes to substantially 
increased hospital costs, with an average mean charge of $93,400 in 2012 dollars (Patrick, Davis, et al., 2015). 
Barriers to Treatment 
Women with OUD and their infants face critical barriers to optimal care such as legal consequences in several 
states with statutes that sanction pregnant women with OUD. The goal of these efforts is to protect the fetus 
or infant from opioid exposure (Guttmacher Institute, 2017; House, 
Coker, & Stowe, 2016) but these legal consequences may drive women 
away from available care, seeking care or continuing to engage in 
care thereby potentially leading to worse outcomes for both the fetus 
and mother (Angelotta, Weiss, Angelotta & Friedman, 2016). The 
dichotomy between such policies and recommendations of healthcare 
professionals (e.g., American Academy of Addiction Psychiatry, 2015; 
American Society of Addiction Medicine [ASAM], 2015; Committee 
on Healthcare for Underserved Women, ASAM, & American College 
of Obstetricians and Gynecologists [ACOG], 2011; Patrick, Schiff, & 
American Academy of Pediatrics [AAP] Committee on Substance Use 
and Prevention, 2017) with regard to substance use disorder (SUD) 
screening and treatment, reporting of substance use during pregnancy 
and the postpartum period, and involvement of child protection 
services can be confusing (House et al., 2016). The shame associated 
with OUD during pregnancy and motherhood and the misinformation 
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among healthcare professionals and systems that results in reluctance to provide care 
for such women, are also significant barriers. Together, these barriers can prevent 
women from receiving essential prenatal care or treatment for their OUD until they are 
close to delivery or in labor. Barriers can also prevent the woman from receiving essential 
care during the postpartum period. Without treatment, pregnant women with OUD face 
increased risks of preterm delivery, low infant birth weight, and transmitting HIV to their 
infants (Binder & Vavrinková, 2008). 
Effective Interventions and Guidelines 
Effective interventions for OUD, including medication-assisted treatment (MAT), do 
exist, and healthy outcomes can occur for both the mother and the infant, but only 
when healthcare professionals can recognize and treat SUDs, which include OUD, 
and substance exposure in infants. The Substance Abuse and Mental Health Services 
Administration (SAMHSA) developed the clinical guidance in this document to meet 
an urgent need among professionals who care for women with OUD and substance-
exposed infants for reliable, useful, and accurate information that can be applied in clinical practice to 
optimize the outcome for both mother and infant. 
Currently, guidelines for treatment of pregnant women with OUD are available at global, country, and 
state levels (e.g., Commonwealth of Pennsylvania, 2016; Council of the Society of Obstetricians and 
Gynaecologists of Canada, 2011; New South Wales Ministry of Health, Australia, 2006; Norwegian Directorate 
of Health, 2011; Vermont Department of Health, Division of Alcohol and Substance Abuse Programs, & 
Department of Vermont Health Access, 2010; World Health Organization [WHO], 2014). SAMHSA has 
published two guides specifically for pregnant women with OUD in recent years: Methadone Treatment for 
Pregnant Women (SAMHSA, 2014) and A Collaborative Approach to the Treatment of Pregnant Women 
With Opioid Use Disorders: Practice and Policy Considerations for Child Welfare, Collaborating Medical, 
and Service Providers (SAMHSA, 2016a). A recent CDC guideline (Dowell, Haegerich, & Chou, 2016) addresses 
issues in opioid prescribing, focusing on nonpharmacologic therapy and nonopioid pharmacologic therapy 
in the treatment of chronic pain in the general population. The CDC guideline recommends that, if opioids 
must be prescribed for acute pain, the effective dosage should be used for 3 or fewer days and rarely more 
than 7 days (Dowell et al., 2016, Box 1, Item #6). The CDC guideline does not specifically address the issue of 
OUD in pregnant women. ASAM National Practice Guideline for the Use of Medications in the Treatment of 
Addiction Involving Opioid Use devotes a chapter to special pharmacotherapy concerns for pregnant and 
parenting women (ASAM, 2015). 
The urgent need for clinical guidance supporting the individualized management of pregnant and 
parenting women with OUD was reinforced during the development of this Guide by audience responses to 
presentations of preliminary recommendations at the 2016 annual conferences of ASAM and the American 
Association for the Treatment of Opioid Dependence. At these conferences, SAMHSA staff and expert panel 
members (Exhibit A.1) provided updates on the completion of the RAND/UCLA Appropriateness Method 
(RAM) report and the development of this Guide. Conference attendees reaffirmed the need for resources 
such as this Guide to provide information on the most current pharmaceutical treatments, specifically MAT, to 
support recovery from opioid use in pregnant women and treatment for infants exposed to opioids in utero. 
This Guide provides comprehensive, national guidance for the optimal management of pregnant and 
parenting women with OUD and their infants based on the recommendations of experts reviewing the limited 
evidence available for this population as of 2017. In the past, only one option was available for OUD treatment 
in pregnant women. Today, more options are available, so healthcare professionals need to provide more 
education to their patients and obtain their detailed informed consent to ensure decision-making is shared 
between the pregnant woman or new mother and the healthcare professional. This Guide will help healthcare 
professionals and patients determine the most clinically appropriate action for a particular circumstance, with 
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Exhibit A.1: Expert Panelists* 
Name, Degree Affiliation 
Shahid Ali, MD, MBBS Meharry Medical College Rainbow Program 
Diana Coffa, MD Department of Family and Community Medicine, University of California San Francisco, School of Medicine 
Deborah Finnell, DNS, PMHNP-BC,
CARN-AP, FAAN 
Department of Acute and Chronic Care, Johns Hopkins University School of Nursing 
Lauren Jansson, MD Department of Pediatrics, Johns Hopkins University School of Medicine, and Center for Addiction and
Pregnancy, Johns Hopkins Bayview Medical Center 
Hendrée E. Jones, PhD, Chair University of North Carolina at Chapel Hill School of Medicine, Department of Obstetrics and Gynecology,
and the UNC Horizons Program 
Marjorie Meyer, MD, FACOG Maternal–Fetal Medicine Division, University of Vermont College of Medicine 
Stephen Patrick, MD, MPH, MS, FAAP Departments of Pediatrics and Health Policy, Division of Neonatology, Vanderbilt University School of Medicine 
Charles Schauberger, MD, MS, FACOG, CPE Gundersen Health System, La Crosse, Wisconsin 
Mishka Terplan, MD, MPH, FACOG Department of Obstetrics and Gynecology, Virginia Commonwealth University School of Medicine 
*The expert panel comprised health professionals and scientists representing diverse geographic areas and disciplines,
including family practice, neonatology, nursing, obstetrics/gynecology, pediatrics, psychology, and psychiatry. 
the expectation that the healthcare professionals will make individualized treatment decisions. A cornerstone
of the Guide is that a healthy pregnancy results in a healthy infant and mother. The Guide recognizes the
mother and infant as a dyad, and the recommendations are provided in light of what actions will optimize
the outcomes for the mother–infant dyad as a whole, with guidance provided from preconception to several
months postpartum and for the first few years of infant development.
 Definition of Terms
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, defines OUD as “a problematic
pattern of opioid use leading to clinically significant impairment or distress” (American Psychiatric Association,
2013). People with OUD typically experience a strong desire for opioids, inability to control or reduce use,
continued use despite interference with major obligations or social functioning, use of larger amounts over
time, development of tolerance, spending a great deal of time to obtain and use opioids, and withdrawal
symptoms that occur after stopping or reducing use, such as negative mood, nausea or vomiting, muscle
aches, diarrhea, fever, and insomnia (SAMHSA, 2015). The term infant is used in this document for infants at
birth to the first 12 months, and the majority of the postnatal materials are focused on infants younger than 12
months, although there are some recommendations for developmental assessments in young children. 
Fetuses exposed to tobacco, alcohol, prescription medications (e.g., benzodiazepines), and illicit substances 
may exhibit signs of physiologic withdrawal from these substances after birth. NAS is a nonspecific term 
assigned to this type of presentation in the newborn. It is widely applied clinically and in the published 
literature to infants withdrawing from opioids. However, the more specific term neonatal opioid 
withdrawal syndrome (NOWS) is becoming more widely used. The utility of the more specific 
from opioid exposure in utero. This distinction is important because specific screening 
NOWS 
term is to more accurately identify the numbers of infants experiencing withdrawal 
and treatment protocols can be used to promote the best outcomes for 
these infants whereas infants not exposed to opioids may require different 
assessment (e.g., Neonatal Intensive Care Unit Network Neurobehavioral 
Scale) and management (e.g., other medication to treat withdrawal). 
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However, the published literature uses the more general NAS term, and, in clinical practice, prenatally 
substance-exposed infants are typically exposed to multiple substances. The research publications relied on 
to support this Guide almost universally studied pregnant women with SUD, rather than OUD only. As such, 
this Guide uses the term NAS when referring to the withdrawal symptoms expressed by infants delivered to 
mothers with SUD, including OUD. 
Creation of the Guide 
This Guide recommends feasible, standard approaches to the care of pregnant and parenting women with 
OUD and their infants that can be adopted in care settings throughout the United States.
 It also provides clinical guidance for healthcare professionals seeking to optimize 
outcomes for women and infants in their care. The following sections briefly describe 
the rationale for selecting the RAND/UCLA Appropriateness Method ([RAM]; Fitch et al., 
2001) to accomplish these goals and how RAM results were clinically translated into this 
Guide. Healthcare professionals may need to adjust their approaches and processes as 
higher quality evidence and new information about OUD treatments become available. 
The rationale for applying RAM to the creation of this Guide is twofold. First, randomized 
clinical trials—the “gold standard” for evidence-based medicine—are generally not 
conducted with this population. Second, even when such trials do exist, they may not 
provide direct evidence at a sufficient level of detail to apply to the range of patients that 
healthcare professionals see in their daily practice. Where there was no robust evidence 
for a particular practice or treatment approach, RAM reviewers rated the treatment 
options based on their expertise and clinical experience with the patient population. 
The expert panelists and Federal Steering Committee 
did not review the use of the long-acting forms of 
buprenorphine because they had not been approved 
by FDA at the time of the RAM review. 
Exhibit A.2: Guidelines Used To Inform the RAM Process 
• Clinical Protocol #21: Guidelines for Breastfeeding and Substance Use or Substance Use Disorder, 
Revised 2015 (Reece-Stremtan, Marinelli, & Academy of Breastfeeding Medicine, 2015) 
• Clinical Report: Neonatal Drug Withdrawal (revised)—Guidance for the Clinician in Rendering 
Pediatric Care (Hudak, Tan, AAP Committee on Drugs, & AAP Committee on Fetus and Newborn, 
2012) 
• Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. Committee on 
Healthcare for Underserved Women, American Society of Addiction Medicine, & American College 
of Obstetricians and Gynecologists. (2012, reaffirmed 2016). 
• Guidelines for the Identification and Management of Substance Use and Substance Use Disorders 
in Pregnancy (WHO, 2014) 
• National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving 
Opioid Use (ASAM, 2015) 
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Exhibit A.3: Scientific Advisors for the Expert Panel 
Name, Degree Affiliation 
Sonia Hernandez-Diaz, MD, DrPH Pharmacoepidemiology Program, Harvard School of Public Health 
Karol Kaltenbach, PhD, Emeritus Pediatrics, Sidney Kimmel Medical College Thomas Jefferson University 
Walter Ling, MD Psychiatry and Biobehavioral Sciences and Integrated Substance Abuse Program, University of California 
Los Angeles, David Geffen School of Medicine 
Exhibit A.4: Agencies and Offices Participating in the FSC 
Assistant Secretary for Planning and Evaluation, HHS National Institutes of Health, HHS 
Centers for Disease Control and Prevention, HHS Office of National Drug Control Policy, The White House 
Centers for Medicare & Medicaid Services, HHS Office of the Assistant Secretary for Health, HHS 
Federal Bureau of Prisons, U.S. Department of Justice Office on Women’s Health, HHS 
Food and Drug Administration, HHS Substance Abuse and Mental Health Services Administration, HHS 
Health Resources and Services Administration, HHS U.S. Department of Defense 
Indian Health Service, HHS U.S. Department of Veterans Affairs 
RAM Methodology 
The expert panelists’ evidence review and rating processes were informed by an extensive literature review 
(Klaman et al., 2017), evidence from 5 published guidelines (Exhibit A.2), expertise of 3 scientific advisors 
(Exhibit A.3) who participated in discussions during the in-person expert panel work session but did not rate 
the items under consideration, and input from the Federal Steering Committee (FSC) representing 14 agencies, 
including SAMHSA (Exhibit A.4). 
The members of the FSC oversaw the entire RAM process and development of the RAM report and provided 
agency perspectives when needed. 
The expert panel and FSC considered the use of methadone, buprenorphine, buprenorphine/naloxone, and 
naltrexone in pregnant and parenting women with OUD as well as the option of medically-supervised withdrawal. 
They did not review the use of the long-acting buprenorphine implant (Probuphine®) because it had not been 
approved at the time of the RAM review. In addition, the product labeling states that the buprenorphine implant 
dose cannot be adjusted, so it may not be the best treatment option for pregnant patients who frequently need 
dose adjustments in later stages of pregnancy (Braeburn Pharmaceuticals, Inc., 2016). 
Limitations to the RAM Process and Gaps Identified in the Research 
Few clinical trials have been conducted on pregnant or parenting women with OUD. In many cases, only a 
few papers exist on this specific topic, and some papers had insufficient statistical power to support strong 
recommendations promoting or discouraging a particular intervention. The RAM process revealed that there 
was a limited evidence base for nearly two-thirds of the clinical actions expected in the management of the 
mother–infant dyad in the context of OUD. Accordingly, expert panelists had to rate the clinical decisions 
based on summary statements from other guidelines and the literature, in tandem with their own clinical 
experience and advice from the scientific advisors and FSC members. A thorough review of the gaps identified 
in the research on pregnant women with OUD is available in Klaman et al. (2017). 
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A detailed report on the RAM process was made available
for public comment for 30 days (SAMHSA, 2016b).
Relevant comments and suggestions from the public were
incorporated into the Guide during its development. 
Healthcare professionals can use the Guide to help
women and their families consider their options and make
critical decisions for themselves and their infants. All RAM
participants were mindful of patient autonomy throughout
the deliberation process. Given the principle of patient autonomy, pregnant and parenting women are free to
make decisions based on their understanding of their illness, its process, and its outcomes. However, because
of the nature of the maternal–fetal dyad and mother–infant dyad, RAM participants were also attentive to
the complexity of offering the best treatment options for the mother and the infant and balancing the needs
of both patients (Velez & Jansson, 2008). The release of this Guide is an important step toward ensuring
that healthcare professionals have access to and are aware of research relevant to the care of pregnant and
parenting women who have OUD and their infants. 
Because of the lack of robust evidence
to inform guidance on clinical actions for
pregnant women, expert panelists used
the RAND/UCLA Appropriateness Method
to establish the best recommendations
possible at the time. 
How To Use the Clinical Guide 
With even the soundest of evidence, research findings can be difficult to apply clinically. In practice, unique patient
variables, the mother’s preferences, the experience of the clinician, and available resources must be considered.
Exhibit A.5: Factsheets in Clinical Guidance for Treating Pregnant and Parenting Women
With Opioid Use Disorder and Their Infants 
Section I: Prenatal Care 
• Factsheet #1: Prenatal Screenings and Assessments 
• Factsheet #2: Initiating Pharmacotherapy for Opioid Use Disorder 
• Factsheet #3: Changing Pharmacotherapy During Pregnancy 
• Factsheet #4: Managing Pharmacotherapy Over the Course of Pregnancy 
• Factsheet #5: Pregnant Women With Opioid Use Disorder And Comorbid Behavioral Health Disorders 
• Factsheet #6: Addressing Polysubstance Use During Pregnancy 
• Factsheet #7: Planning Prior to Labor and Delivery 
• Factsheet #8: Peripartum Pain Relief 
Section II: Infant Care 
• Factsheet #9: Screening and Assessment for Neonatal Abstinence Syndrome 
• Factsheet #10: Management of Neonatal Abstinence Syndrome 
• Factsheet #11: Breastfeeding Considerations for Infants at Risk for Neonatal Abstinence Syndrome 
• Factsheet #12: Infant Discharge Planning 
• Factsheet #13: Early Interventions Strategies and Developmental Assessments 
Section III: Maternal Postnatal Care 
• Factsheet #14: Adjusting Pharmacotherapy Dose Postpartum 
• Factsheet #15: Maternal Discharge Planning 
• Factsheet #16: Maternal Return to Substance Use 
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The Guide consists of Part A: Introduction, Part B: Clinical Guidance (Factsheets 1–16), Part C: Conclusion, and
Appendices A–D. References are located at the end of Part A and at the end of each section in Part B. Appendix
C compiles all the references cited and resources mentioned throughout the Guide for easy reference.
As shown in Exhibit A.5, the factsheets in Part B are grouped into three categories: Section I: Prenatal Care (Factsheets
#1–8); Section II: Infant Care (Factsheets #9–13); and Section III: Maternal Postnatal Care (Factsheets #14–16).
Each factsheet contains four elements, as detailed in Exhibit A.6. The concise recommendations in this Guide
(the Clinical Action Steps) are accompanied by Supporting Evidence and Clinical Considerations that are
more discursive and can assist the healthcare professional in making evidence-informed decisions that are
individualized to the needs of each patient and local circumstances.
Exhibit A.6: Factsheet Elements 
I.  Clinical Scenario
Presents a brief statement to orient the healthcare professional to the situation under
consideration. 
II. Clinical Action Steps
Present recommendations that are derived directly from the rated clinical decisions in the
RAM report and describe what can, might, or should not be done when caring for women
and their infants. 
III. Supporting Evidence and Clinical Considerations
Present strengths and weaknesses of the evidence supporting the clinical action steps.
This section describes how to address or tailor recommended actions to unique patient
variables and preferences, the necessary clinical experience of the provider, and available
community resources. Guidance is based on expert panel and FSC discussions and
additional information on treatment recommendations. For the most part, the topics in
this section lack sufficient evidence to recommend a clear course
of action. Instead, they detail elements that must be taken into
consideration when making a decision with the pregnant woman
or new mother about the best course of action. 
IV. Web Resources 
Provide links to additional online information. 
There are three appendices: Appendix A is a compilation of suitable
development assessments for opioid-exposed infants and children; Appendix B
is a glossary and list of acronyms; and Appendix C is a master list of references.
Users may download the Guide as a single PDF document and print out
sections and factsheets of particular interest. Text in boldface indicates that
more information about the item or the item itself is hyperlinked and can
be downloaded directly from this document. The term FS # is used in the
factsheets to number exhibits (e.g., FS #1.1 indicates the first exhibit in Factsheet
#1). Healthcare professionals are encouraged to sign up at www.samhsa.gov to
receive updates on information in the factsheets. 
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WEB RESOURCES 
2015 National Drug Threat Assessment Summary 
This Drug Enforcement Administration report provides recent data on drug availability and usage,
including heroin and controlled substances.
Advancing the Care of Women With Opioid Use Disorder While Pregnant or Parenting: Clinical
Indications for Developing a National Guide 
This SAMHSA report describes the process by which clinical indications were prepared and the review of
current treatment for pregnant and parenting women with OUD. 
ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving
Opioid Use
This ASAM publication provides information on evidence-based treatment of OUD. 
Children's Bureau Information Memorandum (IM) 
The purpose of this information memorandum from the Administration for Children & Families is to inform
states of the enactment of the 2016 Comprehensive Addiction and Recovery Act (Public Law 114-198)
and provide basic information on the resulting changes in the Child Abuse Prevention and Treatment Act
for child abuse or neglect prevention and treatment programs. This memorandum outlines related best
practices. 
Fact Sheet—FDA Opioids Action Plan 
This 2016 Food and Drug Administration publication details the plans the agency has developed to combat
opioid abuse, dependence, and overdose in the United States.
Protecting Our Infants Act Report to Congress
This SAMHSA report provides information on the Act mandating that HHS conduct a review of planning
and coordination activities related to prenatal opioid exposure and NAS; develop recommendations for the
identification, prevention, and treatment of prenatal opioid exposure and NAS; and develop a strategy to
address gaps, overlap, and duplication among federal programs and coordination efforts to address NAS. 
Substance Use Disorder 
This SAMHSA website provides the facts on common SUDs such as those related to alcohol, tobacco,
cannabis, stimulants, hallucinogens, and opioids. 
TIP addressing Medications for Opioid Use Disorder. In press. 
SAMHSA will release a new TIP on addressing medications for opioid use disorder in early 2018. Please
check the SAMHSA Store for the new TIP. 
U.S. Department of Health and Human Services Final Rule 
This SAMHSA report describes the final rule that expands access to pharmacotherapy by allowing
eligible healthcare professionals to request approval to treat up to 275 patients under section 303(g) 
(2) of the Controlled Substance Act. The final rule also includes requirements to ensure that patients
receive the full array of evidence-based MAT services and to minimize the risk that the treatment
medications are misused or diverted. 
Final Report: Opioid Use, Misuse, and Overdose in Women 
This HHS Office on Women’s Health publication provides an overview of the prevention, treatment, and
recovery issues for women who misuse opioids, have OUD, and/or overdose on opioids. 
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Part B: Factsheets 
Part B consists of 16 factsheets organized into three sections: 
Section I: Prenatal Care 
Factsheet #1: Prenatal Screenings and Assessments 
Factsheet #2: Initiating Pharmacotherapy for Opioid Use Disorder 
Factsheet #3: Changing Pharmacotherapy During Pregnancy 
Factsheet #4: Managing Pharmacotherapy Over the Course of Pregnancy 
Factsheet #5: Pregnant Women With Opioid Use Disorder And Comorbid Behavioral Health Disorders 
Factsheet #6: Addressing Polysubstance Use During Pregnancy 
Factsheet #7: Planning Prior to Labor and Delivery 
Factsheet #8: Peripartum Pain Relief 
Section II: Infant Care 
Factsheet #9: Screening and Assessment for Neonatal Abstinence Syndrome 
Factsheet #10: Management of Neonatal Abstinence Syndrome 
Factsheet #11: Breastfeeding Considerations for Infants at Risk for Neonatal Abstinence Syndrome 
Factsheet #12: Infant Discharge Planning 
Factsheet #13: Early Interventions Strategies and Developmental Assessments 
Section III: Maternal Postnatal Care 
Factsheet #14: Adjusting Pharmacotherapy Dose Postpartum 
Factsheet #15: Maternal Discharge Planning 
Factsheet #16: Maternal Return to Substance Use 
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Section I: Prenatal Care 
Section I consists of eight factsheets: 
Factsheet #1: Prenatal Screenings and Assessments 
Factsheet #2: Initiating Pharmacotherapy for Opioid Use Disorder 
Factsheet #3: Changing Pharmacotherapy During Pregnancy 
Factsheet #4: Managing Pharmacotherapy Over the Course of Pregnancy 
Factsheet #5: Pregnant Women With Opioid Use Disorder and Comorbid Behavioral Health Disorders 
Factsheet #6: Addressing Polysubstance Use During Pregnancy 
Factsheet #7: Planning Prior to Labor and Delivery 
Factsheet #8: Peripartum Pain Relief 
Each factsheet contains four components. 
I. Clinical Scenario
Presents a brief statement to orient the reader to the situation under consideration. 
II. Clinical Action Steps
Present recommendations that are derived directly from the rated clinical decisions in the
RAND/UCLA Appropriateness Method report and describe what can, might, or should not be
done when caring for women and their infants. 
III. Supporting Evidence and Clinical Considerations
Present strengths and weaknesses of the evidence supporting the clinical action steps. This
section describes how to address or tailor recommended actions to unique patient variables
and preferences, the clinical experience of the provider, and available community resources.
Guidance is based on expert panel and Federal Steering Committee discussions and additional
information from published articles. For the most part, the topics in this section lack
sufficient evidence to recommend a clear course of action. Instead, they detail elements
that must be taken into consideration when making a decision with the pregnant woman or
new mother about the best course of action. 
IV. Web Resources 
Provide links to additional online information. 
FACTSHEET #1: Prenatal Screenings and Assessments 
CLINICAL SCENARIO: A pregnant woman with opioid use disorder (OUD) presents for care. 
• Screenings 
• Prescription drug monitoring program 
• Social, medical, and legal consequences 
• Prenatal care access and OUD 
• Pharmacotherapy, pregnancy, and care
coordination 
• Opportunities for positive change 
• Adjusting to pharmacotherapy, other medications,
and pregnancy 
• OUD and HIV/AIDS, viral hepatitis infection, and
sexually transmitted infections 
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FACTSHEET #2: Initiating Pharmacotherapy for Opioid Use Disorder 
CLINICAL SCENARIO: A pregnant woman with OUD requests treatment. 
• Medication-assisted treatment (MAT) 
• Patient education 
• Addressing infant safety and pharmacotherapy 
• Pharmacotherapy and withdrawals and cravings 
• Substance Abuse and Mental Health Services 
Administration treatment directories 
• Informed consent for pregnant patients 
• Individualized treatment plans 
• Discussing treatment-specific potential legal, 
social, and medical consequences, including 
neonatal abstinence syndrome (NAS) 
FACTSHEET #3: Changing Pharmacotherapy During Pregnancy 
CLINICAL SCENARIO: A pregnant woman wishes to discuss changing her existing pharmacotherapy 
for OUD or wants to undergo medically supervised withdrawal from opioids. 
• Prioritizing patient stability 
• Medically supervised withdrawal concerns and 
considerations 
• Discussing changes to opioid agonist treatment 
• NAS severity and maternal pharmacotherapy dose 
not correlated 
• Expanding actions for improving maternal and 
infant health 
• Evolving positions on transitioning between 
combination buprenorphine/naloxone and 
buprenorphine-only products 
• Changes in pharmacotherapy and potential return 
to substance use 
• Daily interactions and observed dosing 
• Discouraging perinatal pharmacotherapy 
withdrawal 
FACTSHEET #4: Managing Pharmacotherapy Over the Course of Pregnancy 
CLINICAL SCENARIO: A pregnant woman treated with pharmacotherapy for OUD is experiencing 
withdrawal or cravings. 
• Common pharmacotherapy adjustments 
• Pregnancy and medication metabolism increases 
• Pharmacotherapy dose not associated with NAS 
• Benefits of counseling 
• Role for peer support specialists 
• Support with mutual-aid groups accepting of 
pharmacotherapy 
FACTSHEET #5: Pregnant Women with Opioid Use Disorder and Comorbid 
Behavioral Health Disorders 
CLINICAL SCENARIO: A pregnant woman with opioid use disorder (OUD) and comorbid behavioral 
health disorders needs help managing these conditions. 
• Balancing maternal mental health needs and fetal 
polypharmacy considerations 
• Comorbid mental health conditions common with 
OUD 
• Considering possible drug interactions 
• Complexity of treating comorbid substance use 
and mental health disorders 
• Antidepressants, anticonvulsants, anxiolytics, and 
NAS 
• Risks of combining benzodiazepines with opioid 
agonist treatment 
• Widespread discrimination, prejudice, and bias 
against people with substance use and/or mental 
disorders 
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FACTSHEET #6: Addressing Polysubstance Use During Pregnancy 
CLINICAL SCENARIO: A pregnant women with OUD requires help on (1) a return to opioid use; 
(2) her use of alcohol, cocaine, cannabis, or tobacco; (3) her comorbid misuse of prescribed 
medications, including benzodiazepines, amphetamines, or other pharmacotherapies, whether 
licitly or illicitly obtained; and (4) the impact of these medications and other substances on her 
health and that of the fetus. 
• Return to opioid use 
• Return to other substance use 
• Return to substance use is common and often a 
dynamic process 
• Polysubstance use concerns for women and infants 
• A variety of prescription and illicit substances can 
affect NAS 
• Pregnancy, medication metabolism, and dose 
adjustment 
• Smoking and association with poorer pregnancy, 
fetal development, and postnatal infant outcomes 
• Cannabis and low birth weight infants 
• Coordination with hospital resources and 
comprehensive healthcare plans 
FACTSHEET #7: Planning Prior to Labor and Delivery 
CLINICAL SCENARIO: A pregnant woman with OUD has questions about NAS, support services, and 
postpartum planning. 
• Patient education on NAS 
• Healthy home environment 
• Contraception, unintended pregnancies, and 
planning future pregnancies 
• Explaining opioid withdrawal and tolerance 
• Discussing various steps to maximize maternal and 
fetal health 
• Including breastfeeding benefits in delivery planning 
• Community-based supports for mothers in recovery 
• Consumer-, patient-, and peer-based community 
supports 
FACTSHEET #8: Peripartum Pain Relief 
CLINICAL SCENARIO: A pregnant woman with OUD, in treatment or not, needs pain relief during 
her labor, delivery, and postpartum period. 
• Pain management options 
• Differentiating OUD pharmacotherapy and pain 
management 
• Documenting pain discussion in medical records 
• Analgesia adequacy and ensuring pain relief 
• Contraindicated medications 
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SECTION 1 
FAC
1 
TSHEET # 
PRENATAL SCREENINGS 
AND ASSESSMENTS 
CLINICAL SCENARIO 
A pregnant woman with opioid use disorder (OUD) presents for care. 
CLINICAL ACTION STEPS 
Screenings 
When a pregnant woman presents requesting prenatal care and help with her substance use disorder, 
conduct a careful, empathetic, and nonjudgmental interview with her that lets her know that all new patients 
are asked the same questions about substance use. Because polysubstance use is common, a validated 
screening instrument for other substance use may also be given to the patient for self-completion and 
reviewed by a healthcare professional. This screening should be conducted in a clinically appropriate and 
therapeutic manner. To ensure that information is gathered and addressed effectively, screening may be part 
of a formal screening, brief intervention, and referral to treatment (SBIRT) protocol such as that created by 
the Substance Abuse and Mental Health Services Administration (SAMHSA). 
Prescription Drug Monitoring Program (PDMP) 
A review of data in the state’s PDMP to identify all reported medications that have been prescribed to the 
woman needs to be included as part of the initial visit and rechecked over the course of the care. 
Medical, Social, and Legal Consequences 
Pregnant women with OUD should receive counseling 
and education on the medical and social consequences 
of pharmacotherapy for OUD, continued use of legal and 
illicit substances while pregnant, and withdrawal from 
opioids while pregnant with inherent risks to mother and 
fetus of relapse. 
Owing to differing state, county and local laws and 
regulations, there is no universal approach to assessing 
the social and legal consequences of legitimate 
pharmacotherapy for OUD or other substance use 
during pregnancy. 
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SUPPORTING EVIDENCE AND CLINICAL CONSIDERATIONS 
Screenings 
• Types of screenings vary. The World Health Organization’s (WHO’s) Guidelines for the Identification and
Management of Substance Use and Substance Use Disorders in Pregnancy recommends that healthcare
professionals ask all pregnant women about their use of alcohol and other substances (i.e., past, present,
prescribed, licit, and illicit use) as early as possible in the pregnancy and at every follow-up visit (WHO,
2014). Healthcare professionals need to determine whether any of their pregnant patients are currently
taking (or have recently taken) methadone,
buprenorphine or other long-acting opioids (Breen
et al., 2003; Chasnoff, 2003; Kraus et al., 2011). 
 Interviews and Instruments
A complete substance use history is essential to
establishing a safe and appropriate treatment
plan that the woman and the healthcare
professionals can agree on (Federation of
State Medical Boards [FSMB], 2013). This
history combines interviews and results from
standardized assessment instruments. Ideally, the history would include (SAMHSA, 2015):
 The nature of the patient’s SUDs. 
 Underlying or co-occurring diseases or conditions. 
 The effect of opioid use on the patient’s physical and psychological functioning.
 Outcomes of past treatment episodes
Exhibit FS #1.1 provides a list of common paper-and-pencil screening tools for substance use. 
 Toxicology Screens
The pregnant woman should be asked to provide informed consent for urine,
blood, or saliva screenings for substance use. Although oral informed consent
is used in many labor-and-delivery clinics, a signed paper or electronic form is
preferred. The healthcare professional should review with the pregnant woman
the risks and limitations of each type of test and the need for confirmatory
testing for any positive results (e.g., using gas chromatography/mass
spectrometry confirmation) and ensure that she understands the process and
meaning of test results before specimen collection (e.g., known false-positive
test results may be due to cross-reactions of other substances such as cold
medicines, which can produce a positive amphetamine result). It is helpful to
ask the pregnant woman what, if anything, she expects might be detected and
to give her an opportunity to describe her substance use patterns and behavior.
The toxicology screen should be obtained even when substance use is self-
reported so that a baseline can be confirmed. In addition to the routine HIV,
sexually transmitted infections, and hepatitis screens ordered for all pregnant
women, other laboratory tests should be ordered when an SUD is possible. The
standard testing for sexually transmitted infections (e.g., syphilis) done at the
initial prenatal assessment may be repeated in the third trimester or at delivery. 
The mother’s history should include illicit and 
licit substance use before and during pregnancy 
with special attention to high-risk behaviors 
such as injecting drug use, current exposure to 
interpersonal violence, and behavioral health 
history such as anxiety, depression, or trauma. 
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Exhibit FS #1.1: Examples of Instruments To Detect Substance Use in Pregnant Women 
Measure Substance/ Health 
Problem Screened 
# of 
Items 
Method of 
Administration 
Training in 
Administration 
Necessary? 
Validation 
Sample(s) 
Sensitivity Specificity 
4P’s Plus©a and Integrated
5P’s 
Integrated 5P’s: 
Violence, mental 
health, tobacco, 
alcohol, and illicit 
substances 
5 Paper-and-
pencil 
No Inpatient 
and 
outpatient 
87% 76% 
Substance Use Risk 
Profile–Pregnancy  
(SURP-Pb,c,d) 
Alcohol and 
substances 
3 Paper-and-
pencil 
No Prenatal 
clinic 
Low risk: 
80–100% 
High risk: 
48–100% 
Low risk: 
61–64% 
High risk: 
84–86% 
Tolerance, Annoyed, Cut-
down, Eye-opener (T-ACE)
Alcohol 4 Paper-and-
pencil 
No Prenatal
clinic 
60–91%d 37–79%d 
Tolerance, Worried,  
Eye-opener, Amnesia,  
K[C]ut-down (TWEAK) 
Alcohol 5 Paper-and-
pencil 
No Prenatal 
clinic 
59–92%d 64–92%d 
aOnly the 4P’s Plus screening tool includes psychometrics; the 5P’s tool is in the public domain.
bThe SURP-P does not have an online version. See Yonkers et al. (2010) to review the instrument. 
cAlcohol, marijuana, cocaine, sedatives, and opioids..
dSensitivities and specificities vary depending on the cut point used to determine risk.
Sources: 4P’s Plus: Ewing 1990; Chasnoff et al., 2005; Integrated 5P’s: Finkelstein, Hutchins &
Mahoney, 2004; SURP-P: Yonkers et al., 2010; T-ACE: Sokol, Martier & Ager, 1989; TWEAK: Russell
& Skinner, 1988. 
19 Section 1: Factsheet 1 
 PDMPs
   
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
   
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
  
  
  
  
  
   
  
 
• State-based PDMPs collect data from pharmacies
on prescriptions of controlled substances. Using
PDMP data, it is possible to determine whether
patients are going to multiple doctors to get
prescriptions for controlled substances (Patrick,
Fry, Jones, & Buntin, 2016). Healthcare professionals
should consult their state’s PDMP for the patient’s
prescription drug use history. Periodically, checking
the PDMP database can confirm the controlled
prescription medications the patient reports taking
and detect unreported use of other controlled
prescription medications that may be hazardous in
pregnancy (FSMB, 2013). State boards of medicine
and pharmacy can provide information about how
to access the PDMP. 
If drug use is possible or confirmed, WHO
recommends conducting a brief intervention (WHO, 2014). SAMHSA’s evidence-based SBIRT protocol identifies,
reduces, and prevents alcohol and illicit drug use. SBIRT builds on a behavioral intervention foundation known
as motivational interviewing. More about motivational interviewing is available in SAMHSA’s Quick Guide for
Clinicians Based on TIP 34: Brief Interventions and Brief Therapies for Substance Abuse (SAMHSA, 2001).
Common laboratory tests for pregnant women 
with possible SUD include:* 
• Urine toxicology screen for opioids and illicit 
drugs used in the community that includes 
confirmatory testing. 
• Urine screen for alcohol that includes 
confirmatory testing. 
• Screen for HIV, hepatitis B and C, and sexually 
transmitted infections 
• Liver enzymes and serum bilirubin test to 
detect liver disease. 
• Serum creatinine levels test to detect silent 
renal disease. 
*Sources: Gourlay, Heit, & Caplan, 2010; Saitz, 2009; SAMHSA, 2015 
Social, Medical, and Legal Consequences 
• Too often, pregnant woman with OUD receive no, or very little, prenatal care. With no healthcare
professional to monitor their pregnancy, women with OUD may present in a hospital emergency department
late in pregnancy or in labor. This happens because women may not recognize they were pregnant, fear
being incarcerated for illicit drug use or for exposing their fetus to illicit drugs, lack funds to pay for services,
transportation or daycare, and/or fear losing custody of their other children (Howard, 2016).
Attending to the woman’s immediate needs is important. For any pregnancy, the healthcare professional’s
priority is to ensure the well-being of the woman and fetus. In the context of a possible SUD, learning as
much as possible about her opioid use (i.e.,
type, amount, route, duration, and time of
last use) provides the foundation for possible
treatment. It is critical to know whether she
is on pharmacotherapy for OUD and, if so,
which medication she receives so that it can be
continued as appropriate. If she is receiving or
desires SUD treatment, obtain her consent to
communicate with her treatment provider or have
a care manager facilitate an effective referral.
• For women who are already on pharmacotherapy for OUD and then become pregnant, it is important
to coordinate care with all healthcare professionals. It could be useful to complete a paper or electronic
consent form such as those provided at https://pcssmat.org/opioid-resources/clinical-tools/ to secure
the sort of information releases that will be necessary to coordinate care among healthcare professionals
who write pharmacotherapy prescriptions, those who may manage other behavioral health issue, and
those providing prenatal care. Electronic systems for managing patient consent to share protected health
information are also an option. One example is SAMHSA’s Consent2Share. 
RESOURCES TO REVIEW 
• Public Policy Statement on Women, Alcohol
and Other Drugs, and Pregnancy (American 
Society of Addiction Medicine [ASAM], 2011) 
• Treatment Improvement Protocol (TIP) 
35: Enhancing Motivation for Change in
Substance Abuse Treatment (SAMHSA, 1999) 
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Other Evidence/Considerations 
• Pregnancy is a time of great potential for positive change.
A woman with OUD may be motivated to enter treatment not only out of concern for the health of the fetus
but also because during pregnancy she can envision a different future for herself and her child. In the past, it
was generally believed that people with OUD could not successfully stop smoking or using other substances
while they discontinued opioid use. However, when people are motivated to change, either to achieve a
positive outcome or to avoid a negative one, they may be more successful at discontinuing substance use
if all the addictive substances that they are using
are addressed at once, whether alcohol, tobacco,
or illicit drugs, including opioids. SUD is recognized
to be a chronic disease with expected lapses. The
pregnant and postpartum woman with OUD should
be encouraged to keep trying, through a combination
of pharmacotherapy and behavioral interventions, not
abstinence, to reach the goal of ending substance use.
However, it is important to recognize that immediate and simultaneous discontinuation of all substances (e.g.,
alcohol, benzodiazepines, opioids) may not be feasible or even safe, particularly during pregnancy because
of the additional risk to the developing fetus, which may also be going through withdrawal unmonitored.
Withdrawal from one or multiple substances may require inpatient care (ASAM, 2015; Commonwealth of
Pennsylvania, 2016; Jones et al., 2008, 2016; McCarthy,
Leamon, Willits, & Salo, 2015; Meyer & Phillips, 2015).
• Women who are new to pharmacotherapy for OUD
may struggle to adjust to the changes related to
pregnancy as well as those related to taking a new
medication. For women new to treatment, receiving
support and information about what to expect
from treatment can ensure that their transition from
the emergency department, or other settings where she may initially present, to the outpatient treatment
environment is successful and care is coordinated with all treating healthcare professionals over time.
Always give patients information on the recovery support and resources available in the community for
pregnant and parenting women. This information may be available through your State Opioid Treatment
Authority or a local recovery community organization. 
• Women with OUD are at higher risk for HIV/AIDS and viral hepatitis infection than women who do not
use substances. Screening for HIV/AIDS and hepatitis B and C should be standard at any initial assessment,
regardless of the stage of pregnancy, and may be done by the SUD treatment provider or prenatal healthcare
professional. A significant body of literature informs treatment for HIV/AIDS in pregnant women; in many
cases, the principles of such medical care also apply to pregnant women with OUD. Appropriate consent
should be obtained to share the test results,
coordinate care, and avoid burdening the patient
with unnecessary repeat testing. 
In the context of OUD, it is important to know
that methadone has significant pharmacokinetic
interactions with many drugs, including
HIV antiretroviral agents (McCance-Katz,
Sullivan, & Nallani, 2010). If a patient is new to
pharmacotherapy for OUD or wishes to resume
SAMHSA offers clinical materials to assess 
clients’ or patients’ readiness to change and 
to end their substance use. Use motivational 
interviewing to identify and support positive 
changes to all health behaviors, starting with 
the riskiest ones. 
SUD is recognized to be a chronic disease with 
expected lapses. The pregnant and postpartum 
woman with OUD should be encouraged to 
keep trying, through pharmacotherapy and 
behavioral interventions, not abstinence, to 
reach the goal of ending substance use. 
CONTENT TO REVIEW 
Review FS#3 for a discussion of the risks
associated with medically-supervised withdrawal. 
This link provides examples of the sort of
information releases that will be necessary to
coordinate care: https://pcssmat.org/opioid-
resources/clinical-tools/. 
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pharmacotherapy for OUD and is HIV-positive,
consider using buprenorphine as the first-
line treatment. Buprenorphine appears to
have fewer clinically significant interactions
with antiretroviral medications (Lee, Kresina,
Campopiano, Lubran, & Clark, 2015). However,
if a patient with co-occurring HIV/AIDS and
OUD is already on a stable, therapeutic dose
of methadone, she should not be switched
to buprenorphine treatment, because of the
potential for destabilization while making this
transition (Bruce, Moody, Altice, Gourevitch, &
Friedland, 2013; McCance-Katz et al., 2010). 
RESOURCE TO REVIEW 
Some HIV medications interact with OUD
pharmacotherapy. All healthcare professionals
must learn which HIV medications will interact
with which opioid agonist medications and
be prepared to work with other treating
healthcare professionals to responsively make
appropriate dose adjustments as needed. More
information is available in Exhibit 3. Potential
Interactions Between Buprenorphine and
HIV Medications in Advisory: Sublingual and
Transmucosal Buprenorphine for Opioid Use
Disorder: Review and Update (SAMHSA, 2016)
and McCance-Katz (2011). 
WEB RESOURCES ON THIS TOPIC 
A Collaborative Approach to the Treatment of Pregnant Women With Opioid Use Disorders: Practice and
Policy Considerations for Child Welfare, Collaborating Medical, and Service Providers 
This SAMHSA document provides information on the treatment of pregnant women with OUD, summarizes
guidelines adopted by a variety of professional organizations, and presents a framework for organizing
community efforts. It provides a coordinated, multisystem approach grounded in early identification and
intervention to assist child welfare, medical, SUD treatment, and other systems in supporting families. 
Advisory: Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update
This 2016 SAMHSA publication gives an overview of the use of sublingual and transmucosal buprenorphine
treatment for OUD.
Clinician Consultation Center Substance Use Warmline 
The University of California, San Francisco’s, Clinician Consultation Center provides
Substance Use Warmline consultation to health center providers. This is a free, real-time
clinician-to-clinician telephone consultation, addressing the care and treatment of substance
abuse, chronic pain, and behavioral health. Access the Warmline toll-free at: 1-855-300-3595
(Monday-Friday, 10 a.m.-6 p.m. EDT).
Clinical Drug Testing in Primary Care (Technical Assistance Publication [TAP] 32) 
This 2012 SAMHSA TAP provides information that healthcare professionals need when
deciding whether to introduce drug testing in their practices and gives guidance on
implementing drug testing. 
Consent2Share 
This web-based application will be available in 2017 for patients to give their healthcare
professionals consent to share their personal health information across the health system. 
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Medication Assisted Treatment (MAT) 
This SAMHSA website provides up-to-date information on MAT, including opioid treatment programs and 
additional information on behavioral therapy and medications to treat SUDs. 
Obstetric Care for Women with Opioid Use Disorder 
The Council on Patient Safety in Women’s Health Care is a consortium that promotes safe health care for every 
woman. This Safety Bundle is designed to facilitate standardization of clinical, scientific, and patient safety 
advances. The processes presented are subject to change as new information emerges. 
Public Policy Statement on Women, Alcohol and Other Drugs, and Pregnancy 
This 2011 ASAM publication provides the organization’s policy on care for women with SUDs. 
Quick Guide for Clinicians Based on TIP 34: Brief Interventions and Brief Therapies in Substance Abuse 
This quick guide was developed to accompany SAMHSA’s TIP 34: Brief Interventions and Brief Therapies in 
Substance Abuse. It is based entirely on the TIP and is designed to meet the needs of the busy clinician for 
concise, easily accessed how-to information. 
TIP 35: Enhancing Motivation for Change in Substance Abuse Treatment 
This SAMHSA TIP is intended to help clinicians influence the change process in their patients by incorporating 
motivational interventions into SUD treatment programs. The document describes different motivational 
interventions that can be used at all stages of change. 
Vermont Guidelines for Medication Assisted Treatment for Pregnant Women 
This document provides healthcare professionals with basic information on 
managing OUD in pregnant women. 
Viral Hepatitis and Young Persons Who Inject Prescription Opioids and Heroin 
This Centers for Disease Control and Prevention website details the threat of 
hepatitis B and C in people who misuse opioids, especially those who inject these 
drugs. 
PDMP Resources 
PDMP Training and Technical Assistance Center (TTAC) 
This website provides a variety of services and resources to fight the misuse, abuse, 
and diversion of prescription drugs. It also has information on the Prescription 
Behavior Surveillance System, an early warning tool to measure trends in controlled 
substance prescribing and dispensing and to provide information about medical use 
and possible nonmedical prescription drug abuse and diversion. 
PDMP TTAC State Profiles 
This webpage provides links to PDMP profiles for each state and links to each state’s 
PDMP database. Although access to PDMP information varies by state, generally 
the information is available only to prescribing clinicians, law enforcement, and, 
sometimes, patients. 
Screening Tool Resources 
SBIRT 
This SAMHSA webpage provides information and links to resources about SBIRT that 
clinicians can use to identify, reduce, and prevent alcohol and illicit drug problems. 
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4P’s Plus/Integrated 5P’s 
The 4P’s Plus screen is not available in the public domain. Instead, healthcare professionals can use the 
Institute for Health and Recovery’s Integrated 5P’s tool, which was adapted specifically for pregnant women. 
The questions in the 5P’s tool ask the pregnant woman about her parents’ and her partner’s past and present 
alcohol and drug use in a nonthreatening manner. 
SURP-P 
The Substance Use Risk Profile-Pregnancy Scale screens for hazardous substance use in pregnant women. The 
scale has three questions; healthcare professionals assess women with a positive screen to determine which 
women need intervention and treatment. 
T-ACE 
The Tolerance, Annoyed, Cut-down, Eye-opener screen detects alcohol use in pregnant women. It takes 
approximately 1 minute to administer and is frequently part of a routine patient questionnaire completed while 
waiting for a prenatal appointment. 
TWEAK 
The Tolerance, Worried, Eye-opener, Amnesia, K[C]ut-down screen is a five-item scale to assess alcohol 
consumption during pregnancy. It takes less than 1 minute to administer and can be incorporated into waiting 
room procedures. 
SECTION 1 
FACTSHEET # 
2 INITIATING PHARMACOTHERAPY FOR 
OPIOID USE DISORDER 
CLINICAL SCENARIO 
A pregnant woman with opioid use disorder (OUD) requests treatment. 
CLINICAL ACTION STEPS 
Medication-Assisted Treatment (MAT) 
A pregnant woman with OUD should be offered MAT consisting of pharmacotherapy with methadone or 
buprenorphine and evidence-based behavioral interventions. 
There is insufficient information about the safety of extended-release injectable naltrexone during pregnancy and 
the effects of intrauterine exposure to this medication. The expert panel did not agree on whether women on 
naltrexone should continue to use it during pregnancy. Women stable on naltrexone can be offered treatment with 
buprenorphine or methadone to prevent return to substance use if they choose to discontinue naltrexone injections. 
However, this transition must be carefully managed because patients on long-acting naltrexone are no longer opioid 
tolerant and the falling naltrexone level will result in increasing agonist activity over time during cross-titration. 
Patient Education 
As soon as a pregnant woman is diagnosed with OUD, healthcare professionals should review and discuss the risks 
and benefits of each antagonist and agonist treatment option with her. Healthcare professional should inform her 
that pharmacotherapy is strongly recommended and that treatment without any pharmacotherapy is complicated 
by poor fetal health, high rates of return to substance use, and the consequences such as risk of overdose. 
Healthcare professionals should inform the pregnant woman of the possibility of neonatal abstinence syndrome 
(NAS) and counsel her on its diagnosis, management, and consequences. The woman should also receive 
education on ways to optimize the well-being of the fetus such as tobacco cessation and early pediatric care after 
delivery and hospital discharge. Healthcare professionals should ensure that she is aware of nonpharmacological 
interventions that should be provided to her infant to reduce NAS symptoms, including rooming-in. 
The pregnant woman should be informed of the potential medical and social consequences of each form of 
therapy, specifically of the consequences that relate to NAS and unmonitored prenatal withdrawal. 
No Known Risk of Increased Birth Defects With Pharmacotherapy for OUD 
The woman should be informed that experts do not agree on whether intrauterine exposure to buprenorphine, 
buprenorphine/naloxone, or methadone results in lasting developmental or other problems for the 
infant. A woman receiving either buprenorphine or methadone should be informed that the benefits of 
pharmacotherapy for OUD during pregnancy outweigh the risks of untreated OUD. Healthcare professionals 
may want to reassure women that, to date, research has not shown that buprenorphine and methadone can 
cause an increase in birth defects and has minimal long-term neurodevelopmental impact. 
She should be informed that tobacco and alcohol exposure are known to be harmful to her and the fetus and 
should be provided with support to limit or preferably discontinue exposure to these substances. 
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SUPPORTING EVIDENCE AND CLINICAL CONSIDERATIONS 
MAT 
• Pharmacotherapy, combined with behavioral interventions, helps people who misuse opioids avoid
experiencing withdrawal symptoms or overwhelming cravings when the opioid misuse is stopped.
By blocking cyclic withdrawal symptoms associated with the misuse of short-acting opioids, methadone or
buprenorphine can provide a more stabilized intrauterine environment. In addition, starting on pharmacotherapy
can help the pregnant woman stop injecting drugs, a primary route of infection for people who use drugs. By
controlling the symptoms of OUD (e.g., withdrawal, cravings), the pregnant woman can regain control, reengage
in important obligations and activities in her life, and rebuild a stable social environment for herself and her
family. Behavioral interventions are also recommended to provide maximum support for long-term recovery.
Additional information on these therapies can be found at www.SAMHSA.gov/treatment. 
• SAMHSA maintains nationwide directories
of healthcare professionals who help people
overcome substance use disorders (SUDs).
Pregnant women and new mothers can seek
treatment for OUD at behavioral health treatment
centers or opioid treatment programs. SAMHSA’s
web-based Behavioral Health Treatment Services
Locator and Opioid Treatment Program Directory
provide information about locations of treatment
facilities for SUDs in the United States and U.S.
territories. 
RESOURCES TO REVIEW 
• Medication-Assisted Treatment Website 
• Substance Use Disorders 
• Treatments for Substance Use Disorders 
FACTSHEETS TO REVIEW 
• Factsheet #6: Addressing Polysubstance
Use During Pregnancy, Exhibit FS #6.1, 
for additional discussion on tobacco use 
cessation and treatment options to address 
other substance use 
• Factsheet #9: Screening and Assessment
for Neonatal Abstinence Syndrome for 
information on the time course of NAS 
expression 
• Factsheet #10: Management of Neonatal
Abstinence Syndrome for strategies to reduce 
NAS symptoms 
Patient Education 
• Conversations about informed consent with
pregnant women who have OUD or who are on
pharmacotherapy for opioid use can be complex. 
Informed consent helps patients understand
the likelihood that a specific pharmacotherapy
will help them. Research indicates that often
patients do not completely comprehend the
risk statements that they are given (Krumholz,
2010). All patients receiving prenatal or medical
treatment must give their informed consent to
be treated and indicate that they understand the
treatment that is being provided, the risks and 
benefits of the treatment, the risk of not treating the OUD, and what to do in an emergency. 
Experts do agree that any change in type of pharmacotherapy or a decision to continue or stop a particular
medication during pregnancy should be made only when informed by the patient’s specific needs and
concerns. In either case, the woman’s fully informed consent should be obtained after review of the risks
and benefits of the course of treatment selected.
Consent requires patient education including answering questions and verifying understanding in order 
to support informed, and patient-centered, shared decision-making. Healthcare professionals should 
inform the pregnant women with OUD about the effects of pharmacotherapy for opioid use on the fetus, 
options for pharmacotherapy (i.e., different medications and scenarios), the risks of not treating OUD, the 
26 Section 1: Factsheet 2 
  
   
 
 
 
 
 
 
 
   
 
 
 
  
  
  
  
  
  
   
 
 
likelihood the baby will develop NAS, and the 
possibility that NAS can worsen with the pregnant 
woman’s use of other substances, especially 
tobacco (Jones et al., 2013a; Patrick et al., 2015). 
Through discussion, the healthcare professional 
and the woman can make a shared decision about 
her course of treatment. 
• Treatment plans need to be individualized. 
Each pregnant woman with OUD who is in 
treatment needs her own individualized plan that 
is developed in collaboration with her healthcare 
team. The plan needs to include elements 
such as which medications are being used and 
why; referrals and coordination of care such as 
scheduling help and follow-up appointments with 
other healthcare professionals; family involvement 
and whether family therapy is indicated; and a 
plan to treat co-occurring medical or behavioral 
health disorders that addresses her goals and 
motivations to engage in treatment (Jones et 
al., 2016; SAMHSA, 2014, 2015; World Health 
Organization [WHO], 2014). The plan should 
be based on shared decision-making, in which 
pregnant women seeking treatment and recovery 
can weigh that information against their personal 
preferences and values (SAMHSA, 2016b). The 
plan should also seek to optimize treatment 
issues that are relevant to the developing fetus 
and infant, particularly protocols for addressing 
an infant’s possible NAS and healthy early 
development. 
• Healthcare professionals should educate women
and their family members about potential legal,
social, and medical consequences of each
treatment option, specifically the risks of NAS. 
NAS is a medical condition that can be diagnosed and effectively treated with available interventions.
Avoidance of NAS should not be the deciding factor in the initiation or dose of pharmacotherapy for
OUD during pregnancy. The dose of medication does not appear to impact the risk or severity of NAS
(Jones, Jansson, O’Grady, & Kaltenbach, 2013b; Jones et al., 2014; Lund et al., 2013; Patrick et al., 2015).
Consequently the dose of medication should be titrated to control withdrawal, limit cravings and prevent
return to opioid use. 
Women who are pregnant and have OUD or another SUD may be fearful of the legal consequences they
may face if they seek SUD treatment. Policies on whether and when to assume custody of a newborn or
older child whose mother has untreated OUD vary by state, county, and even hospital (American Academy
of Addiction Psychiatry, 2015; Guttmacher Institute, 2017; House, Coker, & Stowe, 2016). Healthcare
professionals and office staff need to be aware of the regulations in their region (SAMHSA, 2016a). 
While distinct from informed consent, 
treatment agreements can be a useful tool to 
ensure clear communication and expectations 
about the chosen treatment. A treatment 
agreement document typically includes: 
• Risks and benefits of treatment and no 
treatment. 
• Schedules for follow-up office visits and 
laboratory tests to monitor the patient’s 
progress and health status. 
• Goals for behavioral treatment, social and 
family engagement, or mutual-aid group 
meeting attendance. 
• Opportunities for involvement of family 
members or significant others in treatment. 
• Symptoms that should be reported to the 
prescribing physician. 
• A plan for treating co-occurring medical or 
psychiatric conditions, as well as other SUDs 
including tobacco. 
• Expectations for maintenance of
pharmacotherapy and engagement in other
therapies and, if needed, more intensive levels
of care. 
CONTENT TO REVIEW 
This link provides sample treatment agreements 
and consent forms: https://pcssmat.org/opioid-
resources/clinical-tools/. 
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• Initiating pharmacotherapy needs to be 
individualized to each patient’s medical 
condition. Protocols can provide a useful 
starting point, but healthcare professionals 
should evaluate the patient and review results 
of the initial screening with her to determine 
whether she has other medical conditions or 
polysubstance use and individualize the initiation 
of pharmacotherapy. Withdrawal from one or 
multiple substances may require inpatient care 
(ASAM, 2015; Commonwealth of Pennsylvania, 
2016; Jones et al., 2008, 2016; McCarthy, Leamon, 
Willits, & Salo, 2015; Meyer & Phillips, 2015). 
Individuals who select buprenorphine for 
pharmacotherapy need to be aware of the 
potential for spontaneous or precipitated 
withdrawal during pharmacotherapy induction 
(ASAM, 2015) and must be exhibiting clinical 
withdrawal symptoms before administration of 
the first dose. Many clinics now offer induction 
to buprenorphine as an outpatient service and 
sometimes as partial home induction. Partial 
home induction for pregnant women lacks 
sufficient evidence at this time. 
Women who select methadone for 
pharmacotherapy need to be aware that achieving 
a stable therapeutic dose can take days to weeks. 
Some programs will choose to admit a pregnant 
woman to the hospital with a diagnosis of high-risk 
pregnancy to titrate her dose of methadone more 
quickly under continuous medical supervision and 
minimize the chance that she may attempt to cope 
with unrelieved withdrawal by using illicit opioids. 
RESOURCE TO REVIEW 
American Society of Addiction Medicine 
(ASAM) National Practice Guideline for the Use 
of Medications in the Treatment of Addiction 
Involving Opioid Use to obtain more information 
on evidence-based treatment of OUD 
FACTSHEET TO REVIEW 
Tobacco use cessation is critical to the 
health of the dyad and must be addressed 
with specific interventions. Buprenorphine 
or methadone pharmacotherapy does not 
reduce cigarette smoking rates in pregnant 
women (Chisolm et al., 2012). See Factsheet 
#6: Addressing Polysubstance Use During 
Pregnancy for more information on tobacco 
cessation programs in pregnant women. 
RESOURCE TO REVIEW 
Treatment for pregnant women with OUD 
should promote and facilitate family, community, 
and social support as well as social inclusion by 
cultivating strong links with available childcare, 
economic supports, education, housing, 
and other relevant services as reviewed in A 
Collaborative Approach to the Treatment of 
Pregnant Women With Opioid Use Disorders: 
Practice and Policy Considerations for Child 
Welfare, Collaborating Medical, and Service 
Providers (SAMHSA, 2016a). 
No Known Risk of Increased Birth 
Defects With Pharmacotherapy 
Medications 
• Currently, research indicates no known risk of increased birth defects associated with the use of 
buprenorphine or methadone. A woman receiving either buprenorphine or methadone should be 
informed that the benefits of pharmacotherapy for OUD during pregnancy outweigh the risks of 
untreated OUD. 
Healthcare professionals may want to reassure women that, to date, research has not shown that 
buprenorphine and methadone can cause an increase in birth defects (Committee on Healthcare for 
Underserved Women, ASAM, & American College of Obstetricians and Gynecologists, 2017; Holbrook 
& Rayburn, 2014) and has minimal long-term neurodevelopmental impact (ASAM, 2015). 
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Exhibit FS #2.1: : Decision Considerations When Selecting an Opioid Agonist Medication for a Pregnant Woman 
Considerations Buprenorphine Methadone 
Patient Selection May be preferable for patients who are new to treatment 
because it is easier to transfer from buprenorphine to 
methadone (it can be very difficult to transfer from 
methadone to buprenorphine), who do not like or want 
methadone, or who have requested this medication. 
May be preferable for patients who do not like or want 
buprenorphine treatment or who have requested this 
medication. 
Care Includes a prenatal healthcare professional, parenting 
classes, and SUD treatment. 
Includes a prenatal healthcare professional, parenting 
classes, and SUD treatment. 
Dispensing May be prescribed in an office setting with weekly or 
biweekly prescribing/dispensing or provided in an opioid 
treatment program. 
Requires daily visits to a federally certified opioid treatment 
program; take-home medication is provided for patients 
meeting specific requirements. 
Treatment Retention Some studies show treatment dropout is higher than that for 
methadone. 
Some studies show treatment retention is higher than that 
for buprenorphine. 
Risk of Medication 
Interaction 
Few known interactions with other medications; risk of 
interaction is greatest with central nervous system (CNS) 
depressants and CYP3A4 inhibitors (e.g., clarithromycin, 
itraconazole, ketoconazole, atazanavir). If these medications 
must be used, the clinic should monitor the patient daily for 
increased effect of buprenorphine; healthcare professionals 
should be aware that the development of sign and symptom 
varies and depends on a variety of factors. 
Other agonist/antagonist medications (e.g., butorphanol, 
dezocine, nalbuphine, pentazocine) and full antagonists will 
result in precipitated withdrawal. 
Medications that use CYP450 enzymes are commonly 
involved in a methadone-medication interaction. Methadone 
is metabolized primarily by CYP3A4 and CYP2B6. There is 
evidence that other CYP450 enzymes are also involved 
including CYP2D6. Known interactions with other medications 
in pregnant women are detailed in McCance-Katz (2011). If 
these medications must be used, the clinic should monitor 
the patient daily for increased or decreased effect of 
methadone; healthcare professionals should be aware that 
the development of sign and symptom varies and depends 
on a variety of factors. 
Other agonist/antagonist medications (e.g., butorphanol, 
dezocine, nalbuphine, pentazocine) and full antagonists will 
result in precipitated withdrawal. 
Starting Dose 2–4 mg 20–30 mg 
Target Dose Daily, 16 mg or product equivalent to 16 mg, is the most 
common dosage. The optimal dose will be determined by 
regular assessment of the individual and her response to 
treatment. 
Daily, 80–120 mg. The optimal dose will be determined by 
regular assessment of the individual and her response to 
treatment. 
Interval at Which 
Dose May Be 
Increased 
Daily, but dose changes should not be made without patient 
assessment. 
3 days is a common interval in a clinical practice, but dose 
changes should not be made without patient assessment. 
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Considerations Buprenorphine Methadone 
Risk of Overdose 
and Death 
Generally lower risk compared with full opioid agonists; 
overdose is possible when combined with other CNS 
depressants. 
Continued buprenorphine treatment reduces mortality after 
release from incarceration (Degenhardt et al., 2014). 
Buprenorphine treatment reduces the risk of death in people 
dependent on opioids (Gibson et al., 2008) and drug-related 
mortality in the first 4 weeks of treatment, a high-risk period 
(Kimber, Larney, Hickman, Randall & Degenhardt, 2015). 
Generally greater risk of overdose compared with mixed 
agonist/antagonist opioids; overdose is possible when 
combined with other CNS depressants. 
Continued methadone treatment reduces mortality after 
release from incarceration (Degenhardt et al., 2014). 
Methadone significantly reduces the risk of drug-related 
mortality compared with no treatment (Evans et al., 2015). 
Methadone treatment reduces the risk of death in people 
dependent on opioids (Gibson et al., 2008) and drug-related 
mortality in the first 4 weeks of treatment, a high-risk period 
(Kimber et al., 2015). 
Risk of Sedation Sedation is possible but typically milder than that with full 
mu opioid agonists. 
Sedation is possible and may be greater than that with partial 
agonist opioids (Walsh, Preston, Bigelow, & Stitzer, 1995). 
Ability To Fill a 
Prescription at a 
Local Pharmacy 
Is possible depending on pharmacy availability. Can be filled in a certified pharmacy to treat pain, but 
methadone for the treatment of OUD cannot generally be 
obtained from a pharmacy in the United States. It must be 
administered or dispensed for treatment of OUD at a certified 
opioid treatment program. 
Treatment in 
a Healthcare 
Professional’s Office 
Healthcare professionals who request a waiver to prescribe 
buprenorphine from SAMHSA and receive a unique Drug 
Enforcement Administration registration number for this 
purpose may prescribe buprenorphine for the treatment of 
opioid use disorder in an office-based setting. 
May be possible under federal regulation if specific program 
criteria are fulfilled and relevant state and federal permission 
is sought. 
Risk of NAS Approximately 50% of exposed neonates are treated for 
NAS; NAS may be milder with buprenorphine compared with 
full mu opioid agonists such as most opioid analgesics and 
methadone. 
Approximately 50% of exposed neonates are treated for NAS. 
Time to NAS Onset American Academy of Pediatrics (AAP) recommends 
monitoring prenatally opioid-exposed neonates for a 
minimum of 4–7 days after delivery (Hudak, Tan, & AAP, 2012). 
AAP recommends monitoring prenatally opioid-exposed 
neonates for a minimum of 4–7 days after delivery (Hudak, 
Tan, & AAP, 2012). 
Duration of NAS Most studies show shorter NAS duration compared with 
methadone. 
Most studies show longer NAS duration compared with 
buprenorphine. 
Breastfeeding 
Considerations 
Generally safe if the mother is stable and the ABM Clinical 
Protocol #21 breastfeeding with SUD guidelines are met. 
Generally safe if the mother is stable and the ABM Clinical 
Protocol #21 breastfeeding with SUD guidelines are met. 
Neurodevelopmental 
Outcomes of 
Exposed Children 
Available research suggests there is not a linear cause 
and effect relationship between prenatal buprenorphine 
exposure and developmental problems when compared with 
other opioids; the research base is limited. 
Available research suggests there is not a linear cause and 
effect relationship between prenatal methadone exposure 
and developmental problems when compared with other 
opioids; the research base is limited. 
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WEB RESOURCES ON THIS TOPIC 
A Collaborative Approach to the Treatment of Pregnant Women With Opioid Use Disorders: Practice and
Policy Considerations for Child Welfare, Collaborating Medical, and Service Providers 
This SAMHSA document provides information on the treatment of pregnant women with OUD, summarizes
guidelines adopted by a variety of professional organizations, and presents a framework for organizing
community efforts. It provides a coordinated, multisystem approach grounded in early identification and
intervention to assist child welfare, medical, SUD treatment, and other systems in supporting families. 
Addiction Technology Transfer Center (ATTC) Network
The ATTC is a nationwide, multidisciplinary resource for professionals in the addictions treatment and
recovery services field. Established in 1993 by SAMHSA, the ATTC Network comprises 10 Regional Centers,
4 National Focus Area Centers, and a Network Coordinating Office. The ATTC is a resource for webinars,
websites, and printed materials related to treating OUD.
Advisory: Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update
This 2016 SAMHSA publication gives an overview of the use of sublingual and transmucosal buprenorphine
treatment for OUD. 
ATTC: Tools for Treatment, Family-Centered Behavioral Health Support for Pregnant & Postpartum Women 
This Pregnant and Postpartum Women Project ECHO is the first of its kind to address the behavioral health
needs of pregnant and postpartum women, taking a family-centered approach to the recovery process that
includes family members ranging from the infant to older children, fathers, and extended family.
Baby Friendly Hospital Initiative-USA 
This global initiative was launched by WHO and the United Nations Children’s Fund in 1991 to encourage and
recognize hospitals and birthing centers that offer an optimal level of care for infant feeding and mother– 
infant bonding.
Behavioral Health Treatment Services Locator
This searchable database for treatment services is updated every year based on responses to SAMHSA’s
National Survey of Substance Abuse Treatment Services and National Mental Health Services Survey.
Clinician Consultation Center Substance Use Warmline 
The University of California, San Francisco’s, Clinician Consultation Center provides Substance Use Warmline
consultation to health center providers. This is a free, real-time clinician-to-clinician telephone consultation,
addressing the care and treatment of substance abuse, chronic pain, and behavioral health. Access the
Warmline toll-free at: 1-855-300-3595 (Monday-Friday, 10 a.m.-6 p.m. EDT).
Clinical Opiate Withdrawal Scale (COWS)
This assessment tool measures the adequacy of the initial pharmacotherapy induction dose. It can be re-
administered throughout the induction process to monitor the pregnant woman’s progress. 
Follow Directions: How to Use Methadone Safely 
This SAMHSA publication describes the use of methadone in MAT for OUD. It includes information on how to
use methadone safely, the dangers of methadone overdose, and life-threatening methadone side effects. 
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Legal Action Center 
The mission of this nonprofit law and policy organization includes 
fighting discrimination against people with histories of SUD. The center’s 
website links to numerous resources for healthcare professionals, 
patients, employers, and criminal justice personnel. Among these 
resources are a sample treatment letter that healthcare professionals 
can use to support patients ordered off pharmacotherapy by criminal justice and 
child welfare agencies and a document explaining how state driving under the 
influence (DUI) laws treat drivers taking methadone or buprenorphine and what 
legal strategies are available to drivers charged with a DUI offense for driving while on 
these medications. 
Medication-Assisted Treatment 
This SAMHSA website provides up-to-date information on MAT, including opioid 
treatment programs and additional information on behavioral therapy and medications to 
treat SUDs. 
Medication-Assisted Treatment Models of Care for Opioid Use Disorder 
This Agency for Healthcare Research and Quality research protocol describes the 
available literature on MAT models of care, methods for effective MAT implementation, 
and key issues and gaps in the evidence base. 
Medication Assisted Treatment of Opioid Use Disorder Pocket Guide 
This SAMHSA product includes guidelines for physicians using MAT for patients with OUD. 
It discusses approved medications, screening and assessment tools, and best practices for 
patient care. 
Methadone Treatment for Pregnant Women 
This SAMHSA brochure provides basic information on methadone treatment, the possibility 
and treatment of infant withdrawal, breastfeeding on methadone, the consequences of 
continued drug use, and birth control. 
National Center on Substance Abuse and Child Welfare (NCSACW) 
SAMHSA and the Administration for Children & Families jointly fund NCSACW, which is a national resource 
center providing information, expert consultation, training, and technical assistance to child welfare, 
dependency court, and substance abuse treatment professionals to improve the safety, permanency, well-
being, and recovery outcomes for children, parents, and families. 
National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use 
This ASAM publication provides information on evidence-based treatment of OUD. 
Non-punitive Treatment for Pregnant and Breast-feeding Women with Substance Use Disorder 
This position statement from the American Nurses Association (ANA) Center for Ethics and Human Rights 
recognizes substance addiction is a treatable illness and ANA’s commitment to prevention and treatment as 
primary solutions to perinatal substance abuse and addiction. 
Opioid Overdose Prevention Toolkit: Information for Prescribers 
This SAMHSA toolkit is for healthcare professionals, treatment providers, local communities and 
governments, and first responders. It contains materials to develop practices and policies to prevent opioid-
related overdoses and deaths. 
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Opioid Treatment Program Directory 
The dropdown menu on this SAMHSA website links users to information on the availability of opioid 
treatment programs in the United States and its territories. 
Providers’ Clinical Support System for Medication Assisted Treatment (PCSS-MAT) 
This website describes the overarching goal of PCSS-MAT, which is to make the most effective 
treatments available to patients in a variety of settings, including primary care, psychiatric care, SUD 
treatment, and pain management settings. This network provides mentors and training webinars. 
Providers’ Clinical Support System for Opioid Therapies (PCSS-O) 
PCSS-O is a consortium of major stakeholders and constituency groups with interests in safe and 
effective use of opioid medications. PCSS-O makes available, at no cost, continuing medical education 
programs on the safe and effective use of opioids for treatment of chronic pain and safe and effective 
treatment of OUD. 
Treatment Improvement Protocol (TIP) 35: Enhancing Motivation for Change in Substance Abuse 
Treatment 
This SAMHSA TIP is intended to help clinicians influence the change process in their patients by 
incorporating motivational interventions into SUD treatment programs. The document describes 
different motivational interventions that can be used at all stages of change. 
TIP addressing Medications for Opioid Use Disorder. In Press. 
SAMHSA will release a new TIP on addressing medications for opioid use disorder in early 2018. Please 
check the SAMHSA Store for the new TIP. 
TIP 43: Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs 
This 2012 SAMHSA TIP gives a detailed description of medication-supervised treatment for addiction 
to opioids, including comprehensive maintenance treatment and medically supervised withdrawal. 
Screening, assessment, and administrative and ethical issues are also covered. This publication is due 
to be revised in 2017. 
Treatments for Substance Use Disorders 
This SAMHSA webpage provides a list of treatments and services for SUDs. 
Turn the Tide: Prescribing Opioids for Chronic Pain 
This Surgeon General’s pocket guide provides tools and resources to help clinicians decide whether 
to prescribe opioids and alternative treatments. It explains how to calculate dosage and 
medication changes. 
Vermont Child Health Improvement Program: Improving Care of Opioid-Exposed 
Newborns (ICON) 
This website provides easy access to Vermont state-based resources for health professionals 
caring for women with OUD. The Care Notebook & Construction Guide, a resource guide for 
mothers with OUD, can be customized to adjust to the procedures of individual clinics. 
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SECTION 1 
FACTSHEET # 
3 CHANGING PHARMACOTHERAPY 
DURING PREGNANCY 
CLINICAL SCENARIO 
A pregnant woman wishes to discuss changing her existing pharmacotherapy for 
OUD or wants to undergo medically supervised withdrawal from opioids. 
CLINICAL ACTION STEPS 
Maintaining Patient Stability Is Paramount 
Pregnancy alone is not an indication to change a woman who is stable on an opioid agonist to another 
opioid agonist. 
A pregnant woman who is experiencing cravings or withdrawal should have the effectiveness of her 
pharmacotherapy dose evaluated, and the dose possibly adjusted. Changing from one opioid agonist to 
another is rarely, if ever, warranted on the basis of cravings or unrelieved withdrawal alone. Cravings can 
occur even when OUD is well managed. Women who experience cravings despite optimal pharmacotherapy 
should receive additional behavioral interventions to address new or aggravated stressors. 
Experts do not agree on whether a woman on buprenorphine/naloxone for OUD who states the intention 
to become pregnant or is in the early stages of pregnancy should be switched from the combination 
buprenorphine/naloxone product to the buprenorphine-only product. Experts do agree that any 
change from buprenorphine/naloxone to the buprenorphine-only product or a decision to continue on a 
buprenorphine/naloxone product during pregnancy should be made only when informed by the patient’s 
specific needs and concerns. In either case, the woman’s fully informed consent should be obtained after 
review of the risks and benefits of the course of treatment selected. 
There is insufficient information about the safety of extended-release injectable naltrexone during 
pregnancy and the effects of intrauterine exposure to this medication. The expert panel did not agree on 
whether women on naltrexone should continue to use it during pregnancy. Women stable on naltrexone 
can be offered treatment with buprenorphine or methadone to prevent return to substance use if they 
choose to discontinue naltrexone injections. However, this transition must be carefully managed because 
patients on long-acting naltrexone are no longer opioid tolerant and the falling naltrexone level will result in 
increasing agonist activity over time during cross-titration. 
Medically Supervised Withdrawal Is NOT Recommended 
Pregnant women with OUD, with or without a history of pharmacotherapy for OUD, should be advised that 
medically supervised withdrawal from opioids is associated with high rates of return to substance use and is 
not the recommended course of treatment. 
If a pregnant woman on pharmacotherapy for OUD decides to move forward with medically supervised 
withdrawal, it can be conducted in a controlled setting in any trimester in the pregnancy if the benefits 
outweigh the risks. However, the woman should be informed that discontinuing pharmacotherapy is associated 
with high rates of return to substance use poorer fetal health and is not the recommended course of treatment. 
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SUPPORTING EVIDENCE AND CLINICAL CONSIDERATIONS 
Maintaining Patient Stability Is Paramount 
• Requests to change opioid agonist should prompt careful consideration. Significant problems such as
adverse drug reaction, intolerance of the current pharmacotherapy, or drug–drug interaction may require
consideration of changing opioid agonist. The anticipated benefit of any medication change must be
balanced against the risk of destabilization. Destabilization may result in return to substance use.
It is important to understand the pregnant woman’s motivations for requesting a change in her
medication. They may include pressure from family and friends, the cost of the medication, time
needed for other responsibilities vs. time needed to participate in treatment, fear of prejudice and
discrimination, or concerns for the developing fetus and later child development. She may feel that
her current medication is not working because she is experiencing previously unreported withdrawal
symptoms, cravings, or return to substance use. If this is the case, adjusting the dose of the current
medication is likely the most appropriate action along with increasing social and behavioral supports. 
If there is no indication of return to substance use, withdrawal symptoms, or cravings, identify the
underlying fears and pressures and help her strategize about how to manage them. Talk about the risk
of not receiving pharmacotherapy. If withdrawal is agreed on, create a safety plan to help prevent a
return to substance use and resume pharmacotherapy if return to substance use occurs or is likely. 
• Neonatal abstinence syndrome (NAS) expression and severity are not correlated with maternal
pharmacotherapy dose. In some cases, a woman may want to change or reduce her medication in
hopes of reducing the risk or severity of NAS in her infant. In a meta-analysis, Cleary et al. (2010) found
that the severity of NAS was unrelated to methadone dose and suggest that the practice of reducing
maternal methadone medication to protect the fetus is unwarranted. A similar finding was reported in
women taking buprenorphine during their pregnancy (Patrick et al., 2015).
Healthcare professionals can assure the pregnant woman that, to date, no evidence links the dose of either
methadone or buprenorphine with a number of measures of severity of NAS, such as peak NAS score; total
amount of infant treatment medication (morphine);
length of neonatal hospital stay; duration of
pharmacotherapy for NAS; estimated gestational
age at delivery; Apgar score at 5 minutes; and
neonatal physical parameters of head circumference,
length, and birth weight (Jones, Jansson, O’Grady, &
Kaltenbach, 2013; Jones et al., 2014; Lund et al., 2013). 
• Healthcare professionals should discuss in detail
the risk of return to substance use if the pregnant
woman chooses to change her pharmacotherapy
during her pregnancy. If changing agonist
therapy is imperative (e.g., the pharmacotherapy
is no longer accessible), the woman should be
informed that any change in medication represents
a period of vulnerability to return to substance
use. Behavioral and recovery supports should
be maximized. Changing from buprenorphine to
methadone can be accomplished using a standard
approach to methadone induction. Changing from
FACTSHEET TO REVIEW 
• Factsheet #2: Initiating Pharmacotherapy 
for Opioid Use Disorder for information on 
treatment options 
• Factsheet #6: Addressing Polysubstance Use 
During Pregnancy for discussion on tobacco 
use cessation 
• Factsheet #9: Screening and Assessment 
for Neonatal Abstinence Syndrome for 
information on the potential for NAS with 
pharmacotherapy for OUD 
• Factsheet #10: Management of 
Neonatal Abstinence Syndrome, Exhibit 
Factsheet#10.2, for factors that influence NAS 
expression, severity, and pharmacological and 
nonpharmacological treatment options 
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methadone to buprenorphine requires that the methadone be tapered, and several days of
abstinence may be required before therapy with buprenorphine is initiated (Jones, Suess,
Jasinski, & Johnson, 2006). If, as the methadone dose is lowered, the patient begins to
experience withdrawal that interferes with her functioning or leads to return to substance
use, it is advisable to discontinue the taper and restabilize her on methadone. The added
risk of return to substance use during pregnancy cannot be overstated. 
Whatever the reasons for changing pharmacotherapy, discuss them and help the woman
understand why a medication change may—or may not—be possible. 
• Positions are evolving on using the combination product (buprenorphine/naloxone)
throughout the pregnancy, rather than transitioning the pregnant woman to the
buprenorphine-only product for the duration of her pregnancy. Historically, pregnant
women who had been on the combination product (buprenorphine/naloxone) were
transitioned to the buprenorphine-only product for the remainder of their pregnancy.
One reason for the change in pharmacotherapy was to protect the fetus from exposure
to naloxone. Another reason was that a woman who is not stable and who injects the
combination product at any time (prenatal or postnatal) can have induced precipitated
withdrawal, owing to the intravenous bioavailability of naloxone (Park, Meltzer-Brody, &
Suzuki, 2012). 
Evidence is now building that newborn outcomes are not negatively affected by using the combination
product during gestation and that pregnant women may not need to transition to the buprenorphine-only
product during pregnancy to protect the fetus (Debelak, Morrone, O’Grady, & Jones, 2013; Dooley et al.,
2016; Gawronski et al., 2014; Jumah et al., 2016; Lund et al., 2013; Wiegand et al., 2015). Pregnant women and
their healthcare professionals should make a decision with regard to the use of the buprenorphine/naloxone
combination product in the context of pregnancy based on the benefit vs. the risk to the dyad. 
Medically supervised withdrawal is associated 
with a high rate of return to substance use, 
putting both the pregnant woman and the 
fetus at risk. Medically supervised withdrawal 
should be avoided whenever possible. Factsheet 
#6: Addressing Polysubstance Use During 
Pregnancy provides more information on return 
to substance use. 
Medically Supervised Withdrawal Is NOT Recommended 
• Pregnant women with OUD should not be encouraged to withdraw from pharmacotherapy for OUD
during their pregnancy or shortly after delivery. Pharmacotherapy is the recommended standard of care,
and it is the best option for a pregnant woman with OUD. Remaining on pharmacotherapy will help her
avoid a return to substance use, which has the potential for overdose or death. A decision to withdraw from
pharmacotherapy should be made with great care on a case-by-case basis, and additional supports such as
close observation should be put in place. 
Withdrawal of pharmacotherapy for OUD and tapering during pregnancy have a high failure rate (American
Society of Addiction Medicine, 2015; Jones, O’Grady, Malfi, & Tuten, 2008; Substance Abuse and Mental
Health Services Administration [SAMHSA], 2014; World Health Organization, 2014), and expectant women
with OUD often return to opioid misuse and its attendant risks (e.g., Kaltenbach, Berghella, & Finnegan,
1998; Mattick, Breen, Kimber, & Davoli, 2009). A
Norwegian study (Ravndal & Amundsen, 2010) 
of the mortality risk after inpatient medically 
supervised withdrawal in a nonpregnant population 
found that the elevated risk of dying from an 
overdose within the first 4 weeks of discharge was 
so dramatic that prevention measures should be 
instituted. 
Return to substance use exposes the fetus to the
stress of ongoing drug use and other maternal
factors related to active SUD. However, some studies support the idea that at least a minority of women are
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successful at completing medically supervised
withdrawal and remaining in drug-free treatment
until delivery (e.g., Lund et al., 2012). 
Despite the concern about return to opioid use,
some women will want to try medically supervised
withdrawal, or their community resources will
only support medically supervised withdrawal.
If medically supervised withdrawal is attempted,
healthcare professionals should anticipate
providing the pregnant woman with intensive
behavioral and social supports such as those
available in residential treatment centers, which
provide close monitoring and support to avoid
return to substance use. 
Other Evidence/Considerations 
• The healthcare professional should discuss
other actions the pregnant woman can take
to improve the health of the fetus and herself.
Several actions are available to the pregnant
woman on pharmacotherapy for OUD to help
the developing fetus and her own health.
The pregnant woman should give up or limit
cigarettes, alcohol, and drugs. She should be
provided with tobacco use cessation treatment
services (Minnes, Lang, & Singer, 2011; SAMHSA,
2011) and other substance use disorder (SUD)
treatment services to accomplish this.
When discussing options to maximize the health
of the pregnant woman and infant, remind the
pregnant woman that she CAN take several steps
to protect her health and the fetus: 
• She can enroll in a tobacco cessation program, 
and participate in treatment programs for 
comorbid alcohol, other substance use disorders 
as needed. 
• She can maintain a healthy weight and take 
prenatal vitamins as prescribed. 
• She can learn how NAS is diagnosed and treated. 
• She can learn which nonpharmacological
interventions can reduce the incidence and
severity of NAS. 
• She can inform and prepare herself for 
breastfeeding. 
• She can enroll in parenting classes 
recommended by her prenatal healthcare 
professional. 
Daily interactions and observed dosing should 
be considered possible behavioral interventions 
regardless of whether the woman is receiving 
buprenorphine or methadone. The level of care 
should be tailored to the woman’s response to 
therapy and not necessarily tied to a specific 
medication. 
WEB RESOURCES ON THIS TOPIC 
Advisory: Tobacco Use Cessation During Substance Abuse Treatment Counseling 
This 2011 SAMHSA document offers SUD counselors an introduction to tobacco use
cessation during SUD treatment. It discusses screening and effective treatment approaches
to quitting, including cessation medications and practical and supportive counseling. 
Drug Interaction Checkers: 
• Buprenorphine Interaction Checker (Medscape)
• HIV/AIDS Medication Interactions (U.S. Department of Health and Human Services) 
• Methadone Interaction Checker. Medscape 
• Naltrexone Interaction Checker. Medscape 
Individuals can type in the name of any drug and determine whether there is an interaction
with methadone, buprenorphine, or naltrexone or with HIV/AIDS medications.
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Smokefree.gov 
This tobacco cessation program is supported by the National Cancer Institute and can be accessed on mobile 
and online platforms. It provides a variety of ways to personalize support through smartphone apps, text 
messaging, websites, social media accounts, and access to trained counselors. 
Smoking and Mental Illness Among Adults in the United States 
This is an updated Center for Behavioral Health Statistics and Quality report detailing the rate of cigarette 
smoking in adults with mental illness vs. adults without mental illness and the differences in tobacco cessation 
rates between the two groups. It is based on data from SAMHSA’s 2014 National Survey on Drug Use and 
Health (NSDUH) report. The SAMHSA NSDUH report is an annual survey of 68,000 people ages 12 and older 
on a wide range of behavioral health issues. 
Treatment Improvement Protocol (TIP) addressing Medications for Opioid Use Disorder. In Press. 
SAMHSA will release a new TIP on addressing medications for opioid use disorder in early 2018. 
Please check the SAMHSA Store for the new TIP. 
TIP 43: Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs 
This 2012 SAMHSA TIP gives a detailed description of medication-supervised treatment for addiction to 
opioids, including comprehensive maintenance treatment and medically supervised withdrawal. Screening, 
assessment, and administrative and ethical issues are also covered. This publication is due to be revised in 2017. 
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SECTION 1 
FACTSHEET # 
4 
MANAGING 
PHARMACOTHERAPY 
OVER THE COURSE OF 
PREGNANCY 
CLINICAL SCENARIO 
A pregnant woman treated with pharmacotherapy for opioid use disorder (OUD) 
is experiencing withdrawal or cravings. 
CLINICAL ACTION STEPS 
Need for Periodic Adjustments of Pharmacotherapy for OUD 
A pregnant woman will likely need periodic adjustments to the dose of her pharmacotherapy in response to 
the physiological changes of pregnancy to prevent reemergence of withdrawal symptoms. The behavioral 
interventions provided may also need to be increased or adjusted to prevent return to substance use 
and promote effective strategies for coping with cravings and triggers. By offering the pregnant woman 
information and the opportunity to discuss her concerns, healthcare professionals can support her in arriving 
at a treatment plan that is effective both in preventing withdrawal or return to substance use and in bringing 
about abstinence from other substances, especially tobacco. 
Dose of Pharmacotherapy Does NOT Affect Degree of Neonatal Abstinence Syndrome (NAS) 
The pregnant woman will need reassurance that the amount or dose of the medication used to treat her OUD is not 
associated with the degree of NAS the baby may experience. However, she must also be informed that tobacco use 
is associated with the degree of NAS the baby may experience. 
Section 1: Factsheet 4 
SUPPORTING EVIDENCE AND CLINICAL CONSIDERATIONS 
Need for Periodic Adjustments of Pharmacotherapy for OUD 
• Medication metabolism rate increases as the pregnancy progresses. As the pregnancy 
progresses, doses of methadone typically need adjusting upward, particularly in the third 
trimester (Albright et al., 2011; Jones et al., 2008). These dose increases are needed because 
the rate of methadone clearance is increased when progesterone levels are elevated during 
pregnancy. The increased clearance rates result in decreased blood levels of methadone 
(Park, Meltzer-Brody, & Suzuki, 2012). Dividing the dose of methadone in half (split dosing) 
can help manage the impact of metabolic changes on the methadone level for women in the 
third trimester of pregnancy (Bogen et al., 2013; Jansson et al., 2008). 
Pregnant women using buprenorphine typically have a similar need for increased dose in the 
third trimester (Jones et al., 2005). No standardized approach to dose increases with either 
methadone or buprenorphine can be recommended, because these adjustments need to be 
individualized based on patient assessment. 
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Dose of Pharmacotherapy Does NOT Affect Degree of NAS 
• NAS expression and severity are not correlated with maternal pharmacotherapy dose. A woman may
want to change or reduce her medication in hopes of reducing the chance or severity of NAS in her infant.
Randomized trials of the medications have found no relationship between methadone or buprenorphine
dose and outcomes such as NAS peak score; total morphine needed to treat NAS; neonatal hospital stay
duration; number of days that pharmacotherapy was given for NAS; estimated gestational age at delivery;
Apgar score at 5 minutes; and neonatal head circumference, length, and weight at birth (Jones, Jansson,
O’Grady, & Kaltenbach, 2013; Jones et al., 2014; Lund et al., 2013).
Other Evidence and Considerations 
• Counseling can encourage and motivate women to continue with treatment, while enhancing coping
skills and reducing the risk of a return to substance use. Counseling helps people learn how to make
healthful decisions; handle setbacks, triggers, and stress; and move forward with their lives. A pregnant woman
using pharmacotherapy for OUD should also have access to and be encouraged to talk with a behavioral
health professional, either one-on-one or in a group with others in treatment. Behavioral health treatments may
include cognitive behavioral therapy (CBT), family therapy, and contingency management (CM) to name just
a few. Additional information on these therapies can be found at SAMHSA’s Behavioral Health Treatments
and Services website. Optimally, the woman’s care would be provided by a coordinated team of healthcare
professionals including OB/GYNs, substance use disorder (SUD) treatment specialists, nurses, case managers,
and peer recovery coaches. 
• SAMHSA recommends that people seeking
recovery from substance use have access to
peer support specialists. Pharmacotherapy
can significantly stabilize patients, but patients
may still have unmet needs for long-term
recovery (Chang, Carroll, Behr, & Kosten, 1992).
An example of how to meet these needs is to
connect patients with peer support specialists
(PSS) in the community. PSS are individuals who
are in recovery and have undergone training and
certification to ensure that they operate within the
bounds of sound practice, especially in terms of
privacy and confidentiality (Chinman et al., 2014).
PSS can help others in recovery from a serious
mental illness, an SUD, or co-occurring behavioral
health and substance use disorders, across the
treatment continuum (SAMHSA, 2009). The PSS
approach is relatively new, and evidence about
its effectiveness is still limited (Barlow et al., 2015;
Sanders, Trinh, Sherman, & Banks 1998). 
In some states, Medicaid or other payers reimburse
for PSS services; in some instances, PSS staff may
be volunteers. In other circumstances they are
hired by healthcare organizations, such as hospitals
and rehabilitation centers, inpatient and outpatient
facilities, day treatment programs, and community
programs (Salzer, Schwenk, & Brusilovskiy, 2010).
RESOURCE TO REVIEW 
A Collaborative Approach to the Treatment of
Pregnant Women With Opioid Use Disorders:
Practice and Policy Considerations for Child
Welfare, Collaborating Medical, and Service
Providers (SAMHSA, 2016). This document
provides information on treating pregnant women
with OUD, summarizes guidelines adopted by a
variety of professional organizations, and presents
a framework for organizing community efforts. 
It provides a coordinated, multisystem approach
grounded in early identification and intervention to
assist child welfare, medical, SUD treatment, and
other systems in supporting families. 
Recovery requires more than pharmacotherapy.
SAMHSA has established a working definition of
recovery that defines recovery as a process of
change through which individuals improve their
health and wellness, live self-directed lives, and
strive to reach their full potential. Recovery is built
on access to evidence-based clinical treatment
and recovery support services for all populations.
To optimize chances of achieving full recovery,
SAMHSA recommends having the individual
engage in a variety of behavioral therapies (e.g.,
CBT, CM, family therapy) to determine the best fit.
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• Many people seek support from
organizations known as mutual-aid,
mutual-support, or 12-step programs.
These organizations, which are generally
set up and run by volunteers, can
provide a supportive environment that
helps some people maintain recovery.
Women on pharmacotherapy for OUD
are encouraged to seek out programs
where pharmacotherapy is accepted as
complementary to traditional 12-step
treatment programs and are supportive
of using pharmacotherapy. 
•
FACTSHEETS TO REVIEW 
Factsheet #3: Changing Pharmacotherapy During
Pregnancy for more information on changes the pregnant
woman can make to ensure a healthy pregnancy 
• Factsheet #6: Addressing Polysubstance Use During
Pregnancy for additional discussion on tobacco use
cessation 
• Factsheet #10: Management of Neonatal Abstinence
Syndrome, Exhibit Factsheet#10.2, for factors that
influence NAS expression, severity, and pharmacological
and nonpharmacological treatment options 
WEB RESOURCES ON THIS TOPIC 
A Collaborative Approach to the Treatment of Pregnant Women With Opioid Use Disorders: Practice and
Policy Considerations for Child Welfare, Collaborating Medical, and Service Providers
This document provides information on treating pregnant women with OUD, summarizes guidelines adopted
by a variety of professional organizations, and presents a framework for organizing community efforts. It
provides a coordinated, multisystem approach grounded in early identification and intervention to assist child
welfare, medical, SUD treatment, and other systems in supporting families. 
Core Competencies for Peer Workers in Behavioral Health Services
On this website, SAMHSA defines peer workers and recovery and lists several categories of core competencies
for peer workers. 
Methadone Treatment for Pregnant Women
This SAMHSA brochure provides basic information on methadone treatment, the possibility and treatment of
infant withdrawal, breastfeeding on methadone, the consequences of continued drug use, and birth control. 
National Alliance for Medication Assisted Recovery 
This organization is led by people in recovery and supports all pathways to recovery, including medication.
Recovery Community Centers offer peer support and opportunities to socialize with others in recovery.
Treatment Improvement Protocol (TIP) 35: Enhancing Motivation for Change in Substance Abuse Treatment 
This SAMHSA TIP is intended to help clinicians influence the change process in their patients by incorporating
motivational interventions into SUD treatment programs. The document describes different motivational
interventions that can be used at all stages of change. 
TIP 40: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction 
This 2007 SAMHSA TIP offers practice guidelines to help physicians make decisions about using buprenorphine
to treat opioid addiction. It includes information on patient assessment; protocols for opioid withdrawal; and the
treatment of pregnant women, teens, and polysubstance users. This publication is due to be revised in 2017. 
TIP 43: Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs
This 2012 SAMHSA TIP gives a detailed description of medication-supervised treatment for addiction to
opioids, including comprehensive maintenance treatment and medically supervised withdrawal. Screening,
assessment, and administrative and ethical issues are also covered. This publication is due to be revised in 2017.
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SECTION 1 
FACTSHEET # 
5 
PREGNANT WOMEN WITH 
OPIOID USE DISORDER AND
COMORBID BEHAVIORAL 
HEALTH DISORDERS 
CLINICAL SCENARIO 
A pregnant woman with opioid use disorder (OUD) and comorbid behavioral
health disorders needs help managing these conditions. 
CLINICAL ACTION STEPS 
Comorbid behavioral health disorders are common and may also require pharmacotherapy 
A woman with comorbid behavioral health disorders that would typically require her to take benzodiazepines, selective
serotonin reuptake inhibitors (SSRIs), amphetamines, and/or other pharmacotherapies may need to continue these
medications during her pregnancy. Decisions regarding use of such pharmacotherapy must balance the pregnant
woman’s mental health needs with the impact of psychotropic medications on the developing fetus. Healthcare
professionals should help her understand the risks and benefits of continuing vs. discontinuing such pharmacotherapy
to her baby, her physical health, and her health and recovery, with input from specialists as appropriate. 
Healthcare professionals should also discuss whether any of the other needed medications carry with them a risk
of producing a specific withdrawal syndrome, impact the expression or severity of neonatal abstinence syndrome
(NAS) due to opioid exposure, may affect the infant’s development, or have consequences for breastfeeding. 
SUPPORTING EVIDENCE AND CLINICAL CONSIDERATIONS 
Comorbid behavioral health disorders are common and may also require 
pharmacotherapy 
• Depression and other psychiatric disorders are common among women with OUD. Research has found
that the majority of women entering treatment for OUD have a history of sexual assault, trauma, or domestic
violence and/or come from homes where their caregivers used drugs (Committee on Healthcare for Underserved
Women, American Society of Addiction Medicine [ASAM], & American College of Obstetricians and Gynecologists
[ACOG], 2012, 2017; Covington, 2008). Therefore, when obtaining a psychosocial history to evaluate pregnant
women for OUD, follow the Substance Abuse and Mental Health Services Administration’s (SAMHSA’s) screening,
brief intervention, and referral to treatment (SBIRT) practice and screen them for trauma, depression, anxiety, and
tobacco and alcohol use. Maintaining a caring and nonjudgmental approach to such screening may produce the
most inclusive and accurate disclosure (ASAM, 2015; Banderali et al., 2015; McLafferty et al., 2016).
• Prescribers need to keep in mind possible drug interactions with pharmacotherapies for OUD. Research
on adult males and nonpregnant women finds that when pharmacotherapies for OUD are concurrently used
with psychotropic medications, problematic pharmacokinetic drug interactions may occur. Examples include
the potential for respiratory depression when benzodiazepines are combined with either methadone or
buprenorphine, prolonged QTc when SSRIs or tricyclic antidepressants are concurrently used with methadone,
and serotonin syndrome when monoamine oxidase inhibitors are used with either buprenorphine or methadone
(reviewed in Saber-Tehrani, Bruce, & Altice, 2011).
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In pregnant women, these interactions may be further compounded by a cascade of physiological changes such as
increased hepatic and renal blood flow and increased plasma volume. These changes may alter medication needs
and exacerbate drug interactions; however, few studies address these issues (McCance-Katz, 2011). 
• Selecting the best management for pregnant women who have OUD and concurrent depression and/or anxiety
is a complex decision. Healthcare professionals are aware of the consequences of unaddressed depression
for mother–infant interactions, the pregnant woman’s own health and well-being, and the baby’s development
(Committee on Healthcare for Underserved Women, ASAM, & ACOG, 2012; Yonkers et al., 2009). However, the
impact on the fetus and newborn of chronic exposure to multiple psychotropic drugs is not fully understood at this
time. This lack of understanding extends to whether the infant’s development will be impacted.
Although healthcare professionals and patient decision-making about the use of antidepressants and
anxiolytics during pregnancy is complex given the real and possible risks of in utero exposure including
increased severity of NAS, these risks must be
weighed against the risks of untreated depression
or anxiety, their contribution to risk of return to
substance use and the risks of abrupt cessation of
either type of medication. 
• Some antidepressants, anticonvulsants, and
anxiolytics may impact the expression and severity
of NAS. Many psychiatric medications are associated
with specific withdrawal syndromes in the newborn.
For example, infants whose mothers received SSRIs
during pregnancy are at risk for manifesting clinical
signs of drug toxicity including NAS during their first
week of life (Chisolm & Payne, 2016; Committed on
Healthcare for Underserved Women, ASAM, & ACOG,
2012; Hudak, Tan, American Academy of Pediatrics
[AAP] Committee on Drugs, & AAP Committee on
Fetus and Newborn, 2012; Patrick et al., 2015).
NAS due to in utero exposure may also be
exacerbated when a pregnant woman takes
antidepressants or anxiolytics (Chisolm & Payne,
2016; Kaltenbach et al., 2012). There has also been a report that gabapentin, an anticonvulsant, can
exacerbate NAS (Fujii et al., 2013). Both depression and continuous use of SSRIs during pregnancy are
associated with premature birth (Weisner et al., 2009).
Expectant mothers receiving treatment with buprenorphine or methadone who use benzodiazepines should 
work with a psychiatrist to stabilize their anxiety and reduce their use of benzodiazepines if possible (Lee, 
Kresina, Campopiano, Lubran, & Clark, 2015; World Health Organization, 2014), with a gradual taper of a 
long-acting benzodiazepine (e.g., diazepam) toward the goal of being benzodiazepine free at delivery. 
The mother’s stability and well-being should not be adversely impacted in service of achieving this goal 
however as unrelieved anxiety is associated with return to substance use and may directly have adverse 
effects on the fetus. Infants persistently exposed to benzodiazepines in utero should be expected to 
manifest a benzodiazepine withdrawal syndrome and managed accordingly. 
• The dose of individual psychiatric medications should be evaluated for possible adjustment in the third
trimester. Just as with opioid agonists, the pharmacokinetic changes and increased volume of distribution
associated with the third trimester of pregnancy can lead to decreased serum levels, so it may be necessary
to increase some antidepressant medications in the third trimester to keep depression from worsening or
recurring (Sit, Perel, Helsel, & Wisner, 2008; Sit, Perel, Luther, & Wisner, 2010). 
Section 1: Factsheet 5 
RESOURCE TO REVIEW 
A significant body of literature exists
on treating and managing co-occurring
depression and anxiety in pregnant and
postpartum women. However, little has
been published on treating and managing 
co-occurring behavioral health problems in
pregnant women who have OUD. What is 
known about the impact of these conditions
and their management during pregnancy should
inform decision making for pregnant women
with OUD as well. Figures 4 and 5 in Chisolm
and Payne (2016) provide a recent review of the
use of psychotropic drugs during pregnancy.
See Factsheet #15: Maternal Discharge
Planning for more information on postnatal
comorbid mental disorders.
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Other Evidence and Considerations 
• Discrimination and bias against people who live with serious
mental illness or OUD are widespread—not only among
the general public, but among healthcare professionals,
community leaders, and the media. Discrimination is the
unfair treatment of people for any number of reasons, whereas
bias involves stigmatizing attitudes (Botticelli & Koh, 2016;
Clement et al., 2013). Bias and discrimination stem from similar
roots: misperceptions, misunderstandings, and misinformation.
Individuals who have a substance use disorder (SUD) or severe
mental illness may have their own negative perceptions of their
illness, which could be based on personal experiences with others—including friends and family—or inaccurate
public information. The potent combination of discrimination and bias may compound the reluctance and
fear that pregnant women with OUD or severe mental illness often experience when deciding whether to seek
help for these disorders. Medical care should never be denied to pregnant women with OUD or behavioral
health disorders. Healthcare professionals should take great care that program policies and procedures do
not inadvertently reinforce these fears and reluctance (SAMHSA, 2016). Healthcare professionals are advised
to review training materials produced by the U.S. Department of Health and Human Services and SAMHSA
to address these issues, as well as Changing the Language of Addiction for specific recommendations on
terminology to use when referring to individuals with SUD. 
Combining benzodiazepines with either
methadone or buprenorphine is not
recommended because of the risk of
enhanced respiratory depression (ASAM
2015; Lee et al., 2015). See Factsheet #6:
Addressing Polysubstance Use During
Pregnancy for additional information 
on how to address benzodiazepine 
misuse during pregnancy. 
WEB RESOURCES ON THIS TOPIC 
Current Understanding of the Interaction of Benzodiazepines and Buprenorphine
This Providers’ Clinical Support System continuing medical education course reviews the dangers of combining
benzodiazepines and buprenorphine.
General Principles for the Use of Pharmacological Agents to Treat Individuals with Co-Occurring Mental
and Substance Use Disorders
This SAMHSA document provides information to assist in planning, delivering, and evaluating pharmacological
approaches to supporting the recovery of individuals with co-occurring mental and substance use disorders. 
Moms’ Mental Health Matters
The National Institute of Child Health and Human Development website provides information and materials for
new mothers and clinicians, including action plans to treat postpartum depression. 
SBIRT: Screening, Brief Intervention, and Referral to Treatment
This SAMHSA webpage provides information and links to resources about SBIRT that clinicians can use to
identify, reduce, and prevent alcohol and illicit drug problems.
Treating for Two 
The Centers for Disease Control and Prevention’s Treating for Two initiative aims to improve the health of
women and babies by identifying the safest treatment options for managing common conditions before and
during pregnancy. The program focuses on all drugs, not just illicit drugs, and pharmacotherapy for recovery. 
Use of Psychiatric Medications During Pregnancy and Lactation
This ACOG document provides general recommendations and conclusions on the use of psychiatric
medications by pregnant and breastfeeding women with mental disorders. 
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SECTION 1 
FACTSHEET # 
6 ADDRESSING POLYSUBSTANCE USE 
DURING PREGNANCY 
CLINICAL SCENARIO 
A pregnant woman with opioid use disorder (OUD) requests help on (1) a return to opioid use; (2) her use
of alcohol, cocaine, cannabis, or tobacco; (3) her comorbid misuse of prescribed medications, including
benzodiazepines, amphetamines, or other pharmacotherapies, whether licitly or illicitly obtained; and (4) the
impact of these medications and other substances on her health and that of the fetus. 
CLINICAL ACTION STEPS 
Return to Opioid Use During Pregnancy 
A pregnant woman on pharmacotherapy for OUD who returns to opioid use should have the effectiveness of the
dose of her medication, and possibly the choice of medication, evaluated. She may also benefit from receiving a
higher level of care, such as residential treatment, as long as her pharmacotherapy is not disrupted. A pregnant
woman who is experiencing cravings or withdrawal should be evaluated for a possible medication dose or
schedule change to prevent a possible return to substance use. Changing from one opioid agonist to another is
rarely, if ever, warranted on the basis of cravings or unrelieved withdrawal alone. 
Changing the type of pharmacotherapy (buprenorphine to methadone or vice versa) cannot be specifically
recommended or advised against based on current evidence but may be considered if the interventions
recommended above are fully implemented but unsuccessful, particularly if the woman reports continued cravings in
the absence of unrelieved withdrawal and is receiving maximum behavioral and social supports. Most importantly, the
woman should be reassured and encouraged to remain in treatment and work to stop the opioid use. 
Return to Other Substance Use During Pregnancy 
A pregnant woman on pharmacotherapy for OUD who has concurrent other substance use or who returns
to use of one or more other substances should receive (1) behavioral interventions targeting the use of the
substance(s) and (2) pharmacotherapy, if available and safe in pregnancy for the substance(s) she is using. 
The woman experiencing a return to other substance use may also benefit from a higher level of care (e.g.,
residential treatment) provided her pharmacotherapy is not disrupted. 
Polysubstance Use Concerns for Pregnant Women and Infants 
Women who misuse benzodiazepines, amphetamines, or other pharmacotherapies—whether licitly or illicitly
obtained—or who have a substance use disorder (SUD) involving alcohol, cocaine, cannabis, or tobacco should
receive education on, and have the opportunity to discuss, the known or suspected impact of prenatal exposure
to these substances on the fetus and their own health. 
A woman with an SUD should be offered appropriate evidence-based behavioral, pharmacological, and social
services to support the discontinuation of these substances, especially nicotine and alcohol. The healthcare
professional can take this opportunity to discuss the known associated risk of neonatal abstinence syndrome
(NAS), developmental problems, and impact on breastfeeding when using these substances. 
45 Section 1: Factsheet 6 
   
 
 
 
 
 
 
 
 
 
 
   
  
 
 
 
 
 
 
 
 
   
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUPPORTING EVIDENCE AND CLINICAL CONSIDERATIONS 
Return to Opioid Use During Pregnancy 
• A return to substance use is a common occurrence among people with an SUD. Returning to substance
use is a common occurrence with OUD especially early in treatment when the medication dose is still being
stabilized and the woman is acquiring basic skills to cope with triggers and cravings. Given that returning to
substance use is predictable and common, doing so should not be viewed as a setback or failure, but as an
indication of the need to reassess the patient and adjust the treatment plan. Such adjustments may include
engaging community and behavioral supports. Many people find that, for lasting recovery, they need to control
stress, avoid places and situations where they once used drugs (triggers), and even end relationships with
people involved with drugs. When making these changes, people in recovery may find that peers—such as other
mothers in recovery who experienced a pregnancy affected by OUD—can help them in a way that healthcare
professionals cannot. Limited but promising research supports the role of peers who are in recovery from an SUD
(Barlow et al., 2015; Sanders, Trinh, Sherman, & Banks, 1998). Personal safety and adequate food and housing are
also essential to both short and long-term recovery. 
• Medication metabolism rate increases as the
pregnancy progresses. Dividing the dose of
methadone from once daily to twice daily (split
dosing) takes advantage of the long-acting
properties of methadone to help manage the
impact of metabolic changes on the methadone
level for women in the third trimester of pregnancy.
Metabolism is accelerated during pregnancy resulting
in larger clearances of medications (Albright et al.,
2011; Bogen et al., 2013; Jansson et al., 2008; Jones et
al., 2008; Park, Meltzer-Brody, & Suzuki, 2012). 
Pregnant women treated with buprenorphine
typically have a similar need for increased dose
in the third trimester (Jones et al., 2005). No
standardized approach to dose increases with
either methadone or buprenorphine can be
recommended, because these adjustments need
to be tailored to each patient. 
Return to Other Substance Use 
During Pregnancy 
• Many people in treatment or recovery return to
substance use one or more times before being
able to remain free of substance use. The risk
of return to substance use is highest in the first
6 to 12 months after stabilization is achieved
and then diminishes gradually over the years. A
return to use of depressant drugs (e.g., alcohol,
benzodiazepines) is highly concerning given the
risk for respiratory depression when combined
with opioid agonist therapy. Use of stimulants (e.g.,
Patients and healthcare professionals must learn
to recognize that, although return to substance
use is discouraging, it is not a failure. People
who return to substance use often reestablish a
substance-free lifestyle, continue to participate
in treatment, and achieve long-term recovery.
Healthcare professionals and programs should
not view a woman’s return to substance use as a
reason to discontinue treatment. In fact, efforts to
maintain the woman’s engagement in treatment
should be redoubled in these circumstances. 
As the pregnancy progresses, doses of 
methadone typically need adjusting upward, 
particularly in the third trimester. Dividing 
the dose into a twice daily schedule may also 
help keep the methadone blood levels clinically 
therapeutic. Any adjustment of dose or schedule 
needs to be based on evaluation of the patient. 
Return to substance use is rarely caused or 
triggered by a single factor. It is more often 
the result of an interaction of physiological and 
environmental factors and is best seen as a 
dynamic process in which the patient’s strengths 
and vulnerabilities are affected by other 
external and internal factors (SAMHSA, 2014). 
Consequently the therapeutic response needs to 
encompass an array of services. 
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methamphetamine, cocaine) may destabilize and
cause erratic behavior that interferes with effective
engagement in previously effective treatment and
services. Healthcare professionals may need to
increase the intensity of other treatments if return
to use appears imminent (SAMHSA, 2014). 
Polysubstance Use Concerns for 
Pregnant Women and Infants 
• Decades of evidence of the dangers of smoking
during pregnancy document its adverse effects
on pregnancy, fetal development, and postnatal
infant outcomes. A tobacco use cessation program
is one of the most important therapies to begin
when a woman enters OUD treatment. Between
88 and 95 percent of pregnant women receiving
pharmacotherapy for OUD continue to smoke
(Akerman et al., 2015), and smoking cigarettes is
known to cause more severe NAS and have lasting
developmental effects. Heavy daily smoking in
pregnant women is associated with compromised
birth outcomes such as lower birth weight, small birth
length, lower Apgar scores, and increased lengths
of hospital stays and number of days medicated
for NAS (Jones et al., 2013; Patrick et al., 2015;
Winklbaur et al., 2009). Individual reports document
ways to reduce nicotine consumption in pregnant
women with OUD, but insufficient evidence exists
for recommending one tobacco cessation treatment
approach over another (Akerman et al., 2015). 
• Women with OUD frequently misuse other
substances that can exacerbate NAS. Nicotine and
benzodiazepines may worsen the symptoms of NAS
(Bagley, Wachman, Holland, & Brogly, 2014; Bakstad,
Sarfi, Welle-Strand, & Ravndal, 2009; Jones et al.,
2013; Kaltenbach et al., 2012). Healthcare professionals
should provide behavioral support to reduce, and
ideally stop, the misuse of other substances. Among
the interventions that reduce and end other substance use are cognitive behavioral approaches—including
motivational interviewing and dialectical behavioral therapy—and contingency management. The World Health
Organization’s (WHO’s) Guidelines for the Identification and Management of Substance Use and Substance
Use Disorders in Pregnancy extensively discusses additional interventions to reduce substance use (WHO, 2014).
A variety of evidence-based treatments can be offered to pregnant women, regardless of the substance
use disorder (SUD). These include providing treatment in the early stages of pregnancy, and offering
residential or outpatient treatment for significant lengths of time. Recently, motivational interviewing and
contingency management, with a focus on the mother-infant dyad and integration with child protective
services and the courts have been added to the list of possible approaches (Lester & Twomey, 2008).
Note that it is recommended that these services be offered with simultaneous access to child care and
parenting classes. Exhibit FS #6.1 summarizes treatment approaches for several SUDs. 
Section 1: Factsheet 6 
Factors to consider when making a treatment plan
if a pregnant woman returns to substance use: 
• What environmental factors may have 
contributed to the return to substance use? 
Did use occur because others around her were 
using? Was she coerced to use? Under these 
circumstances, behavioral interventions may 
be more appropriate than dose increase. 
• At what stage of pregnancy is the woman? 
The later the pregnancy stage, the more likely 
the need for an increased pharmacotherapy 
dose or change in dosing schedule. 
• Are blood levels of the medication in a 
therapeutic range? 
• What other medication is she taking? Are there
any potential interactions that would change
the metabolism of the opioid medication that
are contributing to her return to substance use? 
• Are issues of personal safety or inadequate
food or housing contributing to the return to 
substance use? 
Should return to substance use occur, 
healthcare professionals can consider multiple 
options for treating it, including: 
• Examining social, medical, or behavioral factors
that contribute to the woman’s substance use. 
• Increasing or changing the intensity of
psychosocial services. 
• Assessing the effectiveness of current
pharmacotherapy. 
• Engaging a coordinated team of healthcare
professionals including obstetricians, nurses,
case managers, and peer recovery coaches.
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Exhibit FS #6.1: Management Options for SUDs Other Than OUD During Pregnancy 
Substance Treatment Approaches Comments References 
Alcohol • Withdrawal management: 
Benzodiazepine (e.g., diazepam) 
for medication-assisted 
withdrawal 
• Pharmacotherapy: 
• The US Food and Drug 
Administration approved 
naltrexone, disulfiram, and 
acamprosate to treat alcohol use 
disorder. 
• Psychosocial treatment during 
and after withdrawal 
• Alcohol is associated with fetal alcohol spectrum disorders 
and is the number one cause of preventable developmental 
delays in children. 
• In non-pregnant patients, behavioral interventions for 
risky/harmful alcohol use are an effective component of 
care. The effectiveness of these interventions has not been 
well studied in pregnant or postpartum women. 
Although pregnant women are counseled to cease drinking 
alcohol, little specific evidence-based guidance is available 
on how to manage alcohol withdrawal in pregnancy. 
Management should be based on alcohol withdrawal for 
non-pregnant women. 
• Alcohol withdrawal cannot be managed with behavioral 
therapies alone. A long-acting benzodiazepine similar to 
one that would be used with benzodiazepine detoxification 
can be used in addition to behavioral treatments. 
• No published studies have compared the safety or efficacy 
of disulfiram, acamprosate and naltrexone for alcohol use 
disorder in pregnant women. 
Bhat & Hadley, 2015 
Bhuvaneswar, Chang, 
Epstein, & Stern, 2007 
Christensen, 2008 
Whitlock, Polen, Green, 
& Klein, 2004 
DeVido, Bogunovic & 
Weiss, 2015 
Amphetamines/ 
Methamphetamines 
• Behavioral interventions such 
as cognitive behavioral therapy, 
contingency management, and 
motivational interviewing 
• There is no effective pharmacotherapy for withdrawal or 
maintenance of abstinence from stimulants. 
• Peer support is a helpful component of the treatment and 
recovery process 
Rawson, Gonzales, & 
Brethen, 2002 
Sherman, Sanders & 
Yearde, 1998 
Benzodiazepines • Gradual taper with a long-
acting benzodiazepine (e.g., 
diazepam) with the goal of being 
benzodiazepine free at birth 
• Psychosocial treatment during 
dose reduction and after taper is 
complete 
• A long-acting benzodiazepine similar to one that would be 
used with alcohol detoxification can be used in addition 
to behavioral treatments. For withdrawal, behavioral 
treatments alone are not sufficient. 
• May require long term treatment for underlying depression/ 
anxiety. 
McElhatton, 1994 
Cannabis • Behavioral interventions such as 
cognitive behavioral therapy and 
contingency management 
• There is no known effective pharmacotherapy. Budney, Roffman, 
Stephens, & Walker, 
2007 
Conner et al., 2016 
Cocaine • Behavioral interventions such 
as cognitive behavioral therapy, 
contingency management, and 
motivational interviewing 
• There is no known effective pharmacotherapy. 
• Peer support is a helpful component of the treatment and 
recovery process 
Farkas & Parran, 1993 
Sherman, Sanders & 
Yearde, 1998 
48 Section 1: Factsheet 6 
  
 
  
  
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
Substance Treatment Approaches Comments References 
Tobacco • Nicotine replacement therapy (NRT) 
• Bupropion
• Varenicline
•  Behavioral interventions such 
as cognitive behavioral therapy, 
contingency management, 
and especially voucher-based 
reinforcement 
• 5As (Ask, Advise, Assess, Assist,
Arrange) as a brief intervention 
• Data are very limited for NRT (nicotine gum, transdermal
nicotine patches, nicotine nasal spray, nicotine lozenge, and
nicotine inhaler), bupropion (Wellbutrin®), and varenicline
(CHANTIX®) use in pregnancy. These medications should be
used during pregnancy only if the benefit outweighs the
risk to the fetus. 
Cressman, Pupco, Kim,
Koren, & Bozzo, 2012; 
Forinash, Pitlick, Clark,
& Alstat, 2010;
Minnes, Lang, & Singer,
2011 
Osadchy, Kazmin, &
Koren, 2009 
• When caring for pregnant women with OUD, a
comprehensive plan of care should be developed
that lists each health and social problem, how
it will be addressed, and who is responsible
for addressing it. Evaluation for pharmacological
treatment for other SUDs should be provided in
conjunction with medical, social, and environmental
interventions (Fanucchi & Lofwall, 2016; SAMHSA,
2016). A comprehensive assessment of the patient
for medical conditions commonly associated
with substance use should be conducted. Such
an assessment includes examining the patient for
medical conditions linked to injection drug use such as
infective endocarditis, osteomyelitis, HIV, and hepatitis
B and C. Each risk or problem identified should have
a corresponding plan to address it and minimize its
lasting effect on the pregnant woman and the fetus. 
Other Evidence/Considerations 
• Maternal cannabis smoking is associated with
low birth weight infants. American College
of Obstetricians and Gynecologists (ACOG)
recommends against maternal cannabis use
(Committee on Obstetric Practice, ACOG, 2017)
as does a recent National Academies of Sciences,
Engineering, and Medicine (2017) report. Evidence
shows that maternal cannabis smoking induces low
birth weight in the infants (Fegusson, Horwood,
& Northstone, 2002; Gray et al., 2010; Gunn et al.,
2016). Low birth weight is also linked to maternal
use of nicotine, alcohol, cocaine, and opioid misuse
(Behnke, Smith, Committee on Substance Abuse,
& Committee on Fetus and Newborn, 2013; Gouin, Murphy, Shah, & Knowledge
Synthesis Group on Determinants of Low Birth Weight and Preterm Births, 2011). 
FACTSHEETS TO REVIEW 
RESOURCE TO REVIEW 
• Factsheet #5: Comorbid Psychiatric Illness 
During Pregnancy for additional resources 
on behavioral health treatment plans for 
pregnant women with OUD. 
• Factsheet #11: Breastfeeding Considerations 
for Infants at Risk for Neonatal Abstinence 
Syndrome, Exhibit FS #11.1 provides 
examples of when a mother with OUD 
might be advised to breastfeed and when 
breastfeeding is not recommended. 
A Collaborative Approach to the Treatment
of Pregnant Women With Opioid Use
Disorders: Practice and Policy Considerations
for Child Welfare, Collaborating Medical,
and Service Providers (SAMHSA, 2016). This 
document provides information on treating 
pregnant women with OUD, summarizes 
guidelines adopted by a variety of professional 
organizations, and presents a framework for 
organizing community efforts. It provides a 
coordinated, multisystem approach grounded 
in early identification and intervention to assist 
child welfare, medical, SUD treatment, and 
other systems in supporting families. 
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New research is expected on both maternal cannabis smoking and ingestion of 
tetrahydrocannabinol, the principal psychoactive component of cannabis, due to the 
legalization of cannabis use in several states. Until research on this issue is complete, 
pregnant and new mothers should be counseled to avoid cannabis (as well as alcohol 
and nicotine), for either recreational or medical purposes (Committee on Obstetric 
Practice, ACOG, 2017; Jansson, Bunik, & Bogen, 2015; Reece-Stremtan et al., 2015; 
Volkow, Compton, & Wargo, 2017; WHO, 2014). 
WEB RESOURCES ON THIS TOPIC 
Advisory: Tobacco Use Cessation During Substance Abuse Treatment Counseling 
This 2011 SAMHSA document offers SUD counselors an introduction to tobacco use cessation during 
SUD treatment. It discusses screening and effective treatment approaches to quitting, including cessation 
medications and practical and supportive counseling. 
Alcohol Alert: Alcohol and Other Drugs 
This National Institute on Alcohol Abuse and Alcoholism publication includes information on the epidemiology 
of alcohol and drug addiction, the genetics and shared factors of alcohol and drug use disorders, challenges to 
diagnosing SUDs, and addiction terminology. 
A Collaborative Approach to the Treatment of Pregnant Women With Opioid Use Disorders: Practice and 
Policy Considerations for Child Welfare, Collaborating Medical, and Service Providers 
This document provides information on treating pregnant women with OUD, summarizes guidelines adopted 
by a variety of professional organizations, and presents a framework for organizing community efforts. It 
provides a coordinated, multisystem approach grounded in early identification and intervention to assist child 
welfare, medical, SUD treatment, and other systems in supporting families. 
Committee Opinion No. 722: Marijuana Use During Pregnancy and Lactation 
The ACOG Committee on Obstetric Practice summarizes recent clinical and scientific advances related to 
cannabis use in pregnant women. 
Current Understanding of the Interaction of Benzodiazepines and Buprenorphine 
This Providers’ Clinical Support System continuing medical education course reviews the dangers of combining 
benzodiazepines and buprenorphine. 
Health Effects of Cannabis and Cannabinoids: The current state of evidence and recommendations for 
research 
The National Academies of Sciences, Engineering, and Medicine published this report in 2017 to summarize the 
recent changes in cannabis legalization, production and use and provides a review of the scientific evidence 
related to health effects. It concludes with a suggested research agenda. 
Treating for Two 
The Centers for Disease Control and Prevention’s Treating for Two initiative aims to improve the health of 
women and babies by identifying the safest treatment options for managing common conditions before and 
during pregnancy. The program focuses on all drugs, not just illicit drugs, and pharmacotherapy for recovery. 
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Treatment Improvement Protocol 40 (TIP): Clinical Guidelines for
the Use of Buprenorphine in the Treatment of Opioid Addiction 
This 2007 SAMHSA TIP offers practice guidelines to help physicians
make decisions about using buprenorphine to treat opioid addiction.
It includes information on patient assessment; protocols for opioid
withdrawal; and the treatment of pregnant women, teens, and
polysubstance users. This publication is due to be revised in 2017. 
TIP 43: Medication-Assisted Treatment for Opioid Addiction in
Opioid Treatment Programs
This 2012 SAMHSA TIP gives a detailed description of medication-
supervised treatment for addiction to opioids, including
comprehensive maintenance treatment and medically supervised
withdrawal. Screening, assessment, and administrative and ethical
issues are also covered. This publication is due to be revised in 2017. 
WHO Guidelines for the Identification and Management of
Substance Use and Substance Use Disorders in Pregnancy
This WHO guideline reviews the use of numerous illicit substances
in pregnant women and details specific guidelines for the care and
treatment of pregnant women and their infants. 
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SECTION 1 
FACTSHEET # 
7 PLANNING PRIOR TO LABOR 
AND DELIVERY 
CLINICAL SCENARIO 
A pregnant woman with opioid use disorder (OUD) has questions about neonatal 
abstinence syndrome (NAS), support services, and postpartum planning. 
CLINICAL ACTION STEPS 
Patient Education on NAS 
A pregnant woman with OUD should receive the same education and information that all pregnant 
patients receive (e.g., tour of labor and delivery suites, newborn nursery). 
Healthcare professionals should inform the pregnant woman of the possibility of neonatal abstinence 
syndrome (NAS) and counsel her on its diagnosis, management, and consequences. The woman should 
also receive education on ways to optimize the well-being of the fetus such as tobacco cessation and early 
pediatric care after delivery and hospital discharge. Healthcare professionals should ensure that she is 
aware of nonpharmacological interventions that should be provided to her infant to reduce NAS symptoms, 
including rooming-in. 
Caregivers of opioid-exposed infants should be informed that while the infant may carry a genetic 
risk for substance use disorder the fact of experiencing NAS as an infant does not increase the risk of 
developing a substance use disorder in life. 
Healthy Home Environment 
Caregivers should be informed about and supported in providing a stable, 
healthy home environment to enhance protective factors and reduce 
social risk factors that may impact the future risk for substance use 
disorder in the child. 
Contraception 
Women with OUD should be counseled about contraception and have 
immediate, easy access to the contraceptive of their choice after delivery. 
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SUPPORTING EVIDENCE AND CLINICAL CONSIDERATIONS 
Patient Education on NAS 
• Some infants exposed to methadone or buprenorphine in utero experience opioid withdrawal after birth.
NAS is a treatable condition, but caregivers and healthcare professionals need to be alert to signs of NAS in
the infants of women with OUD so that therapy can begin as necessary. Infant withdrawal usually begins a
few days after the baby is born but may begin as late as 2 to 4 weeks after birth. All caregivers should know
what symptoms indicate the onset of NAS and when to seek additional medical care for the infant. Clear
communication about NAS between the new mother and pediatricians, neonatologists, or family practice
doctors, in addition to support from OB/GYNs,
midwives, and nurse practitioners, is critical. 
Predicting the risk of NAS for infants of mothers
with OUD is difficult, because several substances
in addition to opioid exposure can influence the
presentation of NAS, such as smoking tobacco
(Jones et al., 2013a) and using other substances
(Patrick et al., 2015). Infant-related variables can
affect the infant’s NAS course, such as genetics,
gender, and gestational age (Wachman et al., 2013,
2015). NAS is an expected and treatable outcome of
opioid agonist or partial agonist pharmacotherapy
to treat OUD during pregnancy. Recent studies have
shown NAS associated with pharmacotherapy is not
worse than that experienced after untreated heroin
use (Buckley, Razaghi, & Haber, 2013). Being treated
with an opioid agonist such as buprenorphine or
methadone, by itself, is not a basis for determining
parental fitness or child safety. 
A woman may want to change or reduce her
medication in hopes of reducing the chance or
severity of NAS in her infant. Randomized trials of
the medications have found no relationship between
methadone or buprenorphine dose and outcomes
such as NAS peak score; total morphine needed to
treat NAS; neonatal hospital stay duration; number
of days that pharmacotherapy was given for NAS;
estimated gestational age at delivery; Apgar score
at 5 minutes; and neonatal head circumference,
length, and weight at birth (Jones, Jansson, O’Grady,
& Kaltenbach, 2013b; Jones et al., 2013b; 2014; Lund
et al., 2013). In a meta-analysis, Cleary et al. (2010)
and Patrick et al. (2015) found the severity of NAS
was unrelated to methadone dose. The practice of
minimizing or even reducing maternal opioid agonist
medication to protect the fetus is unnecessary and
should be avoided. 
When discussing options to maximize the health
of the pregnant woman and infant, remind the
pregnant woman that she CAN take several
steps to protect her health and the fetus: 
• She can enroll in a tobacco cessation program,
and participate in treatment programs for 
comorbid alcohol, other substance use 
disorders as needed. 
• She can maintain a healthy weight and take
prenatal vitamins as prescribed. 
• She can learn how NAS is diagnosed and treated. 
• She can learn which nonpharmacological 
interventions can reduce the incidence and 
severity of NAS. 
• She can inform and prepare herself for
breastfeeding. 
• She can enroll in parenting classes recommended
by her prenatal healthcare professional. 
FACTSHEETS TO REVIEW 
Reducing the dose of pharmacotherapy 
will not reduce NAS expression or severity. 
No relationship was found between either 
methadone or buprenorphine dose and 
significant infant outcomes, including 
NAS expression or severity. The dose of 
pharmacotherapy should be optimized to 
suppress withdrawal, minimize cravings and 
prevent a return to substance use. Factsheet 
#2 Initiating Pharmacotherapy For Opioid 
Use Disorder and Factsheet #10: Management 
of Neonatal Abstinence Syndrome, Exhibit 
FS #10.2, lists factors that influence NAS 
expression, severity, and pharmacological and 
nonpharmacological treatment options. 
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• When planning for delivery, healthcare professionals should
take time to talk about the benefits of breastfeeding.
Breastfeeding has positive physical and behavioral health
results for mother and baby. When appropriate, any amount
of breastfeeding, however brief, can decrease NAS severity,
reduce the infant’s need for pharmacological treatment,
and decrease the length of pharmacological therapy and
hospitalization (Abdel-Latif et al., 2006; Bagley, Wachman,
Holland, & Brogly, 2014; Jansson et al., 2008a, 2008b; Reece-
Stremtan, Marinelli, & Academy of Breastfeeding Medicine,
2015; Ruwanpathirana et al., 2015). Introduce the concept
of breastfeeding in the last trimester and assure the mother
that a team will be available at the hospital to facilitate her
breastfeeding, including a lactation consultant. However, not all
women with SUD are appropriate candidates for breastfeeding.
Healthy Home Environment 
• Women may be eligible for visits from the Federal
Home Visiting Program, funded by the Administration
for Children & Families’ (ACF’s) Early Head Start
(EHS) programs and Health Resources and Services
Administration’s (HRSA’s) Healthy Start program, a
network of more than 100 grantees nationwide. Each
member program focuses on providing services to families
in the nation’s poorest neighborhoods. These services
attempt to reduce infant mortality, advocate for an end
to health disparities, engage fathers, and encourage
preconception health. 
Planning for labor and delivery should
include inviting members of the
collaborative team to meet with the
pregnant woman before delivery. Many
clinics have a pediatrician/neonatologist
on staff to discuss what to expect after
birth. This consultation builds trust between
the pregnant woman and her care team.
This is an opportune time to introduce the
pregnant woman to a lactation consultant
if one is available. Teaching the mother
how to score NAS in her infant and to
participate in the NAS scoring is also 
beneficial. Factsheet #11: Breastfeeding
Considerations for Infants at Risk for
Neonatal Abstinence Syndrome provides
a discussion on when to breastfeed and
when not to breastfeed.
Discharge plans should be compatible
with and support the plan of safe care
for mother and infant; this includes
addressing potential maternal comorbid
medical or mental disorders. See
Factsheet #15: Maternal Discharge
Planning, for a more extensive discussion 
about implementing a plan of safe care. 
Ideally, each new mother should have the
option to receive a long-acting reversible
contraceptive prior to leaving the hospital.
At a minimum, women should receive
non-coercive contraceptive counseling
and the option to leave the hospital with a
prescription for contraception, contraceptive
supplies, or a contraception plan (Substance
Abuse and Mental Health Services
Administration [SAMHSA], 2014). 
Contraception 
• Preventing unintended pregnancies and planning for future pregnancies is critical. Healthcare
professionals should offer all women, including those with OUD, non-coercive contraceptive counseling and
discuss different forms of birth control and the effectiveness of each method before they are discharged from
the hospital. Whether a woman is on pharmacotherapy
for OUD or continues to misuse opioids, a conversation
about the importance of contraception is critical. Women of
reproductive age who have OUD experience a high rate of
unintended pregnancy (Heil et al., 2011). One study found that
only about half of the women with current opioid use were
using contraception; the majority of women were not using
long-acting reversible contraception (LARC) options, such
as implants or intrauterine devices (IUDs) (Terplan, Hand,
Hutchinson, Salisbury-Afshar, & Heil, 2015). 
The American College of Obstetricians and Gynecologists
(ACOG), 2017) and the American College of Nurse-Midwives
and other nurse professional societies recommend offering immediate postpartum LARC to reduce unintended
or short-interval pregnancy (Committee on Healthcare for Underserved Women, American Society of Addiction
Medicine, & ACOG, 2017). LARC can consist of IUDs or implants. Although there is a higher chance of expulsion
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with the immediate placement of an IUD after delivery, a risk–benefit analysis concluded that, because many
women do not attend their 6-week postpartum visit (at which time a LARC is often provided), insertion while still
at the hospital after delivery is an excellent time to implant the device. Concerns with Medicaid reimbursement are
an issue, but many states are now providing policy statements on reimbursement at time of insertion. 
Healthcare professionals can encourage women already in treatment to consider planning their next
pregnancy with the healthcare team to make sure they are on safe medications, their treatment status is
stable, and they are ready for the stresses of motherhood on top of treatment or recovery. 
Other Evidence/Considerations 
• In some communities, programs to support women with OUD offer services for mothers who
are in recovery. Examples of relevant programs within medication-assisted treatment services
include peer support, medication education, family support and education for childrearing, escape
from interpersonal violence, and stable housing. The support and practical help these programs
provide can make a difference in the day-to-day life of a mother and her infant. Healthcare
professionals might check with local child protection services or opioid treatment programs
(OTPs) to determine whether such programs are available in their area. OTPs can be located
through SAMHSA’s Opioid Treatment Program Directory Opioid Treatment Program Directory. 
• People who are in recovery from SUD or who live with behavioral health disorders often
find support, encouragement, and community in consumer-/patient-led organizations.
These organizations, which are generally set up and run by volunteers, can provide a supportive
environment that helps some people maintain recovery. Women on pharmacotherapy for OUD
are encouraged to seek out programs where pharmacotherapy is accepted as complementary
to traditional 12-step treatment programs and is supportive of using pharmacotherapy. Peer
counselors or recovery coaches can help those who are new to recovery avoid triggers that can
lead to return to substance use. Coaches can provide practical support such as transportation
to and from meetings and show new parents how to securely store all medications, including
pharmacotherapeutics for OUD, so that children cannot get into them. 
WEB RESOURCES ON THIS TOPIC 
Breastfeeding 
Academy of Breastfeeding Medicine Protocol #21: Guidelines for Breastfeeding and Substance Use or
Substance Use Disorder, 2009, Revised 2015 
This protocol provides evidence-based guidelines for the evaluation and management of women with
SUDs who are considering breastfeeding. It includes information on methadone and buprenorphine. 
Baby Friendly Hospital Initiative-USA 
This global initiative was launched by the World Health Organization and the United Nations Children’s
Fund in 1991 to encourage and recognize hospitals and birthing centers that offer an optimal level of care
for infant feeding and mother–infant bonding. 
Breastfeeding Initiatives: Family Resources
This American Academy of Pediatrics (AAP) webpage lists breastfeeding resources for families; some
resources are in Spanish. 
Section 1: Factsheet 7 55 
  
 
 
 
 
 
 
 
 
 
 
 
Childbirth, Breastfeeding, and Infant Care: Methadone and Buprenorphine 
This brochure urges pregnant women who use heroin or abuse opioid prescriptions to seek medication-
assisted treatment with methadone or buprenorphine. It discusses how methadone therapy works and
women’s issues such as breastfeeding, opioid withdrawal, birth control, and child protection services. 
Drug Entry Into Human Milk 
This InfantRisk Center webpage describes in detail the mechanisms of drug entry into human milk and
provides general rules on breastfeeding. 
Drugs and Lactation Database (LactMed) 
This National Library of Medicine searchable database provides information on medications and other
chemicals to which breastfeeding mothers may be exposed. 
Medications and Breastfeeding: Tips for Giving Accurate Information to Mothers 
This two-page AAP document discusses clinical points to consider when prescribing medications to
breastfeeding mothers. 
Policy Statement: Breastfeeding and the Use of Human Milk 
This AAP-updated policy statement reviews the benefits of breastfeeding for the mother and child. 
When Should a Mother Avoid Breastfeeding? 
This Centers for Disease Control and Prevention webpage provides links to information about illnesses and
conditions that contraindicate breastfeeding. 
Home Visiting and Peer Support Services 
Alcoholics Anonymous (AA) 
AA has traditionally emphasized recovery without medication. A person receiving recovery
support from AA may need to attend a variety of meetings to find one that recognizes the
role of pharmacotherapy in recovery. 
Core Competencies for Peer Workers in Behavioral Health Services 
On this webpage, SAMHSA defines peer workers and recovery and lists several
categories of core competencies for peer workers. 
Early Head Start Programs 
Early Head Start EHS programs administered by HHS’s Administration for Children and
Families serve infants and toddlers younger than under the age of 3, and pregnant
women. TheseEHS programs provide intensive comprehensive child development and
family support services to low-income infants and toddlers and their families, and to
pregnant women and their families. 
Federal Home Visiting Program
This webpage provides background about the HRSA and ACF program, its structure, and 
its mission and services, which involve evidence-based, voluntary home visiting programs, 
where families receive help from health, social service, and child development professionals. 
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Healthy Beginnings 
This program meets the U.S. Department of Health and Human Services criterion for an effective childhood 
home visiting service delivery model. In this model, nurse home visitors provide education on infant nutrition, 
family nutrition, and physical activity and address family members’ concerns. Nurse visitors typically made 8 
visits from a prenatal visit through age 24 months. 
Healthy Start 
This webpage describes the HRSA Healthy Start program and links to a technical assistance center with more 
information on program approaches and grantees. The program provides depression screening, healthcare 
services, care coordination, public health services such as immunization and health education, and training for 
community health workers and care coordinators. 
Narcotics Anonymous (NA) 
NA has traditionally emphasized recovery without medication. A person receiving recovery support from NA 
may need to attend a variety of meetings to find one that recognizes the role of pharmacotherapy in recovery. 
National Alliance for Medication Assisted Recovery 
This organization is led by people in recovery and supports all pathways to recovery, 
including medication. Recovery Community Centers offer peer support and opportunities 
to socialize with others in recovery. 
General Resources 
Opioid Treatment Program Directory 
The dropdown menu on this SAMHSA website links users to information on the 
availability of OTPs in the United States and its territories. 
Strong Start for Mothers and Newborns Initiative 
This joint effort by the Centers for Medicare & Medicaid Services, HRSA, and 
ACF aims to reduce preterm births and improve outcomes for newborns 
and pregnant women. 
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SECTION 1 
FACTSHEET # 
8 
PERIPARTUM PAIN RELIEF 
CLINICAL SCENARIO 
A pregnant woman with opioid use disorder (OUD), in treatment or not, needs pain relief
during her labor, delivery, and postpartum period.
CLINICAL ACTION STEPS 
Pain Management Options 
A pregnant woman will naturally be nervous about how her pain will be controlled during labor and delivery.
When a woman is already using pharmacotherapy for OUD or has not started therapy and is misusing opioids,
her options for pain control should include epidural/spinal anesthesia and short-acting opioid analgesics. 
Differentiating OUD Pharmacotherapy and Pain Management During Delivery or Postpartum 
A woman’s existing opioid agonist dose should not be expected to provide adequate pain relief either
intrapartum or postpartum. Do not attempt to increase the woman’s prescribed dose of buprenorphine or
methadone for short-term intrapartum or postpartum pain control. 
Contraindicated Medications 
Do NOT administer butorphanol, nalbuphine, or pentazocine to a pregnant woman with OUD, whether
she is on pharmacotherapy for OUD or not. These medications have partial antagonist properties and will
precipitate acute opioid withdrawal. 
SUPPORTING EVIDENCE AND CLINICAL CONSIDERATIONS 
Pain Management Options 
• Pregnant women with OUD need to be assured that they will receive adequate pain relief during labor
and the postpartum period. Healthcare professionals will need to inform the pregnant woman of her labor
and delivery pain treatment options, talk with her healthcare professional, and consider arranging for her to
meet with the anesthesiologist before she goes into labor.
Patients with long-term opioid use are at risk for hyperalgesia and may derive insufficient pain relief from
standard therapeutic doses of a nonsteroidal analgesic (NSAID), acetaminophen, or short-acting opioid
analgesic (Savage, 1996). During labor and delivery, they are likely to require higher doses of opioid agonist
medication than women who have not experienced long-term opioid use (Alford, Compton, & Samet, 2006;
Meyer, Paranya, Norris, & Howard, 2010; Meyer, Wagner, Benvenuto, Plante, & Howard, 2007). If a woman
needs higher doses of NSAIDs, acetaminophen, or short-acting opioid analgesics for adequate intrapartum
pain relief, this need may continue into the initial postpartum period regardless of the method of delivery. 
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Providing pain relief to women receiving methadone
or buprenorphine, whether via epidural and/or short-
acting opioids, is essential (Jones, Johnson, & Milio, 2006;
Jones et al., 2008, 2009). Morphine sulfate, fentanyl,
or hydromorphone (Dilaudid®) are reasonable options
for acute pain management during labor and delivery
for patients with OUD. These medications need to be
responsibly prescribed following Centers for Disease
Control and Prevention guidelines that, if opioids must
be prescribed for acute pain, the effective dose should
be used for 3 or fewer days and rarely more than 7 days
(Dowell et al., 2016).
Opioid Agonist Therapy for OUD 
Cannot Provide Pain Management 
During Delivery or Postpartum 
• During labor and delivery, the mother should be
maintained on her current dose of opioid agonist
therapy for OUD. The daily pharmacotherapy dose should be considered the new mother’s baseline.
The daily dose of methadone or buprenorphine should not be expected to provide analgesia, and
neither the dose nor the schedule should be altered to relieve pain (Committee on Healthcare for
Underserved Women, American Society of Addiction Medicine, & American College of Obstetricians
and Gynecologists, 2012, 2017; Meyer et al., 2007).
Pregnant women on pharmacotherapy do NOT need to be transitioned from their maintenance
medication before a planned cesarean section (Jones et al., 2006). Labor and operative pain can be
managed while pharmacotherapy is still being administered (Jones, et al., 2009). 
Contraindicated Medications 
• Certain analgesics should NEVER be given to women with OUD. Practitioners must not prescribe
opioid analgesics with antagonist properties (e.g., nalbuphine, butorphanol) to women receiving opioid
agonists (e.g., methadone, buprenorphine) or with an OUD, because of the likelihood of precipitating
acute withdrawal (Cassidy & Cyna, 2004; Jones et al., 2014; Savage, 1996).
Any antepartum discussion or guidance
regarding pain relief during labor, delivery,
and postpartum should be documented in
the antepartum or intrapartum record and
accessible to all members of the treating
team. Documenting recommendations for pain
relief in the patient’s record so that they are 
available to the treatment team during labor
and delivery, as well as postpartum, is a simple
way to improve communication among the
team members. For example, the healthcare
professional responsible for prescribing opioid
agonist therapy can provide instruction to 
the team regarding the management of the 
pharmacotherapy for OUD and guidance for
acute pain management to support the treating
team in achieving adequate pain control. 
WEB RESOURCES ON THIS TOPIC 
FDA Drug Safety Communication: FDA Has Reviewed Possible
Risks of Pain Medicine Use During Pregnancy 
This Food and Drug Administration 2015 communication
discusses its review of published research studies on the use
of pain medicines during pregnancy. It does not make any
recommendations, because of limitations FDA found in the
studies. The communication urges pregnant women to discuss
their medications with their healthcare professionals before
taking them.
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Section II: Infant Care 
Section II consists of five factsheets: 
Factsheet #9: Screening and Assessment for Neonatal Abstinence Syndrome 
Factsheet #10: Management of Neonatal Abstinence Syndrome 
Factsheet #11: Breastfeeding Considerations for Infants at Risk for Neonatal Abstinence Syndrome 
Factsheet #12: Infant Discharge Planning 
Factsheet #13: Early Intervention Strategies and Developmental Assessments 
Each factsheet contains four components. 
I. Clinical Scenario
Presents a brief statement to orient the reader to the situation under consideration. 
II. Clinical Action Steps
Present recommendations that are derived directly from the rated clinical decisions in the
RAND/UCLA Appropriateness Method report and describe what can, might, or should not be
done when caring for women and their infants. 
III. Supporting Evidence and Clinical Considerations
Present strengths and weaknesses of the evidence supporting the clinical action steps. This
section describes how to address or tailor recommended actions to unique patient variables
and preferences, the clinical experience of the provider, and available community resources.
Guidance is based on expert panel and Federal Steering Committee discussions and additional
information from published articles. This section includes supporting information for the Clinical
Action Steps as well as information in where there was insufficient evidence to recommend a
clear course of action. Instead, information in this section will provide elements that must be
taken into consideration when making a decision with the pregnant women or new mother
about the best course of action for herself or her infant. 
IV. Web Resources 
Provide links to additional online information. 
FACTSHEET #9: Screening and Assessment for Neonatal Abstinence 
Syndrome 
CLINICAL SCENARIO: An opioid-exposed infant at risk for neonatal abstinence syndrome (NAS) is
delivered. 
• Screening for NAS 
• Maternal and infant toxicology 
• Informed consent for screening 
• NAS onset time varies 
• Opportunities for positive change 
• Standardized NAS assessment and treatment can
improve outcomes 
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FACTSHEET #10: Management of Neonatal Abstinence Syndrome 
CLINICAL SCENARIO: An infant begins to exhibit signs of neonatal abstinence syndrome (NAS) shortly
after birth. 
• Managing mild NAS 
• Managing moderate to severe NAS 
• Adjuvant pharmacotherapy for severe NAS 
• Additional medical considerations 
• Minimizing hospital stays using standardized
protocols 
• Nonpharmacological interventions for all
substance-exposed mother—infant dyads 
• Nonpharmacological interventions to reduce NAS
severity 
• Recommended medications and medications
under study 
• Not recommended medications for NAS 
• Infant observation period variation and type of
opioid 
FACTSHEET #11: Breastfeeding Considerations for Infants at Risk for 
Neonatal Abstinence Syndrome 
CLINICAL SCENARIO: A mother with an infant at risk for NAS seeks advice on whether to
breastfeed. 
• Stable mother and breastfeeding 
• Low levels of opioid use disorder medications
found in breastmilk 
• Pharmacotherapy and breastfeeding
decision-making 
• Discussing benefits of breastfeeding 
• Situations where mother should not breastfeed 
FACTSHEET #12: Infant Discharge Planning 
CLINICAL SCENARIO: An opioid-exposed infant is ready for discharge home. 
• In-home and follow-up services 
• Caregiver education and home environment 
• Need for acute follow-up 
• Discharge planning before birth 
• Ongoing support for mothers/caregivers and
infants who cannot be quickly weaned from opioid
agonists 
• Healthy home environments contribute to healthy
long-term development 
• Ongoing research on genetic components of
substance use disorders 
FACTSHEET #13: Early Intervention Strategies and Developmental 
Assessments 
CLINICAL SCENARIO: An opioid-exposed infant is ready for discharge home. 
• Effects of NAS on development 
• Effects of extended-release injectable naltrexone 
• Investigating maternal and infant eligibility for
early intervention services 
• Discussing developmental screens and
assessments 
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SECTION 2 
FACTSHEET # 
9 
SCREENING AND 
ASSESSMENT FOR 
NEONATAL ABSTINENCE  
SYNDROME 
CLINICAL SCENARIO 
An opioid-exposed infant at risk for neonatal abstinence syndrome (NAS) is delivered. 
CLINICAL ACTION STEPS 
Screening for NAS 
An infant born to a mother who used opioids (licit or illicit) or had pharmacotherapy for opioid use disorder (OUD)
during her pregnancy should be monitored for 4–7 days and managed according to a formal protocol for NAS. 
Maternal and Infant Toxicology Screening 
The monitoring and management of infants at risk of NAS should be informed by an interview with the
mother about all substance and pharmacotherapy use during her pregnancy, by the clinical status of the
infant, and by toxicology screening of the mother and the infant. 
Informed Consent 
Any toxicology screening of the mother must be done with her informed consent;
toxicology screening in infants does not require informed consent. 
SUPPORTING EVIDENCE AND CLINICAL CONSIDERATIONS 
Screening for NAS 
• The onset of NAS varies among infants and depends on the opioids to which they were exposed. The
timing of the onset of NAS varies among opioid-exposed infants. Those exposed to heroin or other short-acting
opioids will typically present symptoms within 2—3 days of delivery (Beauman, 2005; Chan, Klein, & Koren, 2003),
whereas those exposed to methadone or buprenorphine usually will exhibit NAS symptoms within the first 4
days of birth (Jansson, Velez, & Harrow, 2009). Median time to treatment initiation has been shown to be one day
later in buprenorphine-exposed neonates compared
with methadone-exposed neonates (mean of 3 vs.
2 days, respectively; Gaalema, Heil, Badger, Metayer,
& Johnston, 2013). Consequently, an opioid-exposed
newborn requires a minimum of 4 days (96 hours) 
in the hospital for NAS scoring. If the infant requires 
medication to manage NAS, the exact observation 
time will depend on the infant’s expression of NAS 
and response to treatment (Hudak et al., 2012). 
FACTSHEET TO REVIEW 
For more information on factors that influence 
NAS expression, severity, and pharmacological 
and nonpharmacological treatment options, 
see Factsheet #10: Management of Neonatal 
Abstinence Syndrome.
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• Use of standardized NAS assessment and
treatment protocols improves outcomes. The
2012 AAP Neonatal Drug Withdrawal report
(Hudak et al., 2012) recommends that every labor
and delivery unit have a standardized protocol
for assessing and treating infants at risk and/or
showing signs and symptoms of withdrawal from
opioids, alcohol, and other substances. Nursing
staff members must be trained to administer a
standardized NAS assessment tool reliably to
ensure the consistency of these assessments.
Standardizing care has been shown to reduce
the duration of pharmacological treatment and
the number of infants discharged on medication
(Patrick et al., 2016). Exhibit FS #9.1 outlines the
benefits and challenges of the most common NAS
scoring scales. Little research has been done on
the comparative cost-effectiveness of these tests
or their efficiency in identifying opioid-exposed
infants at birth.
RESOURCES TO REVIEW 
Each hospital should adopt a protocol 
for infants exposed to opioids and other 
substances in utero. The following materials 
provide examples of established NAS treatment 
protocols for hospitals to institute: 
• Cohort Analysis of a Pharmacokinetic-Modeled
Methadone Weaning Optimization for Neonatal
Abstinence Syndrome (Hall et al., 2015) 
• Maternal Drug Use, Infant Exposure and
Neonatal Abstinence Syndrome (Patrick, 2016) 
• Neonatal Abstinence Syndrome After 
Methadone or Buprenorphine Exposure
(Jones et al., 2010) 
• Neonatal Drug Withdrawal (Hudak et al., 2012)
• The Opioid Exposed Newborn: Assessment 
and Pharmacologic Management (Jansson, 
Valez, & Harrow, 2009) 
Exhibit FS #9.1: NAS Scoring Scales 
Scale Name Description References 
Finnegan Neonatal
Abstinence Scoring
System (Finnegan Scale) 
• Dates from the 1970s 
• Was first scale for NAS 
Original: Finnegan, Kron, Connaughton,
& Emich, 1975 
Most recent: Finnegan & Kaltenbach, 1992 
MOTHER NAS Scale (a
modified Finnegan
Scale) 
• Contains 28 items, of which 19 are used for scoring and medication decisions
• Eliminates many symptoms listed in Finnegan Scale (e.g., myoclonic jerks,
mottling, nasal flaring, watery stools)
• Adds 2 items: irritability and failure to thrive 
Jones et al., 2010b 
Lipsitz Tool (Neonatal
Drug Withdrawal
Scoring System) 
• Is recommended in the 1998 AAP statement Neonatal Drug Withdrawal and
again in 2012 updated statement (Hudak et al., 2012) 
• Offers relatively simple metrics with good sensitivity for identifying
clinically important withdrawal 
Lipsitz, 1975 
Neonatal Narcotic
Withdrawal Index 
• Evaluates NAS on a 7-item scale
• Assigns weights of 0 to 2 points per item 
• Provides some validity data
Green & Suffet, 1981 
Neonatal Withdrawal
Inventory 
• Provides a sequence of care procedures
• Uses an 8-point scale to make withdrawal evaluation
Zahorodny et al., 1998 
Withdrawal Assessment
Tool (WAT-1) 
• Assesses signs of opioid and benzodiazepine withdrawal Franck, Harris, Soetenga, Amling, &
Curley, 2008; Kaltenbach & Jones, 2016 
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Maternal and Infant Toxicology Screening 
• When creating a long-term plan for the mother’s recovery and infant’s safety, the healthcare professional
needs to take into account the toxicology results, but should not make decisions solely based on these
results. Relying exclusively on maternal drug screens at the time of delivery to identify drug exposure is not
necessarily the best approach for creating a long-term plan for the mother’s recovery because they generally
reflect only recent substance use (except for tetrahydrocannabinol in chronic cannabis users). Safe care of
the infant and effective support of the mother and other caregivers are best achieved through a trusting and
respectful therapeutic relationship between the mother and the care team. Toxicology screening of the mother
and/or the infant can be a useful component of a NAS risk assessment and the development of a care plan. In
addition to collecting specimens for toxicology testing, healthcare professionals can use screening instruments
and interview the mother about recent drug use and pharmacotherapies she required during her pregnancy
(Hudak, Tan, American Academy of Pediatrics (AAP) Committee on Drugs, & AAP Committee on Fetus and
Newborn, 2012). Hospitals should use a standardized protocol for screening for substance exposure, as well as
for monitoring and treating NAS in an opioid-exposed infant. 
All clinicians and staff members must understand their legal responsibility for reporting substance exposure or
withdrawal of an infant and should be sensitive to the social and legal consequences for the mother and infant
of reporting such concerns to state and local authorities. Healthcare professionals need confirm any positive
test results given the life-changing ramifications for the mother and infant if there is a false positive (Wright,
2015). Reporting requirements vary by state. A Collaborative Approach to the Treatment of Pregnant
Women With Opioid Use Disorders: Practice and Policy Considerations for Child Welfare, Collaborating
Medical, and Service Providers provides more
information on developing and coordinating a long-
term plan for caring for mothers and their infants 
(Substance Abuse and Mental Health Services 
Administration [SAMHSA], 2016). 
Additional testing is often done for benzodiazepines,
barbiturates, methamphetamines, and methadone
as well as other drugs used in the local community.
Testing for synthetic opioids (e.g., oxycodone,
hydrocodone, fentanyl, buprenorphine) must be
ordered as an extended opioid panel. Extended panels
are recommended for women with known substance
use disorders (SUDs), with the understanding that
urine testing cannot detect ALL drugs of abuse. 
Exhibit FS #9.2 summarizes the most common
toxicology screens for infants and mothers at delivery. Little research has been done on the cost-
effectiveness of such testing. To be useful in identifying infants at risk of NAS, test results must be
available quickly. This means some of the more definitive tests are not useful for the early identification
of and intervention in NAS risk. 
FACTSHEET TO REVIEW 
Factsheet #1: Prenatal Screenings and 
Assessments for more information on 
appropriate maternal screens including 
interview instruments and maternal toxicology. 
The easiest testing method is to collect urine 
from the infant. The most commonly ordered 
panel is the National Institute on Drug Abuse—5 
(NIDA-5) to test for cannabis, opioids, cocaine, 
amphetamine, and phencyclidine. Tests results 
need to be available quickly to inform care. 
Informed Consent 
• All testing on the mother requires informed consent; testing on the neonate does not require consent.
Healthcare professionals should review with the woman the risks and limitations of each type of test
(e.g., false-positive results for amphetamines that can be due to cross-reactions of cold medicines) and
the possible need for confirmatory testing for all positive results (e.g., using gas chromatography/mass
spectrometry confirmation). They should also ensure that she understands the specimen collection
process. See Exhibit FS #9.2 for a review of the most common toxicology screens in use. 
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Exhibit FS #9.2: The Most Common Toxicology Screens for Infants and Mothers at Delivery—Neonatal 
Toxicology Tests 
Matrix Benefits Drawbacks 
Amniotic Fluid
and Placental
Tissues 
Placental tissue is noninvasively collected. 
Collection is exempt from maternal consent procedures. 
Placental tissue is not commonly used clinically. 
Amniotic fluid collection is difficult and invasive; the sample may not be 
clinically useful. 
Cord Blood Cord blood is relatively easy to collect and does not pose
a hazard to mother or child. 
Provides rapid results.
Collection is exempt from maternal consent procedures. 
The window of detection in cord blood is very narrow, limiting the
findings of the test. 
Hair Specimen has a wide window of detection for drug use. 
Collection is relatively noninvasive. 
Collection is exempt from maternal consent procedures.
Extraction from specimen is difficult, and testing requires an
experienced laboratory. 
Accuracy of results are limited by the chemical composition of the
drug, the color of the hair (dark hair has greater concentration of drug
metabolites than light hair), and timing of maternal consumption
(Wright, 2015). 
Fetal hair reflects only exposure during the third trimester. 
Collection of hair from the infant may be unacceptable in some cultures.
Meconium Sample is easily collected and readily available. 
Method has a relatively wide window for collection and
detection because meconium continues to pass for up to
48 hours postnatally. 
Collection is exempt from maternal consent procedures 
Test is complex and must be done by an experienced laboratory. 
Sample appears to form at 12 weeks. The volume of meconium
increases throughout gestation, with most meconium being produced
in the last 2 months of gestation (Bakdash et al., 2010); thus, drug
detection is biased to the last 8 weeks in utero. 
Sample is commonly contaminated by fetal urine, which increases the
concentration of substances to which the fetus was exposed near term. 
Testing for drugs is limited by the chemical composition of the drug,
timing of maternal consumption (Wright, 2015), maternal and fetal
metabolism, and placental transport. 
A major drawback for meconium testing is that is does not reflect
periods of abstinence close to term so may be harmful for women in
SUD treatment. 
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Matrix Benefits Drawbacks 
Urine Sample collection is relatively noninvasive and easy to
collect. 
Test is inexpensive and readily available. 
Results are rapidly available. 
Collection is exempt from maternal consent procedures 
Results reflect only recent exposure and depend on the half-life of the
drug. 
Use of workplace standards for drug detection rather than lowest
detectable limits may lead to false-negative results (Farst, Valentine, &
Hall 2011). False-positive results are also possible. 
Many medications can cross-react with the immunoassays used for
preliminary screening causing false-positive results; thus, all positive
results must be confirmed (Markway & Baker, 2011). 
Testing for benzodiazepines often looks only for oxazepam or
nordiazepam, not the parent compound; thus differentiating between
legitimate maternal prescription medication use and illicit street use
can be a challenge. 
Not completing confirmatory urine testing can be disastrous because it
can result in false-positive results that may mean the loss of custody
of children and, in some states, legal prosecution (Wright, 2015).
Umbilical Cord Sample is easily and noninvasively collected. 
Sample appears to accurately reflect fetal drug exposure. 
Collection is exempt from maternal consent procedures. 
Sample does not have ideal reservoirs for the more lipophilic drugs, so
the results are limited by the chemical composition of the drug. 
Exhibit FS #9.2: The Most Common Toxicology Screens for Infants and Mothers at Delivery—Peripartum 
Maternal Toxicology Tests 
Matrix Benefits Drawbacks 
Cord Blood Provides rapid results.
Cord blood is relatively easy to collect and does not pose
a hazard to mother or infant. 
The window for detection for maternal cord blood is very narrow and
severely limits testing for drugs.
Hair Specimen has a wide window for detection for drug use. 
Collection is noninvasive. 
Extraction from specimen is difficult, requires a specialized laboratory,
and can be degraded by environmental exposures such as hair dyes or
sun exposure.
Accuracy of results are limited by the chemical composition of the
drug, the color of the hair (dark hair has greater concentration of
drug metabolites than light or gray hair), and timing of maternal
consumption (Wright, 2015). 
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Matrix Benefits Drawbacks 
Urine Collection is relatively noninvasive. 
Samples are easy to collect. 
Test is inexpensive and readily available. 
Results are rapidly available. 
Results reflect only recent exposure and depend on the half-life of the
drug. 
Both false-positive and false-negative results are possible.
Many medications can cross-react with the immunoassays used for
preliminary screening; thus, all positive results must be confirmed
(Markway & Baker, 2011). 
Testing for benzodiazepines often looks only for oxazepam or nordiazepam, 
not the parent compound; thus, differentiating between legitimate 
prescription medication use and illicit street use can be a challenge. 
Method of ingestion and chronicity of use may affect results. 
Urine can be adulterated or diluted; thus, collection should be observed,
which precludes privacy. 
Not completing confirmatory urine testing can be disastrous because it
can result in false-positive results that may mean the loss of custody
of children and, in some states, legal prosecution (Wright, 2015). 
Saliva Collection is noninvasive and easily obtained. 
Collection method is more dignified than observed urine
sample collection. 
Sample often has a shorter detection window than that of urine.
The majority of substances in saliva are the parent drug rather than
metabolites.
Salivary pH influences drug concentrations in that acid pH decreases
concentrations (Drummer, 2005); this makes test adulteration possible.
Sweat Specialized patch makes collection noninvasive and well
tolerated. 
Collection method offers a cumulative measure of
exposure of the drug over an extended period. 
Less is known about this type of biological matrix for detecting drugs
than other methods, because it is a relatively new methodology. 
Collection is limited by the chemical composition of the drug. 
WEB RESOURCES ON THIS TOPIC 
2017 ICD-10-CM Diagnosis Code 96.1 
This website provides detailed information on the codes for neonatal withdrawal
symptoms used for reimbursement purposes.
A Collaborative Approach to the Treatment of Pregnant Women With Opioid Use
Disorders: Practice and Policy Considerations for Child Welfare, Collaborating
Medical, and Service Providers
This SAMHSA document provides information on treating pregnant women with
OUD, summarizes guidelines adopted by a variety of professional organizations, and
presents a framework for organizing community efforts. It provides a coordinated,
multisystem approach grounded in early identification and intervention to assist
child welfare, medical, SUD treatment, and other systems in supporting families. 
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SECTION 2 
FACTSHEET # 
10 MANAGEMENT OF NEONATAL ABSTINENCE  
SYNDROME 
CLINICAL SCENARIO 
An infant begins to exhibit signs of neonatal abstinence syndrome (NAS) shortly after birth. 
CLINICAL ACTION STEPS 
Management of NAS 
An infant born to a mother who misused opioids (licit or illicit) or required pharmacotherapy to treat opioid use
disorder (OUD) during her pregnancy should be monitored and managed according to a formal protocol for NAS. 
• Managing Mild Signs 
An infant exhibiting mild signs of NAS should be managed with nonpharmacological interventions such as
rooming-in and monitored for progression to more severe symptoms according to a formal NAS protocol. 
• Managing Moderate to Severe Signs 
Infants with moderate to severe signs of NAS should be managed with
addition of pharmacotherapy such as liquid oral morphine or liquid oral
nonpharmacological interventions as for infants with mild NAS, with the
methadone. Neither tincture of opium nor phenobarbital should
be used as first-line agents in the treatment of NAS. Not enough
evidence exists to recommend for or against the use of sublingual
buprenorphine for the management of moderate to severe NAS. 
• Using Adjuvant Pharmacotherapy for Severe NAS 
Clonidine or phenobarbital may be used as adjuvants for infants
with severe NAS not adequately relieved by morphine or
methadone. 
Medical Considerations 
An infant with NAS who cannot maintain adequate hydration or who loses
weight despite optimal management should be evaluated to rule out other
medical conditions, and consideration should be given to transferring the
infant to a neonatal intensive care unit. 
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SUPPORTING EVIDENCE AND CLINICAL CONSIDERATIONS 
Management of NAS 
• Hospital stays for infants with NAS are shortened
when standardized protocols are used. Several
recent publications have emphasized the value
of using a standard assessment and treatment
protocol. The act of implementing a standard NAS
treatment and weaning protocol shortened the
length of infant stays (Asti, Magers, & Keels, 2015;
Patrick et al., 2016). Furthermore, a multicenter
study comparing infants managed with a standard
NAS treatment and weaning protocol with infants
managed without such a protocol found that,
regardless of medication type (methadone or
morphine), infants managed with the standard
protocol required a shorter duration of NAS
medication treatment and a shorter hospital stay
(Hall, Wexelblatt, & Crowley, 2015; Holmes et al.,
2016). 
Although a traditional medication regimen uses
a weight-based approach, some institutions and
research protocols now use a symptom-based
approach in which the dose is based on the
severity of the infant’s symptoms (Jansson et al.,
2009; Kraft & van den Anker, 2012). Exhibit FS
#10.1 provides NAS scores to define the terms
mild, moderate, and severe used in this Guide.
Exhibit FS #10.2 lists the factors that influence
NAS expresssion and severity.
RESOURCES TO REVIEW 
Each hospital should adopt a protocol 
for infants exposed to opioids and other 
substances in utero. The following materials 
provide examples of established NAS treatment 
protocols for hospitals to institute: 
• Cohort Analysis of a Pharmacokinetic-Modeled
Methadone Weaning Optimization for Neonatal
Abstinence Syndrome (Hall et al., 2015) 
• Maternal Drug Use, Infant Exposure and
Neonatal Abstinence Syndrome (Patrick, 2016) 
• Neonatal Abstinence Syndrome After 
Methadone or Buprenorphine Exposure
(Jones et al., 2010) 
• Neonatal Drug Withdrawal (Hudak et al., 0212)
• The Opioid Exposed Newborn: Assessment 
and Pharmacologic Management (Jansson, 
Valez, & Harrow, 2009) 
See Exhibit FS #9.1: NAS Scoring Scales for a list 
of the most commonly used scoring scales. 
Exhibit FS #10.1: NAS Severity Based on Scores Collected 
Using the MOTHER NAS Scale (a Modified Finnegan Scale)* 
Term Score 
(based on peak NAS score, 24-hour
observation with scoring every 3–4 hours) 
Mild 0–8 
Moderate 9–16 
Severe 17+ 
*Source: Jones et al., 2010. 
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Exhibit FS #10.2: Factors that Influence NAS Expression and Severity 
Factors References 
Gestational Age at Delivery Doberczak, Kandall, & Wilets, 1991; Seligman et al., 2008
Prenatal Exposure to Tobacco Smoking Jones et al., 2013 
Prenatal Exposure to Other Substances (e.g.,
Benzodiazepines, Selective Serotonin Reuptake Inhibitors) 
Jansson, Dipietro, Elko, & Velez, 2010; Kaltenbach et al., 2012; Pritham,
Paul, & Hayes, 2012; Seligman et al., 2008; Wachman et al., 2011
Genetic and Epigenetic Variation Wachman et al., 2013, 2015 
• Beginning at birth all infants, whether they manifest signs of NAS or not, should receive
nonpharmacologic care, and the pregnant woman and family caregivers should be educated on this
approach before the infant’s birth. Nonpharmacologic care of the substance-exposed mother–infant dyad
consists of: 
◆ A thorough understanding of the newborn’s functioning with the goals of implementing comforting
techniques and environmental modifications and promoting the infant’s self-regulation and interactive
capabilities.
◆ A thorough understanding of the mother’s strengths and challenges to promote her self-regulation,
confidence as a parent, and ability to respond contingently to and communicate with her infant. 
◆ Attention to the dyadic communication patterns and behaviors and the environment that may need
modifications to support the infant’s physiologic organization and regulation and to encourage the
mother to respond sensitively to the infant’s needs (Velez & Jansson, 2008). 
  Infants with NAS can be described as having 
“dysfunctional regulation” (Velez & Jansson, 2008). The 
nervous system of each infant will mature at a different 
rate, and infants exposed to opioids in utero may have 
specific problems related to neuromaturation. As the 
timing of the developmental milestones related to self-
organization and self-regulation may vary, it is particularly 
important to create individualized NAS management 
plans for caregivers that take into consideration each 
infant’s developmental milestones. This plan and training 
should be sensitive to the individual strengths and 
vulnerabilities of the infant and the mother.  
• Research supports using nonpharmacological
interventions to reduce the severity of NAS before
or in conjunction with medical treatment. Predicting
the risk of NAS for infants of mothers with opioid use
disorder (OUD) is difficult, because the mother may be using several different substances that can influence
the presentation of NAS (Jones et al., 2013a; Patrick et al., 2015). Infant-related variables can affect the infant’s
NAS course, such as genetics, gender, and gestational age (Wachman, et al., 2013; Wachman, et al., 2015). 
NAS is an expected and treatable outcome of opioid agonist or partial agonist pharmacotherapy to treat
OUD during pregnancy. Recent studies have shown NAS associated with pharmacotherapy is not worse
than that experienced after untreated heroin use (Buckley, Razaghi, & Haber, 2013). 
Interventions that target both the mother’s 
understanding of and responses to the 
infant and the infant’s regulatory capacity 
and ability to relay interpretable cues to 
the mother will facilitate mother–infant 
interactions. The goal of the individualized 
infant NAS management plan is to help: 
• The infant self-regulate by increasing the 
length of sleep, increasing time spent 
in the quiet alert state, and promoting 
motor and autonomic control. 
• The mother to understand and respond 
to her infant’s communication sensitively 
and contingently. 
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Any amount of breastfeeding when appropriate and however brief, can decrease the infant’s need
for pharmacological treatment, lead to a decrease in NAS scores, and decrease the duration of
pharmacological therapy and hospitalization (Abdel-Latif et al., 2006; Bagley, Wachman, Holland, &
Brogly, 2014; Jansson et al., 2008a, 2008b).
Promising nonpharmacological treatments include rooming in, extended skin-to-skin contact with the
mother, gentle handling, swaddling, pacifiers, quiet environments, supine positioning and waterbeds
(American Academy of Pediatrics [AAP], 2012; Bagley et al., 2014; d’Apolito, 1999; MacMullen, Dulski,
& Blobaum, 2014; Oro & Dixon, 1988; d’Apolito, 1999; Velez and& Jansson, 2008; American Academy
of Pediatrics [AAP], 2012; Bagley et al., 2014; MacMullen, Dulski, & Blobaum, 2014; World Health
Organization, 2014).
Rooming-in has been consistently associated with a reduced need for medication to treat NAS and a
shortened neonatal hospital stay (Abrahams et al., 2007; Hünseler, Brückle, Roth, & Kribs, 2013; McKnight
et al., 2016; Saiki, Lee, Hannam, & Greenough, 2010). Breastfeeding and rooming-in may go hand in hand,
although it is not clear to what extent extensive breastfeeding while rooming-in drives the reductions
in NAS severity (Bagley et al., 2014). Rooming-in is now the standard of care and as such should be
offered to all mother-infant dyads. Healthcare 
professionals need to work to minimize barriers to 
breastfeeding and seek opportunities to support 
mother–infant bonding and secure attachment 
during the immediate postpartum period; these 
efforts will maximize the well-being of the mother 
and the infant. Exhibit FS #10.3 lists resources on 
nonpharmacological approaches currently available. 
FACTSHEET TO REVIEW 
For more information on when it is appropriate 
to recommend breastfeeding and for 
additional web resources, see Factsheet #11: 
Breastfeeding Considerations for Infants at 
Risk for Neonatal Abstinence Syndrome. 
Exhibit FS #10.3: Nonpharmacological Approaches Currently in Use 
Factors References 
Breastfeeding and skin-
to-skin contact 
Abdel-Latif et al., 2006; Ballard, 2002; McQueen, Murphy-Oikonen, Gerlach, & Montelpare, 2011; O’Connor, Collett, Alto, &
O’Brien, 2013; Welle-Strand et al., 2013 
Rooming-in Abrahams et al., 2007; Bagley et al., 2014; Holmes et al., 2016; Hünseler et al., 2013; McKnight et al., 2016; Saiki et al., 2010,
Acupuncture/Acupressure Filippelli et al., 2012; Schwartz, Xiao, Brown, & Sommers, 2011 
Waterbeds d’Apolito, 1999; Oro & Dixon, 1988 
The caregiver will most likely need education in how to respond to the infant’s behaviors, intensive social
supports during the postpartum period, and continued therapy for any maternal psychiatric problems. 
• Several medications are available to treat NAS. AAP recommends either oral morphine solution or
methadone to treat withdrawal that infants experience following cessation of prenatal opioid exposure
(Hudak, Tan, AAP Committee on Drugs, & AAP Committee on Fetus and Newborn, 2012). Because of
the short half-life of morphine, dosing is needed at least every 4 hours. Healthcare professionals should
be aware that these medications are usually dissolved in alcohol for compounding. Where possible,
compounding with alcohol should be avoided and preservative-free preparations should be used. 
Other medications for the treatment of NAS, such as buprenorphine, are under study (Kraft et al., 2008,
2011). Although there is preliminary evidence that sublingual buprenorphine may be more effective than
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morphine for treatment of moderate to severe NAS (Kraft, Stover, & Davis, 2016, Kraft Adeniyi-Jones,
Chernvoneva, Greenspan, Abatemarco, Kaltenbach & Ehrlich, 2017), further study is needed. Phenobarbital
and clonidine are effective adjuvant therapies to morphine and methadone when maximum dose of the
first-line medication has been reached or when weaning is unsuccessful (Agthe et al., 2009; Kocherlakota,
2014; Kraft, Stover, & Davis, 2016).
• For several reasons, including avoiding medication errors, diluted tincture of opium is no longer widely
used for treating NAS. Diluted tincture of opium is easily confused with deodorized tincture of opium
(both commonly abbreviated DTO) and has a high alcohol content (Langenfeld et al., 2005). Oral morphine
sulfate is now preferred over diluted tincture of opium and is as effective as diluted tincture of opium. 
• Women with OUD who are not receiving treatment with an opioid agonist are likely to misuse a
combination of short- and long-acting opioids, which complicates the infant observation period.
Opioids with a short half-life include codeine, fentanyl, heroin, hydrocodone, hydromorphone, meperidine,
morphine, and oxycodone. Examples of opioids with a long half-life are buprenorphine, levorphanol, and
methadone. If the infant was exposed only to short half-life opioids in utero, observe the infant closely
for 96 hours and then discharge if NAS medication is no longer needed for the infant. If the infant was
exposed to any long half-life opioids in utero, it may be necessary to extend the observation period to 4–7
days from birth before discharge (Hudak, et al., 2012). 
WEB RESOURCES ON THIS TOPIC 
2017 ICD-10-CM Diagnosis Code 96.1 
This website provides detailed information on the codes for neonatal withdrawal symptoms used for
reimbursement purposes. 
Advisory: Tobacco Use Cessation During Substance Abuse Treatment Counseling 
This 2011 Substance Abuse and Mental Health Services Administration document offers substance use
disorder (SUD) counselors an introduction to tobacco use cessation during SUD treatment. It discusses
screening and effective treatment approaches to quitting, including cessation medications and
practical and supportive counseling. 
Childbirth, Breastfeeding, and Infant Care: Methadone and Buprenorphine 
This brochure urges pregnant women who use heroin or abuse opioid prescriptions to seek medication-
assisted treatment with methadone or buprenorphine. It discusses how methadone therapy works and
women’s issues such as breastfeeding, opioid withdrawal, birth control, and child protection services. 
Neonatal Abstinence Syndrome: A Guide for Families 
This 2014 guide was produced by the Ohio Prenatal Quality Collaborative in conjunction with
Dartmouth-Hitchcock Medical Center. It was written to help family members care for infants with NAS,
both while in the hospital and after discharge.
SIDS and Other Sleep-Related Infant Deaths 
This 2016 AAP policy statement on sudden infant death syndrome (SIDS) and other sleep-related infant
deaths provides recommendations for a safe infant sleeping environment. 
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SECTION 2 
FACTSHEET # 
11 
BREASTFEEDING 
CONSIDERATIONS FOR INFANTS
AT RISK FOR NEONATAL  
ABSTINENCE SYNDROME 
CLINICAL SCENARIO 
A mother with an infant at risk for neonatal abstinence syndrome (NAS) seeks advice on whether to breastfeed. 
CLINICAL ACTION STEPS 
Stable Mother and Breastfeeding 
Upon delivery, women who are stable on buprenorphine, buprenorphine/naloxone
combination, or methadone should be advised to breastfeed, if appropriate. 
Although naltrexone in breastmilk has not been studied extensively in the United States,
the benefits of breastfeeding are generally thought to outweigh any risk from naltrexone
exposure. The decision to breastfeed while on naltrexone should be made collaboratively with
the new mother after a full discussion of the lack of research and individual considerations. 
Medical Considerations 
An infant with NAS who cannot maintain adequate hydration or who loses weight despite
optimal management should be evaluated to rule out other medical conditions, and
consideration should be given to transferring the infant to a neonatal intensive care unit. 
SUPPORTING EVIDENCE AND CLINICAL CONSIDERATIONS 
Stable Mother and Breastfeeding 
• Levels of buprenorphine and methadone are very low in breast milk. Few studies have focused on
breastfeeding as an outcome of opioid agonist pharmacotherapy for pregnant women with opioid use
disorder (OUD) (Abrahams et al., 2007; Debelak, Morrone, O’Grady, & Jones, 2013; Johnson et al., 2001).
Buprenorphine and methadone levels in breast milk are very low when the mother is on pharmacotherapy
and pose little risk to infants (Ilett et al., 2012; Jansson et al., 2008a, 2008b, 2016). 
• The decision to use the combination buprenorphine/naloxone product while breastfeeding is a shared
decision, but one that ultimately must be made by the patient once she understands the risks and benefits
to herself and her newborn. Available data suggest that naloxone does not affect lactation hormone levels
in breastfeeding mothers. The mother’s use of buprenorphine with naloxone is not a reason for discontinuing
breastfeeding (Cholst, Wardlaw, Newman, & Frantz, 1984; Johnson, Andrews, Seckl, & Lightman, 1990).
Naloxone’s poor bioavailability when taken either sublingually or transmucosally in the buprenorphine/naloxone
combination product (Ilett et al., 2012) makes it even less likely to transfer to the neonate via breast milk. 
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Recent studies suggest that maternal and infant outcomes on
the combination buprenorphine/naloxone product do not differ
from those of buprenorphine only (Debelak et al., 2013; Dooley
et al., 2016; Gawronski et al., 2014; Jumah et al., 2016; Lund et
al., 2013; Wiegand et al., 2015). Small nonclinically meaningful
amounts of naloxone are present in cord blood (Wiegand et al.,
2016). No increased birth defect risks have been reported after naloxone was used in pregnant women as
an antidote to opioid overdose (Bailey, 2003). However, no long-term follow-up studies that investigate
neurodevelopment in infants exposed to buprenorphine/naloxone in utero have been published. 
• The effects, if any, of naltrexone on child development are not known. There are at least 25 published
prenatal naltrexone implant exposure cases, and all show normal birth outcomes (Hulse, Arnold-Reed,
O’Neil, & Hansson, 2003; Hulse, O’Neil, & Arnold-Reed, 2004; Jones, Chisolm, Jansson, & Terplan, 2012). A
mother’s preference for beginning antagonist therapy may be considered if she resumes pharmacotherapy
in the postpartum period. However, only one case study has reported examining how much naltrexone
is secreted into breast milk (Chan, Page-Sharp, Kristensen, O’Neil, & Ilett, 2004). In this case, only very
low levels of the naltrexone metabolite were detected in the infant plasma (1.1 micro g/L), and the infant
appeared to be healthy, was meeting developmental milestones on time, and showed no adverse effects.
• Healthcare professionals should take time to talk about the benefits of breastfeeding. Any breastfeeding,
however brief, can decrease the infant’s need for pharmacological treatment for NAS and the length of
pharmacological therapy and hospitalization (Abdel-Latif et al., 2006; Bagley, Wachman, Holland, & Brogly,
2014; Jansson et al., 2008a, 2008b; Reece-Stremtan, et al., 2015; Ruwanpathirana et al., 2015). The benefit
that the infants with NAS derive from breastfeeding is attributed to the act of breastfeeding (e.g., making
skin-to-skin contact, holding infant closely) rather than to the amount of maternal opioid agonist secreted
into the breast milk (Kaltenbach & Jones, 2016). 
• Mothers need to know when they should or should not breastfeed. Although a stable mother being
treated for OUD with pharmacotherapy is encouraged to breastfeed her infant, there are some situations
where breastfeeding is not recommended (e.g., the mother is HIV-positive, has tuberculosis, has cracked or
bleeding nipples, is hepatitis C-positive, has returned to illicit drug use including cannabis). Mothers who are
hepatitis B surface antigen-positive or who are infected with the hepatitis C virus may breastfeed (American
Academy of Pediatrics [AAP], Section on Breastfeeding, 2012; Centers for Disease Control and Prevention
[CDC], 2015). CDC (2016) describes other situations in which a mother should avoid breastfeeding. 
Careful consideration regarding breastfeeding is needed for women who 
present to prenatal care and/or SUD treatment during or after the second 
trimester, women who return to illicit substance use/licit substance misuse, 
and women who attained abstinence only in an inpatient setting. In these 
cases, a recommendation for lactation should be determined with the 
collaborative care team and the new mother. Factsheet #16: Maternal 
Return to Substance Use provides more guidance on breastfeeding should 
the mother return to substance use. 
Breastfeeding has many positive 
physical and behavioral health 
effects for mother and infant. 
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The American College of Obstetricians and Gynecologists (ACOG)
recommends against maternal cannabis use (Committee on Obstetric
Practice, ACOG, 2017) as does a recent National Academies of Science
report (National Academies of Sciences, Engineering, & Medicine, 2017).
of tetrahydrocannabinol, the principal psychoactive component of cannabis,
New research is expected on both maternal cannabis smoking and ingestion
due to the legalization of cannabis use in several states. Until research
on this issue is provided, pregnant women and new mothers should be
counseled to avoid cannabis, as well as alcohol and nicotine, for either
recreational or medicinal purposes (Committee on Obstetric
Practice, ACOG, 2017; Jansson, Bunik, & Bogen, 2015; Reece-
Stremtan et al., 2015; Volkow, Compton & Wargo, 2017; World Health
Organization [WHO], 2014). Exhibit FS #11.1 provides examples of
when a mother with OUD might be advised to breastfeed and when
breastfeeding is not recommended.
Exhibit FS #11.1: Breastfeeding Recommendations 
Factors Breastfeeding May Not Be Recommended* 
The mother is enrolled in a medication-assisted treatment program (with
either buprenorphine or methadone) with significant social support and
plans to continue treatment. She has demonstrated that she is stable in
treatment.
The mother has a medical condition or takes medications that are
contraindicated for lactation.
The mother has given written informed consent for healthcare
professionals to discuss her SUD treatment. 
The mother did not receive prenatal care 
The mother’s pain management medications after delivery are not
contraindicated for newborns. 
Close to delivery, the mother has a pattern of regular illicit drug use or
licit substance use meeting criteria for an active SUD. 
The mother’s urine toxicology results were negative except for prescribed
medications at delivery. 
The mother is not willing to engage in SUD treatment or is engaged in
treatment but is not willing to provide consent for contact with anyone in
the program. 
The mother has received consistent prenatal care. The mother’s urine toxicology results were positive for substances or
their metabolites indicating recent use of alcohol or other substances
that are not prescribed to her for the treatment of a medical condition. 
The mother plans to consider SUD treatment in the postpartum period. The mother does not have confirmed plans for postpartum SUD
treatment and pediatric care. 
The mother has been advised of the risk and benefits of taking
antidepressants, anxiolytics, and mood stabilizers during the
breastfeeding period. 
The mother demonstrates behaviors or other indicators of an active SUD 
If the infant has significant NAS, lactation support is available. 
* If the mother meets one or more of these criteria, further evaluation should be conducted to determine whether she can support safe
infant breastfeeding. Evidence is accumulating to recommend eliminating cannabis use during pregnancy, while breastfeeding, or through
secondhand smoke exposure (Jansson, Bunik, & Bogen, 2015). 
Sources: AAP, Section on Breastfeeding, 2012; CDC, 2016; Committee on Obstetric Practice, ACOG, 2017; Hudak et al., 2012; Jansson et al., 2008a,
2008b, 2016; Jansson & Velez, 2015; Reece-Stremtan et al., 2015; WHO, 2014. 
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WEB RESOURCES ON THIS TOPIC 
ABM Protocol #21: Guidelines for Breastfeeding and Substance Use or Substance Use Disorder, Revised 2015
This ABM protocol provides evidence-based guidelines for the evaluation and management of women with
SUDs who are considering breastfeeding. It includes information on methadone and buprenorphine. 
Baby Friendly Hospital Initiative-USA 
This global initiative was launched by WHO and the United Nations Children’s Fund in 1991 to encourage
and recognize hospitals and birthing centers that offer an optimal level of care for infant feeding and
mother–infant bonding.
Breastfeeding Initiatives: Family Resources
This AAP webpage lists breastfeeding resources for families; some resources are in Spanish. 
Childbirth, Breastfeeding, and Infant Care: Methadone and Buprenorphine 
This brochure urges pregnant women who use heroin or abuse opioid prescriptions to seek medication-
assisted treatment with methadone or buprenorphine. It discusses how methadone therapy works and
women’s issues such as breastfeeding, opioid withdrawal, birth control, and child protection services. 
Clinician Consultation Center Substance Use Warmline 
The University of California, San Francisco’s, Clinician Consultation Center provides Substance Use
Warmline consultation to health center providers. This is a free, real-time clinician-to-clinician telephone
consultation, addressing the care and treatment of substance abuse, chronic pain, and behavioral health.
Access the Warmline toll-free at: 1-855-300-3595 (Monday-Friday, 10 a.m.-6 p.m. EDT).
Drug Entry Into Human Milk
This InfantRisk Center webpage describes in detail the mechanisms of drug entry into human milk and
provides some general rules on breastfeeding. 
Drugs and Lactation Database (LactMed)
This National Library of Medicine searchable database provides information on medications and other
chemicals to which breastfeeding mothers may be exposed. 
LactMed
This website provides the most current and comprehensive information on transference of substances to
breast milk.
Medications and Breastfeeding: Tips for Giving Accurate Information to Mothers 
This two-page AAP document discusses clinical points to consider when prescribing medications to
breastfeeding mothers. 
Policy Statement: Breastfeeding and the Use of Human Milk 
This AAP-updated policy statement discusses the benefits of breastfeeding for mother and child. 
SIDS and Other Sleep-Related Infant Deaths 
This 2016 AAP policy statement on sudden infant death syndrome (SIDS) and other sleep-related infant
deaths provides recommendations for a safe infant sleeping environment. 
When Should a Mother Avoid Breastfeeding? 
This CDC webpage provides links to information about illnesses and conditions that contraindicate breastfeeding. 
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SECTION 2 
FACTSHEET # 
12 INFANT DISCHARGE 
PLANNING 
CLINICAL SCENARIO 
An opioid-exposed infant is ready for discharge home. 
CLINICAL ACTION STEPS 
In-home and Follow-up Services 
The discharge plan for infants treated for neonatal abstinence syndrome (NAS) should include home
visitation and early intervention services, such as including attachment-based parenting support, a home
nursing consult, a social work consult, and referrals to healthcare professionals who are knowledgeable
about NAS and are accessible to the family immediately after discharge. 
Caregiver Education and Home Environment 
Caregivers should receive home visitations and early intervention services that help them to recognize NAS
signs in the infant. 
Healthcare professionals can present the benefits of a stable and enriched home environment for the family
and provide support to achieve such a positive environment.
A mother who is worried that her substance use disorder (SUD) history increases the likelihood that her child
will have an SUD in the future should be counseled that genetic and social factors increase the risk of SUD in
children of parents with SUDs but that a stable, healthy home environment can reduce that risk. 
Need for Acute Follow-up 
An infant treated for NAS who has trouble eating or sleeping, is crying more than expected, or has loose
stools after discharge should be promptly evaluated by a healthcare professional. 
SUPPORTING EVIDENCE AND CLINICAL CONSIDERATIONS 
In-home and Follow-up Services 
• When completing the discharge checklist, the assumption is that the infant has remained in the hospital
for a minimum of 4 days or until NAS medical treatment, if warranted, has been completed. It is assumed
that the mother is ready for discharge at the same time as the infant and the proper protocols for maternal
discharge have been followed. In addition to following standard infant discharge procedures (Benitz &
American Academy of Pediatrics [AAP] Committee on Fetus and New Born, 2015), it is recommended that
the checklists in Exhibit FS # 12.1 be completed at discharge and at follow-up visits. 
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Exhibit FS #12.1: Sample Protocol for Discharge and Follow-up Visits* 
Infant Discharge Checklist 
Healthcare Professionals Considerations When Determining Infant Discharge Eligibility Is Infant Ready for Discharge?† 
Infant weaned off medication (if applied) and observed for at least 24 hours after weaning, following a hospital
protocol. 
 
Infant is successfully feeding.  
Caregivers received education about recognition of infant signs of NAS and have the contact information of
responsive medical personnel to call with concerns. 
 
Caregivers have received education about techniques to soothe the infant (e.g., dim lights, softly playing white
noise, skin-to-skin contact, pacifier, swaddling) and ways to recognize and respond to infant dysregulation. 
 
Caregivers are responding to the infant’s needs in a safe and responsive way.  
Caregivers have been educated on the Safe to Sleep campaign and the infant has its own place to sleep to
reduce the risk of sudden infant death syndrome (SIDS), especially as infants with NAS are at an increased risk
for sleep-related deaths. 
 
Caregivers have received education about follow-up plans that include home visits and early pediatric follow-
up appointments (within 5 days of discharge). 
 
†If all boxes are checked, the infant is ready to be considered for discharge. 
Best Practices for Infant Follow-up 
Actions for the Social Worker or Case Manager at or Shortly After Discharge 
• Schedule a pediatric medical follow-up appointment within 2–5 days of discharge. 
• Help the family get to the appointment (e.g., arrange transportation). 
• Call or text family members to remind them of the appointment. 
Medical Follow-up
• Contact the family if the infant misses an appointment and attempt to reschedule it.
• Ensure adequate follow-up if the infant has been exposed to hepatitis B and C. 
• Notify other healthcare professionals involved in the postnatal mother-infant dyad
care if the family cannot be reached.
• Ensure the infant visit schedule follows the AAP Bright Futures Periodicity Schedule or 
schedule more frequent visits if there are concerns about the dyad. 
Infants should only be swaddled
at home if the caregivers have
been given training in swaddling.
The following recommendations on
swaddling were released in the 2016
AAP policy statement on safe sleep
practices (AAP Task Force on Sudden
Infant Death Syndrome, 2016): 
• When an infant is 
swaddled, he or she 
should always be 
placed on the 
back. 
• Because there 
is a high risk 
of death if a 
swaddled infant 
rolls into the face-
down position, 
when an infant 
attempts to roll over, 
swaddling should be 
discontinued. 
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• Although the majority of infants can be weaned from methadone or morphine relatively quickly, some
cannot. These infants will require ongoing help and support, as will their mothers or caregivers. Eighty
percent of infants can be successfully weaned from methadone completely within 5 to 10 days (Hudak,
Tan, AAP Committee on Drugs, & AAP Committee on Fetus and Newborn, 2012). When infants remain in
the hospital for pharmacotherapy, the mothers should be invited to stay with the infant so as to promote
rooming-in and other nonpharmacological practices until the infant is weaned from medication. 
Caregiver Education and Home Environment 
• Infant discharge planning should begin before birth, with discussions on ways to reduce NAS expression
and severity and promote healthy attachment. Maternal support in the hospital that promotes rooming-in,
breastfeeding when appropriate, and skin-to-skin contact increases the opportunities for mothers to nurture
their infant and develop parenting skills. With education,
support, and mentoring resources, mothers may develop
healthy attachment, bonding, and other caregiving behaviors
(Abrahams et al., 2007). A small study following prenatally
opioid-exposed children for 5 years concluded that a parent– 
healthcare professional relationship established in pregnancy
and continued during the postpartum period facilitated a long-
lasting relationship with childhood professionals and reduced
court-ordered placements and reports of developmental
disorders (Roy et al., 2011). 
• Healthcare professionals should remind parents that
a healthy home environment is critical to healthy
development—from infancy to adolescence—and work to ensure the necessary in-home services and
resources are available to make this possible regardless of the family’s circumstances. The home must
be secured from safety hazards, and prescription drugs must be out of reach, preferably stored under lock
and key. Routine pediatric health maintenance is critical, especially in the first 2 years (Smith & Wilson,
2016). This includes pediatric well-child visits for growth and development assessment, preventive care, and
immunizations. Healthcare professionals have a unique opportunity to recognize and assess a child’s risk, to
intervene to protect the child, and to help parents improve both parenting skills and the home environment. 
The most promising prevention interventions provide reduction of risks and boosts
of protective factors across multiple domains (individual and peer, family, school
and community; Jackson, Geddes, Haw & Frank, 2012). 
• Research to understand the genetics of SUDs is still emerging. Researchers
believe that some of the same genes that increase a person’s risk for problems with
alcohol might also put him or her at greater risk for other SUDs. Moreover, those
same genes might increase the risk for other psychiatric problems, such as conduct
disorder and adult antisocial behavior (i.e., externalizing behaviors) (Dick & Agrawal,
2008). Recent studies suggest that the genetic variability of μ-, δ-, and κ-opioid
receptor genes OPRM1, OPRD1, and OPRK1 can modulate the efficacy of opioid
treatments (Bauer, Soares, & Nielsen, 2015; Wachman et al., 2013, 2015). Currently, it
is difficult to translate these findings into meaningful guidance
for families. Healthcare professionals should emphasize
modifiable risk factors such as maintaining parental recovery
and supporting a stable home environment. 
The infant discharge plan should
be compatible with and support
the plan of safe care for mother
and infant; this includes addressing
potential maternal comorbid medical
or mental disorders. See Factsheet
#15: Maternal Discharge Planning,
for a more extensive discussion about
implementing a plan of safe care for
both the mother and infant.
The mother’s ongoing engagement
in treatment and recovery support
for OUD is an essential element of a
healthy home environment.
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WEB RESOURCES ON THIS TOPIC 
Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 4th Edition 
This multimodal library of materials for stakeholders involved in improving health care for infants, children,
and adolescents was first published in 2000 by AAP. It includes evidence-based toolkits that cover all
aspects of pediatric health care.
Bright Futures/AAP Periodicity Schedule
This chart presents the screenings, assessments, physical examinations, procedures, and timing of
anticipatory guidance recommended for each age-related well-child visit in Bright Futures: Guidelines for
Health Supervision of Infants, Children, and Adolescents (Hagan, Shaw, & Duncan, 2017). 
Federal Home Visiting Program
This webpage provides background about the Health Resources and Services Administration (HRSA) and
Administration for Children & Families program, its structure, and its mission and services, which involve
evidence-based, voluntary home visiting programs, where families receive help from health, social service,
and child development professionals. 
Healthy Start
This webpage describes the HRSA Healthy Start program and links to a technical assistance center with
more information on program approaches and grantees. The program provides depression screening,
healthcare services, care coordination, public health services such as immunization and health education,
and training for community health workers and care coordinators. 
Maternal & Child Health Topics: Perinatal and Infant Health 
This webpage describes HRSA goals related to perinatal and infant health and lists programs and
initiatives that help HRSA achieve its goals.
Neonatal Abstinence Syndrome: A Guide for Families 
This 2014 guide was produced by the Ohio Prenatal
Quality Collaborative in conjunction with Dartmouth-
Hitchcock Medical Center. It was written to help
family members care for infants with NAS, both
while in the hospital and after discharge. 
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SECTION 2 
FACTSHEET # 
13 
EARLY INTERVENTION 
STRATEGIES AND 
DEVELOPMENTAL 
ASSESSMENTS 
CLINICAL SCENARIO 
At a routine pediatric visit, a mother is concerned that her child has developmental delays
from opioid exposure or from experiencing neonatal abstinence syndrome (NAS). 
CLINICAL ACTION STEPS 
Effects of NAS on Development 
Caregivers of prenatally opioid-exposed infants should be told that although genetic and social risk and protective
factors contribute to the child’s eventual risk for developing substance use disorders (SUDs), future SUDs or
developmental problems are not known to be long-term consequences of NAS. However, caregivers who
express concerns about the development of a child who was exposed to opioids in utero or who
professional. The child should have developmental screenings and ongoing assessments and should
experienced NAS should be carefully interviewed about their concerns by a knowledgeable pediatric
receive early intervention services if requested by the caregiver. 
Effects of Extended-Release Injectable Naltrexone on Development 
There is no information on the safety of extended-release injectable naltrexone during
pregnancy or the long-term effects on the infant of in utero exposure to this medication. 
SUPPORTING EVIDENCE AND CLINICAL CONSIDERATIONS 
Effects of NAS on Development 
• When a mother expresses concern about her child’s development, a healthcare professional should
discuss assessments and screenings to address these concerns. As with all infants, experts recommend
that opioid-exposed infants be screened while in the hospital and on subsequent pediatric visits for
developmental milestones and whenever concerns arise about neurodevelopment. There are many
unknowns; the recommendation is to follow the infant closely and order specialized assessments if the
healthcare professional or caregiver have concerns. 
Healthcare professionals should review normal developmental milestones with caregivers of opioid-exposed
infants (e.g., infant smiles, sits alone, makes eyes contact), so they can better understand the importance of
achieving these milestones within a certain timeframe. 
Infants born to mothers who received methadone or buprenorphine during pregnancy were found as
toddlers to have no more problems with certain developmental tasks than those from a normative sample of
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children of mothers without SUD, after controlling for
confounding factors, such as maternal psychological
distress and instability in the home environment.
(Sarfi, Sundet, & Waal, 2013). The American College
of Obstetricians and Gynecologists (ACOG) reports
that current data on in utero opioid-exposed
infants are limited (Committee on Healthcare
for Underserved Women, American Society of
Addiction Medicine, & ACOG, 2012, 2017); however,
earlier studies did not find significant differences in
cognitive development between children up to age
5 who had been exposed to methadone in utero and
those who had not.
The process used in developing this Guide
determined that there was insufficient evidence
to attribute subsequent neurodevelopmental
problems to a history of NAS but did
conclude that developmental assessments
should be conducted whenever there is
concern. Appendix A: Suitable Developmental
Assessments for Opioid-Exposed Infants 
and Children provides information on age-
appropriate developmental screens. Chapter 3 in
the National Institute on Drug Abuse’s (NIDA’s)
Principles of Substance Abuse Prevention for
Early Childhood describes evidence-based early
childhood interventions (NIDA, 2016). 
Effects of Extended-Release Injectable 
Naltrexone 
• The effects, if any, of naltrexone on child
development are not known. There are at least 25
published prenatal naltrexone implant exposure
cases, and all show normal birth outcomes (Hulse,
Arnold-Reed, O’Neil, & Hansson, 2003; Hulse,
O’Neil, & Arnold-Reed, 2004; Jones, Chisolm,
Jansson, & Terplan, 2012). A mother’s preference for
beginning antagonist therapy may be considered if
she resumes pharmacotherapy in the postpartum
period. However, only one case study has reported
examining how much naltrexone is secreted into
breast milk (Chan, Page-Sharp, Kristensen, O’Neil, &
Ilett, 2004). In this case, only very low levels of the
naltrexone metabolite were detected in the infant
plasma (1.1 micro g/L), and the infant appeared to
be healthy, was meeting developmental milestones
on time, and showed no adverse effects.
Medicaid may support postpartum care, which
would include home visits after the birth of
the child through the Health Resources and
Services Administration (HRSA) Federal Home
Visiting Program and the Administration
for Children & Families’ (ACF’s) Early Head
Start (EHS) programs. Caregivers who are
concerned about their child’s development
after exposure to opioids in utero may request
a developmental assessment through this
program. Infants exposed to opioids in utero
and their mothers may be eligible for early
intervention services (e.g., screenings, case
management, family support, counseling,
parent/caregiver skills training).
FACTSHEET TO REVIEW 
Factsheet #15: Maternal Discharge Planning 
for more information on managing postnatal 
mental disorders including depression and 
anxiety. 
WEB RESOURCES ON THIS TOPIC 
A Collaborative Approach to the Treatment of Pregnant Women With Opioid Use Disorders: Practice
and Policy Considerations for Child Welfare, Collaborating Medical, and Service Providers
This Substance Abuse and Mental Health Services Administration document provides information on the
treatment of pregnant women with OUD, summarizes guidelines adopted by a variety of professional
organizations, and presents a framework for organizing community efforts. It provides a coordinated,
multisystem approach grounded in early identification and intervention to assist child welfare, medical,
SUD treatment, and other systems in supporting families. 
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Ages and Stages Questionnaire, 3rd Edition (ASQ-3) 
This screening tool measures developmental progress in children between ages 1 month and 5 years. 
Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 4th Edition 
This multimodal library of materials for stakeholders involved in improving health care for infants, children, 
and adolescents was first published in 2000 by the American Academy of Pediatrics. It includes evidence-
based toolkits that cover all aspects of pediatric health care. 
Early Head Start Programs 
EHS programs administered by ACF serve infants and toddlers younger than age 3 and pregnant women. 
These programs provide intensive comprehensive child development and family support services to low-
income infants and toddlers and their families and to pregnant women and their families. 
Federal Home Visiting Program 
This webpage provides background information about the HRSA and ACF program, its structure, and its 
mission and services, which involve evidence-based, voluntary home visiting programs, where families 
receive help from health, social service, and child development professionals. 
Healthy Beginnings 
This program meets the HHS criterion for an effective childhood home visiting service delivery model. In 
this model, nurse home visitors provide education on infant nutrition, 
family nutrition, and physical activity and address family members’ 
concerns. Nurse visitors typically make 8 visits from a prenatal visit 
through age 24 months. 
Principles of Substance Abuse Prevention for Early Childhood: A 
Research Based Guide 
This 2016 comprehensive NIDA guide provides research on risk 
factors and interventions in the early childhood period. Chapters 
1–4 cover three decades of research-based early intervention and 
prevention for children ages 0–3. Chapter 3 includes a table of risks 
addressed through specific age-appropriate strategies, and Chapter 4 
highlights research-based substance abuse prevention program, with 
contact details. 
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Section III: Maternal Postnatal Care 
Section III consists of three factsheets: 
Factsheet #14: Adjusting Pharmacotherapy Dose Postpartum 
Factsheet #15: Maternal Discharge Planning 
Factsheet #16: Maternal Return to Substance Use. 
I. Clinical Scenario
Presents a brief statement to orient the reader to the situation under consideration. 
II. Clinical Action Steps
Present recommendations that are derived directly from the rated clinical decisions in the
RAND/UCLA Appropriateness Method report and describe what can, might, or should not be
done when caring for women and their infants. 
III. Supporting Evidence and Clinical Considerations
Present strengths and weaknesses of the evidence supporting the clinical action steps. This
section describes how to address or tailor recommended actions to unique patient variables
and preferences, the clinical experience of the provider, and available community resources.
Guidance is based on expert panel and Federal Steering Committee discussions and additional
information from published articles. This section includes supporting information for the Clinical
Action Steps as well as information in where there was insufficient evidence to recommend a
clear course of action. Instead, information in this section will provide elements that must be
taken into consideration when making a decision with the pregnant women or new mother
about the best course of action for herself or her infant. 
IV. Web Resources 
Provide links to additional online information. 
FACTSHEET #14: Adjusting Pharmacotherapy Dose Postpartum 
CLINICAL SCENARIO: A new mother with opioid use disorder (OUD) is interested in changing her
pharmacotherapy. 
• Dose adjustments due to oversedation 
• Dangers of mixing opioid agonists and
benzodiazepines 
• Closely observing postpartum dosing 
• Discussing risks and benefits of changing or
tapering pharmacotherapy 
• Cost, availability, preauthorization requirements,
and complications with transitioning 
110 
FACTSHEET #15: Maternal Discharge Planning 
CLINICAL SCENARIO: A new mother with OUD is ready for discharge after delivery. 
• Comorbid mental disorder care planning 
• Mental health and/or substance use disorders and 
consumer-/patient-led organizations 
• Avoiding abrupt discontinuation of 
pharmacotherapy 
• Referring families to federal programs providing 
perinatal and infant health services 
FACTSHEET #16: Maternal Return to Substance Use 
CLINICAL SCENARIO: A new mother returns to substance use, whether alcohol, benzodiazepines, 
cocaine, marijuana, methamphetamine, opioids, or tobacco. 
• Adjusting pharmacotherapy dose 
• Changing or resuming pharmacotherapy 
• Breastfeeding in the context of return to substance 
use 
• Working across disciplines and specialties and 
providing additional services via a collaborative 
care model 
• Assessing marijuana, alcohol, and tobacco use in 
the context of many unknowns 
• Considerations for discontinuation of 
breastfeeding 
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SECTION III 
FACTSHEET # 
14 ADJUSTING PHARMACOTHERAPY DOSE 
POSTPARTUM 
CLINICAL SCENARIO 
A new mother with opioid use disorder (OUD) is interested in changing her pharmacotherapy. 
CLINICAL ACTION STEPS 
Dose Adjustment Due to Oversedation 
In the immediate postpartum period, complaints of drowsiness and somnolence (a strong desire for sleep, or
sleeping for unusually long periods) should prompt evaluation of the new mother’s dose of agonist therapy.
A dose effective in pregnancy may be too high during the postpartum period. The patient may present with
these complaints while still in the hospital or shortly after discharge. 
Pharmacotherapy Changes 
Struggling with cravings even without a return to substance use may prompt a new mother to ask about
changing her medication. Cravings alone do not justify changing to a different pharmacotherapy for OUD.
The effectiveness of the patient’s pharmacotherapy dose should be evaluated, and the dose possibly
adjusted. Cravings can occur even when OUD is well managed. Patients who report cravings during the
postpartum period should receive additional behavioral interventions to address new or aggravated stressors.
Consideration may be given to a new mother’s request to change the form of pharmacotherapy for OUD
based on her preference and on health or social considerations after delivery. The reasons for and risks and
benefits of such a change should be thoroughly discussed with other treating healthcare professionals, with
the patient’s permission, before the decision is made. 
SUPPORTING EVIDENCE AND CLINICAL CONSIDERATIONS 
Dose Adjustment Due to Oversedation 
• If a new mother is exhibiting signs of oversedation and is breastfeeding, the healthcare professional
should assess both the mother and the infant. Because of the variability in dosing amounts
before delivery, healthcare professionals are advised to use signs of somnolence to guide their
recommendations on tapering the postpartum dose for new mothers using either methadone
or buprenorphine (Jones et al., 2008a, 2008b). The mother could be drowsy because she
has a demanding newborn who does not sleep or eat well. Thus, dose changes need to be
individualized, and uniform dose changes postpartum cannot be made. Evidence supporting
the need to lower methadone or buprenorphine doses after delivery is mixed (Bastian et al.,
2016; Bogen et al., 2013; Jones et al., 2008a; Pace, Kaminetzky, Winter, & Walley, 2014). 
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After delivery, a new mother’s body will go through multiple
physiological changes; her previously effective dose
pharmacotherapy for OUD may, therefore, need to be adjusted.
When oversedation is reported or observed, pharmacotherapy
dosages can be titrated as indicated (Bogen et al., 2013;
Committee on Healthcare for Underserved Women, American
Society of Addiction Medicine, & American College of
Obstetricians and Gynecologists, 2012, 2017; Jones et al., 2008a;
Pace et al., 2014).
Mothers being treated with opioid agonists need to be especially
careful to avoid alcohol or any sedating medications, especially
benzodiazepines. Between 2000 and 2010, the number of
substance use treatment admissions involving a benzodiazepine
and narcotic pain reliever combination increased from 5,032
to 33,701 (Wyatt, 2015). Many more people have begun using
these medications without prescriptions, and this combination is
especially dangerous to breastfed infants. 
Watch for signs of oversedation. The
mother and family members should
be informed of what to watch for and
instructed to contact the healthcare
professionals if signs or symptoms of
oversedation appear. The healthcare
professional should schedule a 
follow-up visit with the mother as
early as possible after discharge.
Healthcare professionals must 
be keenly aware of the dangers 
of mixing opioid agonists and 
benzodiazepines for both the 
mother and infant. 
Given the lack of research 
on the safety of naltrexone 
for breastfeeding infants, the 
decision to use naltrexone 
during breastfeeding should be 
undertaken only after an individual 
risk–benefit analysis. 
FACTSHEET TO REVIEW 
Factsheet #3: Changing
Pharmacotherapy During Pregnancy
includes more information about
the risks associated with changing
pharmacotherapy. 
Pharmacotherapy Changes 
• A mother who wants to change pharmacotherapy for OUD
should first consider the risks and benefits with her clinician.
When a new mother who is currently stable on methadone
or buprenorphine requests a switch to naltrexone, begin a
conversation about the risks of changing a medication, including
the potential for destabilization and return to substance use.
The risk of return to substance use is high in this case, and the
woman should be advised that the change should not be made
without a compelling reason. A new mother who is not stable
on her current medication may need to have behavioral health
and support services added to her care plan, and healthcare
professionals can consider making dose adjustments to her
postpartum care plan to address cravings or withdrawal signs
(Bogen et al., 2013; Jones, 2008a; Pace et al., 2014).
Naltrexone may be the best pharmacotherapy for some women.
Because no systematic research exists on the safety of naltrexone
exposure via breast milk, the healthcare professional and the
mother should carefully discuss the risks and benefits of continued
breastfeeding. Every effort should be made to avoid premature
discontinuation of agonist therapy given the overall benefits of
breastfeeding to both mother and child in appropriate dyads.
Nevertheless, the result of the discussion may be a decision to
begin formula-feeding the infant. In general, unless safety is a
concern, discontinuing one pharmacotherapy to start another
should be avoided until breastfeeding is naturally concluded. 
• Some mothers will want to taper off their pharmacotherapy
during the period they are breastfeeding. Some women will
attempt to taper off pharmacotherapy while breastfeeding and
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be faced with deciding whether to resume pharmacotherapy because of a return to substance use or a risk
of returning to use. The mother can be reassured that the amount of prescribed pharmacotherapy to which
the baby is exposed via breast milk is extremely small, while the risk of harm to the infant from her return to
substance use is much greater.
Healthcare professionals should make every effort to avoid premature discontinuation of pharmacotherapy
for OUD in light of the overall benefits of breastfeeding to both mother and child. Discontinuation of
pharmacotherapy should, at the very least, be delayed until after the infant is consistently sleeping through
the night and has completed breastfeeding. The longer the patient continues on OUD pharmacotherapy, the
lower her risk of return to substance use when she eventually chooses to taper. 
• Transitioning medications can be challenging because of cost, availability, and preauthorization
requirements. Sometimes the logistics, reimbursement, or regulatory issues accompanying a change in
pharmacotherapy for OUD can be daunting. The costs of medications may become an issue, regardless of
the patient’s insurance payer; securing the required insurance prior authorization can be challenging and
time consuming. If the patient opts to switch medications, all documentation needs to be completed and the
preauthorization received before the change is made to avoid gaps in treatment (Krans & Patrick, 2016). 
WEB RESOURCES ON THIS TOPIC 
National Center on Substance Abuse and Child Welfare (NCSACW) 
Webinar Series on Opioid Use Disorders and Treatment 
Several NCSACW-sponsored webinars are specific to treatment of pregnant 
women with OUD or are focused on infants and children prenatally exposed 
to opioids. 
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SECTION III 
FACTSHEET # 
15 MATERNAL DISCHARGE 
PLANNING 
CLINICAL SCENARIO 
A new mother with opioid use disorder (OUD) is ready for discharge after delivery. 
CLINICAL ACTION STEPS 
Comorbid Mental Disorders 
Any new mother with OUD should be screened for comorbid mental disorders before discharge from the
hospital and again at the postpartum outpatient appointment. 
Discontinuation of Pharmacotherapy 
Discontinuation of pharmacotherapy for OUD should generally be avoided in the immediate postpartum
period but may be considered later if the mother is stable and the mother and child are well bonded and
have a safe, stable social environment and home. 
Every effort should be made to avoid discontinuing pharmacotherapy for OUD at the request of the
patient’s family, social service provider, parole or probation officer, or judge. Pharmacotherapy for OUD
should be discontinued only when in the best interest of the mother and infant. 
Contraception 
A woman with OUD, whether she is receiving pharmacotherapy or not, should be counseled regarding
contraception and have immediate, easy access to her contraceptive of choice before her discharge. 
SUPPORTING EVIDENCE AND CLINICAL CONSIDERATIONS 
Comorbid Mental Disorders 
• The discharge plan should be compatible with and support the plan of safe care for mother and infant;
this includes addressing potential maternal comorbid medical or mental disorders. The plan of safe
care should be made for the mother and the infant that includes addressing potential maternal comorbid
medical or mental disorders. The plan of safe care should address any existing maternal comorbid
medical or psychiatric condition and recognize that the physiologic change after delivery, stress and sleep
deprivation the new mother experiences may exacerbate these conditions or trigger a return to some form
of substance use. The discharge plan should include strategies for the new mother to get immediate and
nonjudgmental assistance if she feels she is or may become unstable. 
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• People who are in recovery from a substance use disorder (SUD)
or who live with behavioral health disorders often find support,
encouragement, and community in consumer-/patient-led
organizations. Peer counselors or recovery coaches assist people
seeking recovery from SUDs by supporting them and helping them
avoid triggers that can lead to return to substance use (Substance
Abuse and Mental Health Services Administration [SAMHSA],
2015). Coaches can provide transportation to and from meetings
and show parents how to securely store all medications, including
pharmacotherapy for OUD, so that young children cannot get
into them. SAMHSA has compiled a list of core competencies that
healthcare professionals should expect from peer support staff
(SAMHSA, 2015). The effectiveness of peer support has not been
extensively evaluated, and such evaluations are even rarer for
programs involving pregnant women with SUDs (Barlow et al.,
2015; Sanders, Trinh, Sherman, & Banks, 1998). 
The relapse rate for women
with SUD increases for women
after delivery (Helmbrecht &
Thiagarajah, 2008) and can
be impacted by issues such as
postpartum/maternal depression
and the stress of parenting.
Healthcare professionals should
consider providing the mother
with support services for longer
than the traditional 6-week
postpartum period.
FACTSHEET TO REVIEW 
See also Factsheet #14: Adjusting
Pharmacotherapy Dose Postpartum
and FS #16 Maternal Return to
Substance Use for additional
information on adjusting medications
and support postpartum. 
Discontinuation of Pharmacotherapy 
• Explain the importance of not abruptly discontinuing
pharmacotherapy. Sometimes people feel that they no longer
need pharmacotherapy for OUD and would like to stop taking
these medications. Plans to stop taking a medication should be
made by the mother in conjunction with her treatment team.
Pharmacotherapy with methadone or buprenorphine must
be tapered gradually to prevent withdrawal. A safety plan for the mother and family needs to be in place
before the tapering starts in order to know what to do if she relapses to opioid use. Discontinuation of
pharmacotherapy should, at the very least, be delayed until after the infant is consistently sleeping through
the night and has completed breastfeeding. The longer the patient continues on OUD pharmacotherapy, the
lower her risk of return to substance use when she eventually chooses to taper. 
Reducing the pharmacotherapy dosage can be considered if the
mother chooses when she is living in a safe and stable environment
(Jones et al., 2014). The best time to begin initiating discontinuation
of medication-assisted treatment is after the infant is consistently
sleeping through the night, has completed breastfeeding, and the
dyad has multiple indicators of life stability (Jones et al., 2014). 
People can safely continue
pharmacotherapy for OUD for as
long as they need it. For some,
this may be months or a year; for
others, it may be a lifetime. 
Contraception 
• Preventing unintended pregnancies and planning for future pregnancies are critical. Healthcare
professionals should offer all women, including those with OUD, non-coercive contraceptive counseling and
discuss different forms of birth control and the effectiveness of each method before they are discharged
from the hospital. Whether a woman is on pharmacotherapy for OUD or continues to misuse opioids, a
conversation about the importance of contraception is critical. Women of reproductive age who have OUD
experience a high rate of unintended pregnancy (Heil et al., 2011). One study found that only approximately
half of women with a history of current opioid use were using contraception; the majority were not using
long-acting reversible contraception (LARC), such as implants or intrauterine devices (IUDs) (Terplan, Hand,
Hutchinson, Salisbury-Afshar, & Heil, 2015). 
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The American College of Obstetricians and Gynecologists
(Committee on Healthcare for Underserved Women, American
Society of Addiction Medicine, & American College of Obstetricians
and Gynecologists [ACOG], 2012, 2017) and the American College of
Nurse-Midwives and other nurse professional societies recommend
offering immediate postpartum LARC to reduce unintended or
short-interval pregnancy. Although there is a higher chance of
expulsion with the immediate placement of an IUD after delivery,
a risk–benefit analysis concluded that, because many women do
not attend their 6-week postpartum visit (at which time a LARC
is often provided), insertion while still at the hospital after delivery
is an excellent time to implant the device. Concerns with Medicaid
reimbursement are an issue, but many states are now providing
policy statements on reimbursement at time of insertion. 
Healthcare professionals can encourage women already in treatment to consider planning their next
pregnancy with the healthcare team to make sure they are on safe medications, their treatment status is
stable, and they are ready for the stresses of motherhood on top of treatment or recovery. 
Ideally, each new mother should 
have the option to receive a long-
acting reversible contraceptive
prior to leaving the hospital.
At a minimum, women should
receive non-coercive contraceptive
counseling and the option to leave 
the hospital with a prescription
for contraception, contraceptive 
supplies, or a contraception plan
(SAMHSA, 2014). 
Other Evidence/Considerations 
• Give referrals to services that provide perinatal and infant 
healthcare to increase access to quality care, promote 
healthy development, and reduce the risk of infant or 
maternal morbidity and mortality. Support for the new mother 
is important to facilitate her bonding with the infant. The Health 
Resources and Services Administration (HRSA) Federal Home 
Visiting Program provides an array of services to vulnerable 
families through home visits, which may include assisting 
mothers with guidance on how best to breastfeed and care for 
their babies; helping parents understand child development 
milestones and behaviors; promoting parents’ use of praise and 
other positive parenting techniques; and working with mothers 
to set goals for the future, continue their education, and find 
employment and childcare solutions. 
FACTSHEETS TO REVIEW 
• Factsheet #7: Planning Prior to
Labor and Delivery for topics to
discuss with women during their
pregnancy, including postpartum
contraception plans 
• Factsheet #12: Infant Discharge
Planning for discussions of home
visitation services and peer
support services available to new
mothers and caregivers 
• Factsheet #16: Maternal Return
to Substance Use for guidance on
preventing return to substance use
and supporting recovery 
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WEB RESOURCES ON THIS TOPIC 
ACOG Immediate Postpartum Contraception Options 
This ACOG website provides numerous policy documents and practice bulletins on the use of LARC
immediately postpartum as well as material on access to contraception. 
Current Understanding of the Interaction of Benzodiazepines and Buprenorphine 
This Providers’ Clinical Support System continuing medical education course reviews the dangers of
combining benzodiazepines and buprenorphine. 
Federal Home Visiting Program
This webpage provides background about the HRSA and Administration for Children & Families program,
its structure, and its mission and services, which involve evidence-based, voluntary home visiting
programs, where families receive help from health, social service, and child development professionals. 
Healthy Start
This webpage describes the HRSA Healthy Start program and links to a technical assistance center with
more information on program approaches and grantees. The program provides depression screening,
healthcare services, care coordination, public health services such as immunization and health education,
and training for community health workers and care coordinators. 
Resources for Consumers and Families
This joint SAMHSA–HRSA Center for Integrated Health Solutions webpage provides links to information
to help families understand medication-assisted treatment and how it helps, as well as a guide for
patients developed by the American Society of Addiction Medicine and essays collected by Faces and
Voices of Recovery and the National Association of Medication Assisted Recovery. 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
SECTION III 
FACTSHEET # 
16 MATERNAL RETURN TO 
SUBSTANCE USE 
CLINICAL SCENARIO 
A new mother returns to substance use, whether alcohol, benzodiazepines, cocaine, marijuana,
methamphetamine, opioids, or tobacco 
CLINICAL ACTION STEPS 
Adjusting Pharmacotherapy Dose 
A new mother who returns to substance use should be assessed for possible adjustment of the dose
or schedule of her pharmacotherapy for opioid use disorder (OUD) and should receive more intensive
behavioral interventions. 
Changing or Resumption of Pharmacotherapy 
If changing from one pharmacotherapy to another is necessary, healthcare professionals should carefully
discuss with the new mother the risks of further destabilization in the context of active substance use. No
change should be undertaken without her fully informed consent. 
Breastfeeding in the Context of Return to Substance Use 
A new mother who was previously stable on buprenorphine or methadone but has returned to opioid use
should be assessed for dose adjustment, should receive additional behavioral interventions, and should be
counseled on her lactation options. 
SUPPORTING EVIDENCE AND CLINICAL CONSIDERATIONS 
Adjusting Pharmacotherapy Dose 
• Return to substance use is a common occurrence among people with a substance use disorder (SUD).
Some people in recovery may never return to substance use; others may do so many times before
establishing stable and lasting recovery. Given that returning to substance use is predictable and
common, doing so should not be viewed as a setback or failure, but as an indication of the need to
reassess the patient and adjust the treatment plan. Such adjustments may include engaging community
and behavioral supports. Many people find that, for lasting recovery, they need to control stress, avoid
places and situations where they once used drugs (triggers), and even end relationships with people
involved with drugs. When making these changes, people in recovery may find that peers—such as
other mothers in recovery who experienced a pregnancy affected by OUD—can help them in a way that
healthcare professionals cannot. Limited but promising research supports the role of peers who are in
recovery from an SUD (Barlow et al., 2015; Sanders, Trinh, Sherman, & Banks, 1998). 
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• A collaborative care model enables healthcare professionals
to work across disciplines and specialties and to provide
services as needed to reduce maternal stress and risk of
return to substance use. Using a collaborative care approach
(McLafferty et al., 2016; Substance Abuse and Mental Health
Services Administration [SAMHSA], 2016), prenatal healthcare
professionals, pediatricians, and behavioral health treatment
providers work together to provide behavioral health services to
reduce maternal stress. Behavioral health services often focus on
preventing a return to substance use, such as through teaching
new mothers how to manage triggers and connecting these
clients to peer recovery support groups and programs that help
new parents. Ideally, these healthcare professionals should be
co-located in the same building, if not integrated into a single
program, to facilitate postnatal care. If this is not feasible, then
providing referrals and regularly communicating with all the
healthcare professionals involved in the case is recommended.
Healthcare professionals are advised to review the 2016 SAMHSA report A Collaborative Approach to the
Treatment of Pregnant Women With Opioid Use Disorders: Practice and Policy Considerations for Child
Welfare, Collaborating Medical, and Service Providers for a more detailed description of this approach.
Privacy requirements are higher with issues of SUD than with other conditions, so it is especially important
to obtain signed informed consent agreements tailored to SUD issues to facilitate sharing of information
among healthcare professionals. It could be useful to complete a paper or electronic consent form
such as those provided at https://pcssmat.org/opioid-resources/clinical-tools/ to secure the sort of
information releases that will be necessary to coordinate care
among healthcare professionals who write pharmacotherapy
prescriptions, those who may manage other behavioral health
issue, and those providing prenatal care. Electronic systems
for managing patient consent to share protected health
information are also an option. One example is SAMHSA’s
Consent2Share. 
FACTSHEETS TO REVIEW 
• Factsheet #6: Addressing 
Polysubstance Use During 
Pregnancy for recommendations 
on how to treat a return to 
substance use in the prenatal 
period 
• Factsheet #14: Adjusting 
Pharmacotherapy Dose 
Postpartum for information 
on adjusting current 
pharmacotherapy doses 
before considering changing 
pharmacotherapy 
Resumption of Pharmacotherapy 
• If pharmacotherapy is discontinued postpartum and
the behavioral supports are insufficient to prevent or
interrupt return to substance use, the option to resume
pharmacotherapy should be considered. A new mother
should restart pharmacotherapy for OUD if behavioral
supports are insufficient to prevent a return to substance use.
Pharmacotherapy selection should be informed by what worked
well in the past and whether the mother is breastfeeding.
A mother’s preference for beginning antagonist therapy may be considered if she resumes
pharmacotherapy in the postpartum period. However, only one case study has reported examining how
much naltrexone is secreted into breast milk (Chan, Page-Sharp, Kristensen, O’Neil, & Ilett, 2004). In this
case, only very low levels of the naltrexone metabolite were detected in the infant plasma (1.1 micro g/L),
and the infant appeared to be healthy, was meeting developmental milestones on time, and showed no
adverse effects.
CONTENT TO REVIEW 
This link provides treatment
agreements and consent forms to
promote collaborative care plans in
a SUD treatment setting: https:// 
pcssmat.org/opioid-resources/ 
clinical-tools/. The two exceptions
to the privacy rule affecting
behavioral health care are: 
• If it appears the woman may
harm herself or others. 
• If she has been ordered into
treatment by the courts. 
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Breastfeeding in the Context of Return to Substance Use 
• If the new mother returns to substance use, healthcare team members will have to consider whether to
discontinue breastfeeding based on their knowledge of the
patient and her access to behavioral and recovery support
services. If there is a return to substance use, healthcare
professionals are advised to review the American Academy of
Pediatrics (AAP) policy statement on breastfeeding (Hudak, 
Tan, & AAP, 2012) and the Academy of Breastfeeding Medicine 
(ABM) Clinical Protocol #21: Guidelines for Breastfeeding 
and Substance Use or Substance Use Disorder, Revised 2015 
(Reece-Stremtan, Marinelli, & ABM, 2009, revised 2015). 
It may not be necessary to stop breastfeeding after an isolated
incident of substance use that is quickly under control. The World
Health Organization’s (WHO’s) Guidelines for the Identification
and Management of Substance Use and Substance Use Disorders in Pregnancy suggest carefully reviewing
the mother’s situation before recommending discontinuation of breastfeeding (WHO, 2014). 
FACTSHEET TO REVIEW 
Factsheet #11: Breastfeeding 
Considerations for Infants at 
Risk for Neonatal Abstinence 
Syndrome for information on the 
benefits of breastfeeding if the 
mother is stable on medication-
assisted treatment and when to 
bottle feed 
Other Evidence/Considerations 
• There are many unknowns when assessing cannabis, alcohol, and tobacco use by pregnant women and
new mothers. Not enough data exist to determine the long-term consequences of cannabis exposure in
infancy. The prevalence of past-month cannabis use increased from 2.37 percent in 2002 to 3.85 percent
in 2015 (Brown et al., 2017). Although fetal exposure to cannabis, the illicit drug most commonly used by
pregnant women, is not known to cause clinically important neonatal withdrawal signs, such exposure
may have effects on long-term neurobehavioral outcomes (Campolongo, Trezza, Palmery, Trabace, &
Cuomo, 2009). Maternal cannabis smoking has been found to be related to lower birth weight in offspring
(Fegusson, Horwood, & Northstone, 2002; Gray et al., 2010; Gunn et al.,
2016; National Academies of Sciences, Engineering, & Medicine, 2017). 
Return to use of these substances by a mother while caring for her infant
should prompt review of her treatment plan and consideration of adjusting
medical, behavioral, and peer services to support discontinuation of these
substances. 
Until more is known about the long-term effects of exposure to these
substances through breast milk or secondhand smoke, mothers should
be counseled to avoid cannabis and tobacco smoke, as well as alcohol
(Committee on Obstetric Practice, American College of Obstetricians
and Gynecologists, 2017; National Academies of Science, Engineering, &
Medicine, 2017; Reece-Stremtan et al., 2015; Volkow, Compton & Wargo,
2017; WHO, 2014). 
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WEB RESOURCES ON THIS TOPIC 
ABM Protocol #21: Guidelines for Breastfeeding and Substance Use or Substance Use Disorder,
Revised 2015
This protocol provides evidence-based guidelines for the evaluation and management of women with
SUDs who are considering breastfeeding. It includes information on methadone and buprenorphine. 
Breastfeeding Initiatives: Family Resources
This AAP webpage lists breastfeeding resources for families; some resources are in Spanish. 
A Collaborative Approach to the Treatment of Pregnant Women With Opioid Use Disorders:
Practice and Policy Considerations for Child Welfare, Collaborating Medical, and Service Providers 
This SAMHSA document provides information on the treatment of pregnant women with OUD,
summarizes guidelines adopted by a variety of professional organizations, and presents a framework
for organizing community efforts. It provides a coordinated, multisystem approach grounded in early
identification and intervention to assist child welfare, medical, SUD treatment, and other systems in
supporting families. 
Drug Entry Into Human Milk
This InfantRisk Center webpage describes in detail the mechanisms of drug entry into human milk
and provides some general rules on breastfeeding. 
Drugs and Lactation Database (LactMed)
This National Library of Medicine searchable database provides information on medications and other
chemicals to which breastfeeding mothers may be exposed. 
Medications and Breastfeeding: Tips for Giving Accurate Information to Mothers 
This two-page AAP document discusses clinical points to consider when prescribing medications to
breastfeeding mothers. 
Policy Statement: Breastfeeding and the Use of Human Milk 
This AAP-updated policy statement reviews the benefits of breastfeeding for mother and child. 
When Should a Mother Avoid Breastfeeding?
This Centers for Disease Control and Prevention webpage provides links to information about
illnesses and conditions that contraindicate breastfeeding. 
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CONCLUSION 
This Guide responds to urgent calls from across the United States for clinical guidance to help healthcare
professionals deliver evidence-based individualized care to pregnant and parenting women with opioid use
disorder (OUD) and their infants. 
The clinical recommendations presented in this Guide are informed by the best available evidence and clinical
experience. They are notable for their emphasis on the need for individualized, risk–benefit-based clinical decision-
making and the imperative to ensure the health and well-being of mothers to promote optimal outcomes for their
infants. Several strategies are critical to success in caring for women with OUD and their infants: 
• Identifying and implementing screening for pregnant women for substance use disorders (SUDs), including
OUD, and mental health comorbidities using appropriate screening, assessment, and diagnostic procedures. 
• Identifying and implementing a community-based team of clinicians (prenatal healthcare professionals,
pediatrics, and SUD treatment provider), counselors, and social workers, with
an emphasis on rapid referral and engagement into treatment. Methods for
multidisciplinary communication and compliance should be developed. 
• Making available and offering pharmacotherapy for OUD and mental health
comorbidities at the earliest opportunity. 
• Including pregnancy monitoring assessment of fetal growth and risk of preterm
birth, as well as strategies to reduce tobacco use. 
• Focusing on the postpartum period as an especially vulnerable time for return
to substance use and managing treatment accordingly. Breastfeeding should be
encouraged when appropriate. 
• Offering non-coercive contraceptive counseling and the option to leave the
hospital with a prescription for contraception, contraceptive supplies, or a
contraception plan. 
• Developing protocol-driven screening, assessment, monitoring, and treatment of
neonatal abstinence syndrome (NAS) for substance-exposed infants. Postnatal
care should include careful discharge planning and in-home supports
Where should you begin to address the needs of your patients and community? Numerous
online resources and educational materials are provided and hyperlinked in the body of this Guide and its
appendices. For example, https://pcssmat.org/opioid-resources/clinical-tools/ provides templates of consent
forms and treatment agreements that can be modified to meet the specific requirements of the healthcare
program and the unique needs of each patient. How to implement the guidance provided in the factsheets
depends on what types of care you provide and how care is coordinated in your community.
Exhibit C.1 presents to-do lists for engaging in the care of pregnant and parenting women with OUD. If you are
new to the treatment of pregnant women with OUD, you should begin with the items in the column labeled
“Easy Steps You Can Take.” If you are already treating pregnant women with OUD, you should look closely at
the column titled “Advanced Steps.” 
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 Exhibit C.1: Getting Started and Staying Engaged With Treatment for Pregnant and Parenting Women With OUD
In Your Clinic 
Easy Steps You Can Take 
1. Have your staff review this Guide. 
2. Explore websites of the Substance Abuse and Mental Health
Services Administration (SAMHSA) and professional organizations
(e.g., American Society of Addiction Medicine [ASAM]) for training
opportunities for you and your staff. 
3. Attend national meetings of your society to learn about specific
clinical practices for pregnant and parenting women. 
4. Learn about state regulations for mandatory reporting of positive
drug test results for pregnant and parenting women. 
5. Complete buprenorphine waiver training. 
6. Instruct your staff to participate in online or in-person MAT training. 
7. Get a mentor at PCSS-MAT.org. 
8. Join listservs to receive alerts, guidance, and information from
experts (e.g., SAMHSA–Health Resources and Services Administration
Center for Integrated Solutions, Providers’ Clinical System Support). 
9. Identify and implement screening tools for SUDs. 
10. Ask public and commercial insurance companies or agencies with
whom you have contracts what billing and reimbursement methods
are available. 
Advanced Steps 
1. Develop multidisciplinary protocols for the identifying, referring,
and prioritizing pregnant and parenting women for treatment. 
2. Develop a mechanism for communication on treatment compliance,
sharing of urine testing results, and other procedures. 
3. Build a team (e.g., comprising a maternity care provider, an advance
nurse practitioner, physician assistants, and peer counselors) with
knowledge in treating pregnant and parenting women. 
4. Prepare for the transition of care after delivery. Ensure the patient
has a primary care provider and pediatrician. Develop a long-term
treatment and recovery program. 
5. Implement MAT for the treatment of pregnant and parenting
women. 
6. Educate and encourage staff to commit to a patient-centered,
flexible, and accepting practice for pregnant women in treatment. 
7. Learn about business strategies to sustain your practice within the
healthcare marketplace through SAMHSA’s Business Plus Project for
Providers. 
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Exhibit C.1: Getting Started and Staying Engaged With Treatment for Pregnant and Parenting Women With OUD
In Your Professional Community 
Easy Steps You Can Take 
1. Take advantage of existing resources and reach out to partners
and local experts (e.g., state chapters of ASAM, American Academy
of Pediatrics, American College of Obstetrician and Gynecologists,
American Academy of Family Physicians, nurse practitioner/ 
physician assistance [NP/PA] associations, nurse midwife groups,
state opioid task force).
2. Check with your single state agency (SSA), state opioid treatment
authority (SOTA), and state Medicaid authority about resources and the
process for accessing treatment and supports in your community. 
3. Visit a nearby opioid treatment program (OTP) or office-based opioid
treatment (OBOT) practices to find out how clients are being served
and learn best practice for the care of pregnant and parenting women.
Assess how your program might participant in a network. 
4. Develop relationships with an experienced referral center. Check
with your SSA or SOTA to identify potential referral centers. 
5. Initiate or participate in regular calls with other care providers in
your community to informally discuss cases and share expertise. 
6. Initiate or participate in local meetings with your staff and staff
at nearby labor and delivery units, nurseries, and local treatment
specialists. 
Advanced Steps 
1. If you are a prenatal healthcare professional, partner with treatment
centers and aid in the early and easy entrance of newly pregnant
women in recovery to your practice. 
2. If you are currently caring for patients with OUD and would like
to treat pregnant or parenting women, identify OB/GYNs, family
practice physicians, nurses, psychiatrists, and other healthcare
professionals who will accept referrals for women with OUD and
their infants.
3. Identify pediatricians who can provide best care for newborns at
risk for the development of NAS. 
4. Identify and reach out to community health centers, OTPs, OBOT
practices, outpatient and residential services, and inpatient detoxification
settings to identify resources for your clients, coordinate services,
and aid in the early and smooth care coordination. 
In Your Stakeholder Community 
Easy Steps You Can Take 
1. Identify patient-appropriate resources and use them to educate
all of your patients about the needs of women with SUDs and
substance-exposed infants (e.g., Childbirth, Breastfeeding, and
Infant Care: Methadone and Buprenorphine; Pregnancy: Methadone or
Buprenorphine; Methadone Treatment for Pregnant Women). 
2. Develop a mentoring group by attending local conferences related to
the education of professionals treating pregnant women with OUD. 
3. Offer to mentor/educate your peers or trainees in your community. 
4. Encourage clients who have been successful in treatment to share their
stories with individuals in their community who may need support. 
Advanced Steps 
1. Reach out to child welfare agencies, courts, social workers, and other
stakeholders working with pregnant and parenting women to provide
education about the benefits of MAT and start building trust. 
2. Work with partners (e.g., law enforcement, hospitals, university
medical centers, SSA, SOTA) to develop and host forums or town
halls to educate your community. 
3. Engage state and local public health leaders in your community and
offer to be a resource for pregnant and parenting women with OUD. 
If you have questions or need additional information to get started, contact SAMHSAinfo@SAMHSA.gov.
Acting now can produce better outcomes for both mothers and opioid-exposed infants. 
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Appendix A: Suitable Development 
Assesments for Opioid-Exposed Infants 
and Children 
Measure Description Age Range Format Time 
Screening Measures 
Ages & Stages 
Questionnaire®, 
Third Edition (ASQ-
3™) 
• Screens infants and young children for developmental 
delays. 
• 30 questions provide scores on 5 skills: fine motor, 
gross motor, problem solving, personal—social, and 
communication. 
1—66 months Parent or 
caregiver, 
teacher, or 
clinician 
10—20 minutes 
Developmental 
Activities Screening 
Inventory, Second 
Edition (DASI-II) 
• Provides early detection of children with developmental 
disabilities. 
• 67 questions cover 15 skills including sensory intactness, 
means-end relationships, and causality to memory, seriation, 
and reasoning yielding a developmental quotient. 
Birth—60 months Teacher or 
clinician 
25—30 minutes 
Targeted Assessment Measures 
Infant Behavior 
Questionnaire, 
Revised (IBQ-R) 
• Measures infant’s temperament. 
• 191 items yield scores in 14 domains: activity level, distress 
to limitations, fear, duration of orienting, smiling/laughter, 
high-intensity pleasure, low-intensity pleasure, ability to 
be soothed, falling reactivity/rate of recovery from distress, 
cuddliness, perceptual sensitivity, sadness, approach, and 
vocal reactivity. 
3—12 months Parent or 
caregiver 
15—30 minutes 
Infant Toddler 
Sensory Profile® 
(ITSP) 
• Evaluates child’s sensory processing abilities and the effect 
of sensory processing on functional performance in daily life. 
• 36 items assess children 0—6 months and 48 items assess 
children 7—36 months yielding scores in 4 areas: low 
registration, sensation seeking, sensory sensitivity, and 
sensation avoiding. 
• Low threshold score is a total of the sensory sensitivity and 
sensation avoiding quadrant scores. 
Birth—36 months Parent or 
caregiver 
15 minutes 
Mullen Scales of 
Early Learning, AG5 
Edition (MSEL-AG5) 
• Assesses cognitive functioning in young children. 
• 5 skill areas are scored: gross motor, visual reception, fine 
motor, expressive language, and receptive language. 
Birth—68 months Trained examiner Age 1: 15 minutes 
Age 3: 25—35 
minutes 
Age 5: 40—60 
minutes 
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Measure Description Age Range Format Time 
Screening Measures 
Neonatal Intensive 
Care Unit Network 
Neurobehavioral 
Scale (NNNS) 
• Assesses neonatal neurologic and behavioral functioning and 
stress/abstinence signs in infants. 
• Neurologic items reflect central nervous system integrity and 
maturity. 
• Behavioral assessment items are adapted from the Neonatal 
Behavioral Assessment Scale, and stress/abstinence items 
are adapted from the Finnegan Neonatal Abstinence Scoring 
System. 
• Additional items capture stress signs exhibited by infants 
exposed to drugs and other at-risk infants. 
• NNNS yields 13 summary scales: habituation, attention, 
handling, quality of movement, regulation, nonoptimal 
reflexes, asymmetric reflexes, stress/abstinence, arousal, 
hypertonicity, hypotonicity, excitability, and lethargy. 
Gestational age > 
30—48 weeks 
Trained examiner 30 minutes 
Parenting Stress 
Index™, Fourth 
Edition (PSI™-4) 
• Assesses parental stress from the parent—child relationship. 
• 120 items measure stress in 2 domains: child domain, with 
6 subscales (distractibility/hyperactivity, adaptability, 
reinforces parent, demandingness, mood, and acceptability) 
that measure stress from child behavior as reported by 
the parent; parent domain, with 7 subscales (competence, 
isolation, attachment, health, role restriction, depression, and 
spouse/parenting partner relationship) that measure stress 
from parent functioning. 
• Life stress scale measures amount of parent stress caused by 
situational factors other than those from the child or parent. 
Birth—144 months Parent or caregiver 15 minutes 
Receptive-Expressive 
Emergent Language 
Test, Third Edition 
(REEL-3) 
• Identifies infants and toddlers with language impairments or 
developmental issues that affect language development. 
• 66 items measure 2 areas: receptive language and expressive 
language. 
• Supplementary subtest provides inventory of vocabulary 
words. 
Birth—36 months Trained examiner 
with a parent or 
caregiver 
10—15 minutes 
Temperament and 
Atypical Behavior 
Scale (TABS) 
Assessment Tool 
• Identifies potential problems with temperament and/or self-
regulation. 
• 55 items cover areas such as temperament, attention, 
attachment, social behavior, play, vocal and oral behavior, 
sense and movement, self-stimulation and self-injury, and 
neurobehavioral state. 
11—71 months Parent or 
caregiver 
15 minutes 
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Measure Description Age Range Format Time 
Screening Measures 
Battelle 
Developmental 
Inventory™, Second 
Edition Normative 
Update (BDI-2™ NU) 
• Depicts child progress in intervention programs, identifies 
children with special needs, and provides a comprehensive 
analysis of functional capabilities. 
• 341 items use 3 sources to gather information: direct observation, 
structured task, and interview with parents and teachers. 
• 96 items identify a child who may need further assessment 
and provide scores on motor skills (fine, gross, and perceptual), 
language (expressive and receptive), cognition (conceptual 
development, reasoning, academic skills, attention, and 
memory), personal—social expressions (adult interaction, self-
concept and social growth, and peer interaction), and adaptive 
skills (personal responsibility and self-care). 
Birth—95 months Teacher and 
behavioral health 
professional 
60—90 minutes 
Screening test: 
10—30 minutes 
Bayley Scales of 
Infant and Toddler 
Development®, Third 
Edition (Bayley-III®) 
• Provides comprehensive assessment of infant development. 
• 5 core scales consist of 3 based on interaction with the child 
(cognitive, motor, and language) and 2 based on parent 
questionnaire (social-emotional and adaptive behavior). 
1—42 months Trained examiner 30—90 minutes 
BRIGANCE® Inventory 
of Early Development, 
Second Edition (IED II) 
• Assesses child’s strengths and weaknesses in multiple areas 
of functioning. 
• Number of items depends on section. 
• Developmental section assesses behaviors with regard to 
pre-ambulatory motor skills, gross motor skill, and fine 
motor skills; self-help skills; speech and language skills; and 
social-emotional development. 
• Early academic skills section assesses general knowledge 
and comprehension, readiness, basic reading skills, 
manuscript writing, and math. 
Birth—84 months Teachers, no 
training required 
Developmental 
section: varies 
by age 
Early academic 
skills section: 
varies by age 
Devereaux 
Early Childhood 
Assessment Infant 
and Toddler Program 
(DECA-I/T) 
• Assesses protective factors that lead to the development of 
child resilience. 
• 4 scoring profiles are used in DECA-I for children 1—18 
months, and 1 scoring profile is used in DECA-T for children 
18—36 months. 
• 37 items provide scores in 3 areas: initiative, attachment, and 
self-control. 
• 10 items screens for possible problem behaviors. 
1—36 months Parent and 
teacher 
20 minutes over 
4 weeks 
Devereaux 
Early Childhood 
Assessment 
Preschool Program, 
Second Edition 
(DECA-P2) 
• Extends DECA-I/T up to age 5. 
• 38 items measure initiative, attachment/relationships, self-
regulation, and behavioral concerns. 
36—60 months Parent and 
teacher 
20 minutes over 
4 weeks 
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Appendix B: Glossary and Acronyms 
GLOSSARY 
12-step program 
A group providing mutual support and fellowship for people recovering from addictive behaviors. The first 
12-step program was Alcoholics Anonymous (AA), founded in 1935; an array of 12-step groups following 
a similar model have since emerged and are the most widely used mutual aid groups and steps for 
maintaining recovery from alcohol and drug use disorders. It is not a form of treatment, and it is not to 
be confused with the treatment modality called Twelve-Step Facilitation. 
Abstinence 
Refraining from the use of alcohol, illicit drugs, and the misuse of prescription and over-the-counter 
medications. Abstinence includes refraining from the inappropriate use of prescription medications 
including opioid agonists to treat opioid use disorder. See also the entry for medically supervised 
withdrawal. 
Addiction 
See the entry for substance use disorder. 
Analgesic 
Compound that alleviates pain without causing loss of consciousness. Opioids have pain relieving 
properties mediated by binding to specific receptors in the central nervous system to block the perception 
of pain or affect the emotional response to pain. Opioids as an analgesic class include opium and its 
derivatives, as well as several synthetic compounds. 
Assessment 
Process of identifying the precise nature and extent of a patient’s substance use disorder and other 
medical, mental health, and social problems as a basis for treatment planning. Assessment usually begins 
during program admission and continues throughout treatment. It includes a personal substance use 
history, physical examination, laboratory evaluation, and determination of disease morbidity. Severity 
of disease often is assessed further in terms of physiological symptoms, organ system damage, and 
psychosocial morbidity. Assessment may also involve determining the patient’s coping skills, motivation, 
and readiness for change. 
Behavioral health 
The condition of well-being aligned with the prevention and intervention, treatment, and recovery supports 
for people with mental and substance use problems or disorders. 
Benzodiazepine 
One of a group of medications having a common molecular structure and similar pharmacologic activity, 
including antianxiety, sedative, hypnotic, amnestic, anticonvulsant, and muscle-relaxing effects. Diazepam, 
chlordiazepoxide, clonazepam, alprazolam, and lorazepam are examples of benzodiazepines. 
Buprenorphine 
Synthetic mu opioid receptor partial agonist approved by the Food and Drug Administration for 
use in maintenance treatment for opioid use disorder. Buprenorphine is commercially available as a 
buprenorphine-only product or a combination buprenorphine/naloxone product. When taken as directed 
it does not produce the euphoria and sedation associated with heroin or other opioids but can reduce or 
eliminate withdrawal symptoms, including cravings, in individuals with opioid use disorder. 
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Cannabis 
The dried leaves, flowers, stems, and seeds of the marijuana plant Cannabis sativa, which contains 
psychoactive compounds. Concentrated forms of cannabis include hashish and hash oil. 
Cocaine 
Powerful central nervous system stimulant made from the leaves of the South American coca plant. Cocaine 
is used nonmedically to produce euphoria or mental alertness. Chronic use may have serious physiological 
and psychological effects, such as seizures, paranoia and substance use disorder. 
Cognitive behavioral therapy (CBT) 
A type of psychotherapy where the client works with a psychotherapist in a structured format, working on 
specific problem behaviors or negative emotions during a limited number of sessions. 
Comorbidity 
Coexistence of two or more illnesses. 
Contingency management (CM) 
A treatment where tangible rewards (e.g., money or reduced appointments) are used to reinforce positive 
behaviors. 
Coordinated Care 
Care that integrates the efforts of medical, social service, and behavioral health service professionals 
to address an individual’s health and wellness. 
Craving 
Urgent, seemingly overpowering desire to use a substance; often associated with tension, anxiety, 
or other dysphoric, depressive, or negative affective states. 
Detoxification 
See the entry for medically supervised withdrawal. 
Evidence-based practice (EBP) 
Evidence-based practice “requires the integration of the best research evidence with … clinical expertise and 
… patient’s unique values and circumstances” (Straus, Glasziou, Richardson, & Haynes, 2011, p. 1). An EBP is a 
continually evolving process, with repeated integration of clinical expertise with current research findings. 
Fetal alcohol spectrum disorder (FASD) 
Pattern of impaired growth, cognitive and behavioral deficits, and characteristic facial abnormalities found in 
some children exposed to alcohol during pregnancy. 
Healthcare professional 
Individuals providing medical care in a variety of settings. The term includes nurse practitioners, midwives, 
family medicine doctors, obstetricians, pediatricians, neonatologists, and behavioral health care professionals. 
Level of care 
Intensity and type of treatment needed by an individual based on severity of disease. Different levels of care 
may be provided in a single setting or across a range of settings. 
Maintenance treatment 
Providing medications to achieve and sustain clinical remission of signs and symptoms of opioid use disorder 
and support the individual process of recovery without a specific endpoint. 
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Medically supervised withdrawal 
Using a medication in tapering doses to help a patient discontinue illicit or prescription medications. 
(This guide does not use the term detoxification to mean the process of dose tapering from maintenance 
medication, because that usage incorrectly suggests that opioid treatment medications are toxic.) 
Medication-assisted treatment (MAT) for opioid use disorder (OUD) 
Type of comprehensive substance use disorder (SUD) treatment that provides both maintenance 
pharmacotherapy—using an opioid agonist, a partial agonist, or an antagonist medication, usually 
provided in a certified, licensed opioid treatment program or a healthcare professional’s office-based 
treatment setting—and other treatment services, including medical and psychosocial support services 
such as employment assistance or family services. Some healthcare professionals use the term MAT when 
any medication is used for an SUD regardless of whether specialized behavior therapy or counseling is 
provided. The use of medications to treat OUD is also referred to as pharmacotherapy. 
Methadone 
A synthetic, long-acting, full mu opioid receptor agonist that can produce analgesia, sedation, euphoria and 
respiratory depression by binding to mu opioid receptors. At a therapeutic dose and schedule methadone 
can eliminate withdrawal symptoms and reduce cravings in individuals with opioid use disorder. 
Mutual-aid, mutual-help, mutual-support program 
Program offering the benefits of peer support to people with substance use disorders, through attendance 
at group meetings and other activities. Twelve-step programs are one type of mutual-help program. See 
also the entry on 12-step program. 
Naloxone 
Short-acting opioid antagonist or blocker. Naloxone is used in emergencies to reverse opioid poisoning 
or overdose. The naloxone molecule has a higher affinity for the mu opioid receptor and displaces opioids 
from these receptors. In this way it interrupts their action but can also precipitate acute withdrawal. It does 
not activate the mu receptor, cannot cause euphoria and has no abuse potential. Naloxone is combined 
with buprenorphine in some products as an abuse deterrent. It may also be used to assess the physiologic 
readiness of an individual to begin pharmacotherapy with a long-acting antagonist such as naltrexone. 
Naltrexone 
Synthetic opioid antagonist approved by the FDA for the prevention of relapse to opioid use in persons 
who have completed medically supervised withdrawal from opioids. 
Neonatal abstinence syndrome (NAS) 
Group of physiologic and neurobehavioral signs of withdrawal that may occur in a newborn who was 
exposed to psychotropic substances in utero. The syndrome may be managed with nonpharmacologic 
interventions, but may require pharmacotherapy. 
Neonatal opioid withdrawal syndrome (NOWS) 
The constellation of physiologic manifestations of withdrawal specifically attributable to opioids seen 
in opioid exposed newborns. NOWS can occur as part of multidrug withdrawal syndromes in mothers 
using multiple substances. The opioid withdrawal symptoms are observed in some newborns of mothers 
who had opioid use disorder or were using pharmacotherapy for opioid use disorder during pregnancy. 
The term NOWS captures more accurately than does the term NAS the numbers of infants experiencing 
withdrawal from opioid exposure in utero. The infant’s withdrawal symptoms can be reduced using 
medications and nonpharmacological treatments. See also the entry for neonatal abstinence syndrome. 
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Office-based opioid treatment (OBOT) 
Providing medication for opioid use disorder in settings other than certified opioid treatment programs. 
Opiates 
Opiates are compounds that are directly derived from opium, including its three natural derivatives: morphine, 
codeine, and thebaine. Note, opioids are compounds that are broadly related to opium, although not all opioids 
will be structurally similar or derived from derivatives of opium. These include medications such as methadone, 
buprenorphine, and oxycodone. 
Opioid addiction 
See the entry for opioid use disorder. 
Opioid agonist 
Drug that has an affinity for and stimulates physiological activity at cell receptors in the central nervous system 
that are normally stimulated by opioids. 
Opioid antagonist 
Drug that binds to cell receptors in the central nervous system that normally are bound by opioid psychoactive 
substances but that blocks the activity of opioids at these receptors without producing the physiologic effects 
of opioid agonists. Naltrexone is an opioid antagonist. 
Opioid receptor partial agonist 
Drug that binds to opioid receptors in the central nervous system without fully activating them. Partial/agonists 
produce effects similar to those of a full mu opioid receptor agonist, but may not produce additional effects 
above a certain dose. Buprenorphine is an opioid receptor partial agonist. 
Opioid treatment program (OTP) 
Refers to specialized programs that are certified by SAMHSA to provide methadone and/or buprenorphine, 
counseling, and urine testing to treat OUD. 
Opioid use disorder (OUD) 
Is defined in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (American Psychiatric 
Association [APA], 2013). The diagnosis of OUD can be applied to someone who uses opioid drugs and has 
at least 2 of the 11 symptoms occurring within a 12-month period. Key aspects of OUD include loss of control, 
continued use despite adverse consequences, tolerance, and withdrawal. It is important to note that tolerance 
and withdrawal are not counted toward the diagnosis in individuals experiencing these symptoms when using 
opioids under appropriate medical supervision (APA, 2013). Medications for OUD should not be used in a 
person without physical dependence on opioids except in special circumstances (e.g., a person with a history 
of moderate to severe OUD who is not currently physically dependent, but assessed to be at high risk for 
relapse). 
Opioids 
Opioids are compounds that are broadly related to opium, although not all opioids will be structurally similar 
or derived from derivatives of opium. These include medications such as methadone, buprenorphine, and 
oxycodone. Note, opiates are compounds that are directly derived from opium, including its three natural 
derivatives: morphine, codeine, and thebaine. 
Pain management 
The treatment of acute or chronic pain by various methods that may include administration of opioid 
medications. 
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Peer support services, peer support specialist, peer coach, peer worker 
Peer support services involve the use of peer support specialists in recovery to provide nonclinical (i.e., not 
requiring training in diagnosis or treatment) recovery support services to individuals in recovery from SUDs and 
to their families. 
A peer support specialist is someone in recovery who has lived experience with mental illness, trauma, and/or 
substance use disorder, plus skills learned in formal training. Peer support specialists may be paid professionals 
or volunteers. They are distinguished from members of mutual-help groups because they maintain contact 
with treatment staff. They offer experiential knowledge that treatment staff often lack (e.g., what to expect at 
different mutual help meetings, how to talk to people they spent time with when using drugs). 
People-first language (PFL) 
Language that emphasizes the person rather than the person’s disability or disorder. An example is using “a 
person with a substance use disorder” rather than “an addict.” 
Person in recovery 
An individual who is consciously seeking to improve his or her health and wellness by changing substance use 
behaviors. 
Pharmacotherapy 
The use of prescribed medication to treat disease. 
Recovery 
A process of change through which individuals improve their health and wellness, live a self-directed life, and 
strive to reach their full potential (SAMHSA, 2012). 
Referral 
A means of assuring access to needed treatment, recovery or social services when not all services are offered 
at a single program site. When a person must see a variety of service providers in multiple settings in order to 
obtain needed services, treatment program staff members should arrange the referrals, coordinate care and 
monitor patient progress. 
Relapse 
See the entry for return to substance use. 
Return to substance use 
A single instance or pattern of substance use occurring after a period of abstinence. It is preferred to the term 
relapse. 
Screening 
Process of determining whether a person is at risk of harm from substance use or has a substance use disorder. 
Screening usually involves use of one or more standardized techniques, most of which include a questionnaire 
or a structured interview. Screening may also include observation of known presenting complaints and 
symptoms that are indicators of substance use disorders. 
Screening, brief intervention, and referral to treatment (SBIRT) 
Comprehensive, integrated public health approach to the delivery of early intervention and treatment services 
for people with substance use disorders, as well as those who are at risk of developing such disorders. SBIRT 
may be conducted at primary care centers, hospital emergency departments, trauma centers, and other 
community settings provide opportunities for early intervention with people who are at risk for substance 
abuse before more severe consequences occur. 
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Stabilization (stability) 
Provision of immediate assistance, such as with an opioid agonist, to eliminate withdrawal symptoms and drug 
craving in order to promote an individual’s safety. 
Substance use disorder (SUD) 
Condition in which repeated or continuous use of alcohol and/or drugs causes an individual clinically and functionally 
significant impairments, such as health problems, disability, and failure to meet major responsibilities at work, school, 
or home. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5; American Psychiatric 
Association, 2013) determines the level of severity (mild, moderate, or severe) of a substance use disorder by the 
number of diagnostic criteria met by an individual. According to the DSM-5, a diagnosis of substance use disorder is 
based on evidence of impaired control, social impairment, risky use, and pharmacological criteria. 
Take-home medication 
Medication for the treatment of opioid use disorder furnished to patients for unsupervised self-administration. 
Tolerance 
A state of physiologic adaptation in which repeat or sustained exposure to a drug induces changes that result 
in a decrease of one or more of the drug's effects. See also withdrawal. 
Treatment guidelines 
A listing of best practices for assessing or managing a health condition; the majority of guidelines are produced 
by a group of experts after a review of the evidence. 
Treatment plan 
Describes the patient’s short and longer term goals and what strategies, including therapeutic modalities, their 
schedule and frequency, recovery supports, care coordination and social supports will be employed to achieve 
them. 
Urine drug screen, urine testing 
Analysis of urine samples from patients to determine the presence or absence of specific drugs. Widely used 
in substance use disorder treatment, urine testing is an important tool for assessing individual progress in 
treatment, effectiveness of the individual treatment plan, and safety. In aggregate, the test results can be used 
to make programmatic decisions. Methods of urine testing vary widely. 
Withdrawal 
Expected syndrome of signs and symptoms experienced to varying degrees after abrupt discontinuation or 
rapid decrease in use of a substance that has been consumed regularly over a period of time. Withdrawal signs 
and symptoms are usually the opposite of the pharmacological effects of a psychoactive substance. 
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ACRONYMS 
Acronym Definition 
ACF Administration for Children & Families 
ATTC Addiction Technology Transfer Center 
CDC Centers for Disease Control and Prevention 
FDA Food and Drug Administration 
HHS U.S. Department of Health and Human Services 
HRSA Health Resources and Services Administration 
MAT Medication-assisted treatment 
MOTHER Maternal Opioid Treatment: Human Experimental Research 
NAS Neonatal abstinence syndrome 
NCSACW National Center on Substance Abuse and Child Welfare 
NICHD National Institute of Child Health and Human Development 
NICU Neonatal intensive care unit 
NIDA National Institute on Drug Abuse 
NIH National Institutes of Health 
NOWS Neonatal opioid withdrawal syndrome 
NSDUH National Survey on Drug Use and Health 
N-SSATS National Survey of Substance Abuse Treatment Services 
OUD Opioid use disorder 
OWH Office on Women’s Health 
RAM RAND/UCLA Appropriateness Method 
SAMHSA Substance Abuse and Mental Health Services Administration 
SBIRT Screening, brief intervention, and referral to treatment 
SSRI Selective serotonin reuptake inhibitor 
SUD Substance use disorder 
WHO World Health Organization 
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